Cranberry metabolites with urinary anti-adhesion activity by Coleman, Christina M.
University of Mississippi 
eGrove 
Electronic Theses and Dissertations Graduate School 
1-1-2014 
Cranberry metabolites with urinary anti-adhesion activity 
Christina M. Coleman 
University of Mississippi 
Follow this and additional works at: https://egrove.olemiss.edu/etd 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Recommended Citation 
Coleman, Christina M., "Cranberry metabolites with urinary anti-adhesion activity" (2014). Electronic 
Theses and Dissertations. 1505. 
https://egrove.olemiss.edu/etd/1505 
This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been 
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more 
information, please contact egrove@olemiss.edu. 
  
CRANBERRY METABOLITES WITH  
URINARY ANTI-ADHESION ACTIVITY 
 
 
 
 
 
A Dissertation 
presented in partial fulfillment of the requirements 
for the degree of Doctorate of Philosophy 
in the Department of BioMolecular Sciences 
School of Pharmacy 
The University of Mississippi 
 
 
 
 
 
by 
CHRISTINA M. COLEMAN 
August 2014 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2014 by Christina M. Coleman 
All rights reserved. 
ii 
 
 
 
ABSTRACT 
The fruit of the American cranberry (Vaccinium macrocarpon Aiton, Ericaceae) is a 
common food and a top selling dietary supplement in the U.S. Cranberry juice is traditionally 
used for the prevention of urinary tract infections (UTIs), many of which are caused by P-
fimbriated Escherichia coli. Human urine produced after cranberry juice consumption can 
prevent E. coli adhesion, but the urinary metabolites responsible for this activity are currently 
not known. High-molecular weight components of cranberry juice, specifically 
proanthocyanidin oligomers (PACs), are currently believed to be responsible for the ability of 
cranberry juice to prevent UTIs. Cranberry PACs can prevent the adherence of P-fimbriated E. 
coli to uroepithelial cells in vitro and are hypothesized to act by a similar mechanism of action 
in vivo. Many questions exist, however, regarding the potential for PACs to be absorbed, 
metabolized, and excreted into urine. Adult female sows were therefore fed spray-dried 
cranberry juice powder (5 g/kg/d) and urine was collected via catheter. Urine fractions were 
tested for anti-adhesion activity using a human red blood cell (HRBC) anti-agglutination assay 
with uropathogenic P-fimbriated E. coli. Active urine fractions but not control urine or inactive 
fractions were found to contain complex mixtures of oligosaccharides but not PACs. An 
octasaccharide, consisting of a tetrameric, β-(1→4)-linked D-glucose backbone and possessing 
two D-xylose-L-arabinose side chains, was purified from the oligosaccharide mixture of active 
urine fractions in sufficient quantity to assign the full structure. Oligosaccharide mixtures of 
similar character were subsequently identified in cranberry products using methods adapted 
from those applied to urine samples. Cranberry oligosaccharides were enriched in large scale 
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from three sources of cranberry material and were shown to have activity in both the anti-
agglutination assay and a second anti-adhesion assay that used uropathogenic E. coli and 
uroepithelial cells. The results of these studies indicate that the compounds responsible for the 
anti-adhesion properties of urine after cranberry juice consumption are oligosaccharides that 
are structurally related to those found in cranberry. These findings overturn the current 
paradigm regarding the active components of cranberry juice that prevent UTIs and provide 
many new directions for future research.  
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CHAPTER 1: CRANBERRY JUICE & URINARY TRACT INFECTIONS 
A. The American Cranberry 
The American cranberry (Vaccinium macrocarpon Ait., Ericaceae) is a perennial, 
evergreen, low-growing, shrub-like plant that is native to North America (Roper & Vorsa 1997, 
McCaleb et al. 2000, Neto & Vinson 2011) (Appendix A color plates: Figure 94). The 
American cranberry is closely related to the European cranberry, or lingonberry (V. vitis-
idaea), to blueberries (V. corymbosum), and to myrtlberries, or bilberries (V. myrtillus). Many 
Vaccinium species have received attention regarding their chemistry and biological properties 
and all are known for their flavonoid composition, acidic or tannic taste, and distinctive flavors. 
As with other plants in the Vaccinium genus, cranberry prefers acidic, bog-type soils. It is 
cultivated in northern areas of the U. S., with different agricultural varieties suited to different 
geographic regions. The oldest cranberry cultivars include ‘Early Black’, ‘Howes,’ ‘McFarlin,’ 
and ‘Searles’, and many other varieties are actively being developed to improve disease 
resistance, fruit production, and suitability to different growing environments. Fruits are hollow 
with a waxy cuticle, ripen in the fall, and are typically harvested through a unique method that 
involves flooding bogs and knocking the fruit from plants with specialized mechanical beaters. 
Cranberry fruit has long been part of the American diet, and cranberry products are 
familiar to most people as common food items including cranberry juice, sweetened-dried 
cranberries, and cranberry sauce (McCaleb et al. 2000, Neto & Vinson 2011). Cranberry juice 
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is industrially prepared by pressing fresh berries, and the resulting liquid is filtered and 
concentrated via spray drying or reverse osmosis to yield juice powder or a concentrated syrup, 
respectively. Powder and syrup are used as ingredients for the preparation of many different 
cranberry-based products, especially juices and sweetened juice blends. The pressed berries 
may be re-infused with a sugar solution and dried to yield sweetened-dried cranberries which 
may be sold and consumed directly or used as an ingredient in other commercial food products.  
Cranberry fruit products are prominent in the U. S. dietary supplement market due to 
their purported medicinal properties, and cranberry was the number one top selling herbal 
dietary supplement in 2011, with sales of just over $40 million (Blumenthal et al. 2012). 
Cranberry dietary supplements are typically composed of fruit or juice powder in capsule form 
with additional inert ingredients that act as binders (gelatin), fillers (cellulose), or stabilizing 
agents (ascorbic acid). Fruit and juice materials may be concentrated or extracted using 
methods that are not disclosed by manufacturers to yield products that are marketed as “extra-
strength” or “concentrates.”  
Cranberry fruit and juice products have been the focus of many studies regarding 
chemical composition and biological properties and these materials will also be a focus of this 
report.  
B. Cranberry Chemical Composition 
The majority of compound isolation and characterization has been done with the ‘Early 
Black’ cultivar, in part because of its prominence in the food industry, and studies that compare 
the known chemistry of multiple varieties of cranberry typically do so with a food industry 
perspective (Justesen et al. 1998, Vvedenskaya & Vorsa 2004). The known compounds of 
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cranberry have been reviewed (Hong & Wrolstad 1986, Pappas & Schaich 2009, Neto & 
Vinson 2011) and highlights relevant to the present studies are included below. Investigation of 
cranberries using metabolomics-type methods have indicated that many thousands of 
compounds are additionally present that remain uncharacterized (Brown et al. 2012a,b). 
Flavonoids were the first compounds isolated and identified from cranberry (Grove & 
Robinson 1931) and are consequentially the best studied group of compounds. Flavonoids such 
as anthocyanins are the main pigments in the berries, and the first of these identified included 
cyanidin-3-arabinoside, peonidin-3-arabinoside, cyanidin-3-galactoside, and peonidin-3-
galactoside (Sakamura & Francis 1960, Zapsalis & Francis 1965). Many early studies involving 
cranberry flavonoid pigments followed common themes of improving color quality or color 
stability in commercial cranberry products (Fuleki & Francis 1968a–d, Fuleki & Francis 1967). 
Work on cranberry anthocyanins has also involved quantification using Matrix-Assisted Laser-
Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF-MS) and other 
methods (Wang & Sporns 1999, Krueger et al. 2004). 
Carotenoids and volatile aroma constituents were the next two groups of compounds 
investigated in cranberry. Compound identifications were based on comparisons of retentions 
times, fragmentation patterns by GC-MS, and UV spectra to those of standard compounds, and 
led to the identification of 23 carotenoids and about 45 volatile constituents (Curl et al. 1963, 
Anjou & Von Sydow 1967, Anjou & Von Sydow 1968, Croteau & Fagerson 1968). 
Studies have also examined varietal differences in relative quantities of glucose, 
fructose, sucrose, pectins, ascorbic acid, benzoic acid, and 6-benzoyl-D-glucose (Schmid 1977, 
Marwan & Nagle 1986a, Marwan & Nagle 1982), and of the flavonoid monomers catechin, 
epicatechin, myricetin, and quercetin (Wang et al. 1978, Justesen et al. 1998). 
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The identification of various cranberry bioactivities and the availability of improved 
technology and resources led additional researchers to investigate cranberry chemistry. These 
researchers examined differences in the profiles of known aromatic acids and flavonoids 
present in fresh and canned cranberry juice before and after acid hydrolysis (Chen et al. 2001), 
identified two new iridoid glucosides and several organic acids (Jensen et al. 2002), and 
reported several additional volatile constituents as part of a controlled atmosphere study 
examining the stability of berries during storage (Gunes et al. 2002). The presence of both cis- 
and trans-resveratrol in fresh cranberry juice was initially reported as part of a study to 
determine the presence and relative quantity of resveratrol in fruit juices and wines (Wang et al. 
2002), and was later confirmed independently (Rimando et al. 2004). Resveratrol was also later 
identified from other Vaccinium species (Rimando & Barney 2005, Rimando & Cody 2005). A 
series of flavonoid glycosides has been isolated from spray dried cranberry juice powder 
(Vvedenskaya et al. 2004), and several complex organic and aromatic acids, additional 
glycosylated flavonoids, plant sterols, terpenoids, a peroxypyran, two additional iridoid 
glucosides, and a depside have also been reported (Turner et al. 2007).  
Interest in the anti-adhesive properties of cranberry led to the identification of 
proanthocyanidins (PACs) as compounds of interest. Plant PACs are complex, oligomeric 
flavonoids, commonly referred to as condensed tannins. They typically occur as a complex, 
heterogeneous pools of polymers, with both A- and B-type linkages between units, and 
decoration with galloyl groups and sugars (Foo & Porter 1980, Foo & Porter 1981, Foo et al. 
2000b, Porter et al. 2001). Proanthocyanidin-enriched fractions of cranberry are typically 
prepared via extraction with EtOAc and the use of dialysis membranes and gel filtration resins 
such as Sephadex LH-20 or Sephadex G-10 (Foo & Porter 1980, Portor 1988). More soluble, 
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dialyzable, lower molecular weight (MW) polymers are typically fractionated by gel filtration 
into groups containing dimers and trimers or tetramers through octamers, while higher MW, 
non-dialyzable material (NDM) can be retained by dialysis membranes of different MW cut-
offs (Delehanty et al. 2007). Enriched fractions may then be further purified using high-
performance liquid chromatography (HPLC) combined with ultraviolet (UV) spectroscopy and 
various types of mass spectrometry (MS) to detect and isolate pure compounds (Mabry et al. 
1970, Prior et al. 2001, Berhow 2002). Using methods such as these, epicatechin dimers and 
trimers with A- and B-type linkages (Figure 1) have been isolated from fresh-pressed 
cranberries (Foo et al. 2000a,b) and from fresh cranberry juice (Vorsa et al. 2003). The NDM 
fraction of cranberry juice has been partially characterized, is reported to lack sugars, proteins, 
and other low MW compounds, and is believed to consist of PACs with MWs of greater than 
14,000 or 6,000 depending on the dialysis membrane and method used (Bodet et al. 2007b).  
The structural characteristics and complexities of purified cranberry PACs have been 
investigated using MALDI-TOF-MS with the aid of calculations to determine the number of 
polymeric units based on mass fragments (Neto et al. 2006, Howell et al. 2005, Krueger et al. 
2004, Reed et al. 2005), and MALDI-TOF-MS has been combined with ESI-MS, 13C NMR 
spectroscopy, and acid catalyzed degradation with phloroglucinol for comprehensive structural 
assignments (Foo et al. 2000b). Additional chemical analysis methods may also be used to aid 
in structural characterization (Mabry et al. 1970, Foo & Porter 1981, Berhow 2002, Gu et al. 
2003). Proanthocyanidin bioactivities are typically reported for crude PAC subfractions due to 
the structural complexity of these polymeric compounds and the difficulties of isolating pure 
entities. Proanthocyanidin-enriched extracts are typically prepared by the research group 
conducting a given biological study and are often presumed to be free of lower MW, non-PAC 
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molecules. Proanthocyanidin-enriched fractions are typically characterized by MS alone or in 
conjunction with UV spectroscopy, TLC, and other methods (Mabry et al. 1970, Porter et al. 
2001, Howell et al. 2005). Methods typically used cannot, however, assess sample purity or 
provide information about all other compounds that may be present, and the use of MS-based 
methods alone for the characterization of PAC-enriched fractions may cause minor constituents 
to be overlooked or masses to be incorrectly assigned to isobaric compounds. 
Proanthocyanidin-enriched fractions that are known to contain other flavonoid molecules with 
potential bioactivity have even been used in some assays (Kandil et al. 2002), making it 
difficult to determine if PACs or other compounds are responsible for a reported bioactivity. 
 
 
Figure 1. Structure of an oligomeric PAC with indicated A- and B-type linkages. 
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C. Cranberry Bioactivity 
Cranberry juice has been reported to possess numerous bioactivities, many of which 
have been attributed to PACs, other flavonoids, and other compounds known to be present 
(Cook & Samman 1996, Beecher 2004, Pappas & Schaich 2009, Neto & Vinson 2011). For 
many studies assessing biological properties, purified compounds with confirmed biological 
activity are not obtained. 
1. Anti-oxidant Activity 
Anti-oxidant properties of cranberry have been recognized in numerous studies and are 
typically attributed primarily to flavonoids such as PACs, flavonols, flavonol glycosides, and 
anthocyanins. Other compounds also likely contribute to the anti-oxidant properties of 
cranberry materials, may of which still have yet to be identified. Anti-oxidant assays examining 
cranberry materials have assessed the oxidation of low density lipoproteins (Porter et al. 2001, 
Wilson et al. 1998), free radical scavenging ability (Neto et al. 2003), and TPA-induced 
ornithine decarboxylase activity (Kandil et al. 2002), among others (Gunes et al. 2002). The 
anti-oxidant properties of cranberry phytochemicals are thought to be a mechanism by which 
cranberry possesses antitumor activity (Gao et al. 1994, Yan et al. 2002), and promotes 
cardiovascular health (McKay & Blumberg 2007, Porter et al. 2001, Wilson et al. 1998).  
2. Antitumor Activity 
The potential antitumor activity of cranberry has been assessed primarily using in vitro 
antiproliferation assays with various tumor cell lines (Neto 2007, Neto et al. 2008, Singh et al. 
2012, Vu et al. 2012, Kresty et al. 2008). Fractions and individual compounds from cranberry 
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have been found to inhibit the growth of a range of tumor cell lines and are proposed to act by a 
variety of mechanisms (Kandil et al. 2002; Neto et al. 2003; Neto et al. 2006). Studies 
examining the antiproliferative properties of PACs have typically used crude PAC-enriched 
materials with minimal, if any, structural elucidation of the presumed bioactive components 
(Ferguson et al. 2004, Ferguson et al. 2006; Bomser et al. 1996; Seeram et al. 2004, Seeram et 
al. 2006). Cranberry PACs may be able to prevent the proliferation of several tumor cell lines, 
but further studies are needed to identify and confirm the structures of the components 
responsible and to determine the in vivo relevance of cranberry as a cancer chemopreventative. 
3. Antimicrobial & Anti-adhesion Activity 
The reported antimicrobial properties of cranberry juice may be due, in part, to 
numerous mechanisms that work synergistically to prevent microbial growth (Leitão et al. 
2005, Shmuely et al. 2012, Lee et al. 2000). Historically, cranberry juice antimicrobial 
properties were attributed to the high benzoic acid content (Marwan & Nagel 1986). More 
recent studies examining cranberry anthocyanins and PAC-enriched fractions (Leitão et al. 
2005, Hui et al. 2004) have suggested that PACs may possess antimicrobial properties against 
certain select organisms under specific growth conditions. Decreased growth rates were 
observed for Staphylococcus aureus, while P-fimbriated Escherichia coli growth was 
unaffected in the presence of cranberry PACs (Hui et al. 2004). Cranberry juice and high-MW 
cranberry PACs are also reported to possess antiviral activity, hypothesized to be the result of 
the inhibition of viral particle binding to target cell surface receptors (Weiss et al. 2005, Lipson 
et al. 2007, Su et al. 2010). 
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Observed antimicrobial effects of cranberry juice may be due in part to indirect effects 
resulting from the inhibition of microbial adhesion to substrates. The prevention of adhesion 
can slow growth rates by preventing the binding of microbes to food sources and can prevent 
biofilm formation (Hui et al. 2004). High-MW cranberry PACs have been reported to prevent 
the formation of biofilms and subsequent oral disease and tooth decay caused by human mouth 
bacteria, including Streptococcus sp. (Duarte et al. 2006, Steinberg et al. 2004, Gregori et al. 
2007, Yamanaka et al. 2004), and Porphyromonas sp. (Labrecque et al. 2006). Cranberry juice 
has also been found to interfere with the co-aggregation of different species of oral plaque 
bacteria (Weiss et al. 1998). Cranberry juice and high-MW PACs have been shown to interfere 
with the adhesion of Helicobacter pylori to gastric mucous (Shmuely et al. 2004, Burger et al. 
2000). Studies have also shown that high-MW NDM cranberry PACs bind to the Lipid A 
moiety of lipopolysaccharides (LPS) from Gram negative bacteria, preventing the association 
of LPS with epithelial cell surface receptors and the subsequent release of signal-transduction 
components involved in inflammation (Delehanty et al. 2007, Bodet et al. 2007a,b, Johnson et 
al. 2008). Lipopolysaccharide-induced inflammation plays a role in periodontitis and inhibition 
of this process may contribute to the ability of cranberry to promote oral health (Bodet et al. 
2007a,b). Many of these studies have established that the ability of cranberry juice to prevent 
the adhesion of various bacteria is not due to cytotoxic or antimicrobial effects (Allison et al. 
2000, Steinberg et al. 2004, Yamanaka et al. 2004) or to direct interference with host cell 
surface receptors such as those on epithelial cells or mucous (Burger et al. 2000), but rather to 
direct interactions between cranberry components and microbial cells (Ofek et al. 1996, Liu et 
al. 2006, Liu et al. 2008). 
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Cranberry juice has been shown in vitro to prevent the adhesion of P-fimbriated 
uropathogenic E. coli to the receptors found on epithelial cells. Atomic force microscopy 
(AFM) studies indicate that this inhibition of E. coli adhesion is due to molecular-scale changes 
in the conformation of E. coli surface macromolecules resulting from contact with cranberry 
juice (Liu et al. 2006, Liu et al. 2008). Bioassay-guided fractionation using an in vitro human 
red blood cell (HRBC) anti-agglutination assay has led to the identification of A-type PACs 
with a degree of polymerization of 3–6 as compounds that could be responsible for the E. coli 
anti-adhesion properties of cranberry juice (Foo et al. 2000a,b). Anti-adhesion studies 
comparing PAC-enriched fractions to whole cranberry juice indicate, however, that additional 
anti-adhesion compounds may be present in the juice (Turner et al. 2005, Pinzón-Arango et al. 
2009, Holguin et al. 2008, Tao et al. 2011, Ermel et al. 2012, Kimble et al. 2014). 
Bacteria are known to bind to carbohydrate receptors on the surfaces of human 
epithelial cells using protein adhesins. These adhesins, such as the P-type and Type-1 fimbriae 
of E. coli, are differentially expressed by various strains of a given pathogen (Ofek & Beachey 
1978, Enerbäck et al. 1987, Dodson et al. 2001, Hull et al. 2002, Lane & Mobley 2007), and 
many pathogens have the ability to simultaneously express multiple types of adhesins (De Man 
et al. 1987, Sharon 2006, Pieters 2007). Different adhesins selectively bind to carbohydrate 
ligands with different structures, thereby resulting in cell and tissue tropism (Abraham et al. 
2002, Pieters 2007, Dodson et al. 2001, Strömberg et al. 1991). Compounds that mimic the 
natural binding ligands of microbial adhesins or that interfere with adhesin-ligand binding 
would be able to interfere with microbial adhesion to cell surfaces, thereby preventing 
subsequent infection (Beachey 1981, Sharon & Ofek 2000, Sharon 2006, Pieters 2007). The 
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identification of the anti-adhesive compounds present in cranberry is therefore of great medical 
interest (Sobota 1984, Ofek et al. 1991, Howell et al. 1998, Shoaf-Sweeney & Hutkins 2008). 
Several types of assays have been used to assess the E. coli anti-adhesion properties of 
cranberry. These typically measure the ability of the study organism to bind to (a) a purified 
receptor bound to an artificial substrate, (b) human red blood cells (HRBCs), or to (c) the target 
epithelial cells. Purified receptor assays are highly specific and are typically used to help 
identify the binding epitope of specific microbial adhesins (De Man et al. 1987, Zafriri et al. 
1989). Results of these assays are informative regarding adhesin binding sites and the 
mechanisms of microbial binding, but cannot be reliably extrapolated to in vivo systems. The 
PapG adhesin of P-fimbriated E. coli binds to the α-Gal-(1→4)-β-Gal disaccharide epitope 
found on the surfaces of (A1, Rh+) HRBCs causing agglutination (Leffler & Svanborg-Edén 
1980, Kallenius et al. 1980, Leffler & Svanborg-Edén 1981, Winberg 1984, Enerbäck et al. 
1987, Lane & Mobley 2007). In vitro assays that measure HRBC agglutination have been 
generally accepted as a suitable, indirect measure for bacterial adherence to eukaryotic 
epithelial cells. They typically measure hemagglutination visually, however, and may therefore 
be susceptible to inter-experiment and inter-observer variations that can make it difficult to 
quantify results (Johnson et al. 1997). Bacterial-epithelial cell adhesion assays are superior to 
bacterial-HRBC anti-agglutination assays as they more closely simulate in vivo systems. These 
assays are logistically more difficult to perform and maintain, but can provide quantifiable, 
direct measures of bacterial-epithelial cell adhesion (Turner et al. 2005, Mathison et al. 2013, 
Kimble et al. 2014). The studies discussed in this report used both bacterial-HRBC anti-
agglutination and bacterial-epithelial cell anti-adhesion assays (Howell et al. 2010, Mathison et 
al. 2013, Kimble et al. 2014) to assess fraction anti-adhesion properties. 
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D. Urinary Tract Infections & Cranberry 
Cranberry juice is commonly used as a traditional American folk remedy for the 
prevention of urinary tract infections (UTIs) and there is increasing use of cranberry dietary 
supplements for the same application (Zafriri et al. 1989, Ofek et al. 1991, Blumenthal et al. 
2012, Smith 2013). 
1. Urinary Tract Infections 
Types of UTIs include cystitis (bladder infection) and the more severe pyelonephritis 
(kidney infection) which can lead to permanent kidney damage, bloodstream infections, sepsis 
and death (Winberg 1984, Scholes et al. 2005). Nearly half of all women are believed to 
experience a UTI at some point in their lives, and recurrent UTIs are common (Kunin 1994b, 
Foxman 2010). Uropathogenic P-fimbriated E. coli (UPEC) cause up to 80% of uncomplicated, 
community-acquired UTIs (Kunin 1994b, Dowling et al. 1987, Enerbäck et al. 1987). Bacteria 
are typically inoculated into the urinary tract from the gastrointestinal (GI) tract or are 
introduced by medical devices during hospitalization (Scholes et al. 2005, Foxman 2010). 
Bacteria adhere to and then infect the cells lining the urinary tract, known as uroepithelial cells 
(UECs), causing inflammation and pain associated with uroepithelial cell shedding (Beachey 
1981, Justice et al. 2004, Mulvey et al. 1998, Hull et al. 2002). A variety of antimicrobial 
agents are used to treat UTIs, but drug resistant infections are a common problem (Kunin 
1994a, Foxman 2010). This is partly due to the formation of dormant E. coli reservoirs that are 
protected from antimicrobial agents and partly due to the presence of resistant E. coli strains in 
the GI tract that serves as the infection source (Mulvey et al. 2001, Justice et al. 2004, Howell 
& Foxman 2002). 
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The high incidence of UTIs results in an estimated $2.3 billion in annual (2010) direct 
health care costs and other societal costs (Foxman 2010). As the initiation of a UTI requires 
bacterial adhesion to uroepithelial membranes, compounds or products that interfere with such 
adhesion are of great clinical interest (Sobota 1984, Sharon & Ofek 2000, Howell & Foxman 
2002). Women who have recurrent UTIs may be given low doses of antimicrobial agents as 
prophylaxis, but such prophylactic treatments can eventually lead to increased drug resistance 
for the strains of uropathogenic E. coli that infect these women (Gupta et al. 2001, Kunin 
1994a, Howell & Foxman 2002). Prevention of UTIs is generally preferable to treatment with 
antimicrobial agents, as the use of preventive strategies would not provide a selective pressure 
for the development of antibacterial drug resistance (Kunin 1994a, Signoretto et al. 2012, Reid 
et al. 2003). Preventative therapies are also generally equally effective against both drug-
susceptible and drug-resistant strains of bacteria (Howell & Foxman 2002, Shoaf-Sweeney & 
Hutkins 2008). 
2. Clinical Use of Cranberry for UTIs 
Anecdotal and clinical evidence supports the ability of cranberry juice to help prevent 
UTIs (Zafriri et al. 1989, Avorn et al. 1994, Ofek et al. 1991, Ofek et al. 1996, Reid et al. 
2003, Howell et al. 2010). These reports often employ cranberry juice, cranberry juice 
concentrate, or cranberry juice powder, and the use of native cranberry juice material rather 
than extracts or “enriched” fractions may have contributed to the success of these studies (Reid 
et al. 2001, Howell et al. 2010, Wang et al. 2012a, Jepson et al. 2012). In contrast, other 
reports are inconclusive or do not directly support the effectiveness of cranberry as a 
preventative agent, and these studies often used extracts or cranberry dietary supplements with 
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unknown chemical composition (Beerepoot et al. 2011, Jepson et al. 2012). Studies that have 
used meta-analyses to evaluate available clinical trials concerning the use of cranberry for the 
prevention of UTIs have reached differing conclusions as to whether cranberry should be 
recommended as a UTI preventative (Wang et al. 2012a, Jepson et al. 2012, Smith 2013). 
These conflicting reports highlight the current mix of results that exists regarding the efficacy 
of cranberry products and prompt questions regarding which cranberry products are the most 
effective. Many of these studies may be assessing the efficacy of specific preparations or 
products rather than the efficacy of actual cranberry constituents, and a better understanding of 
cranberry bioactive constituents is necessary to resolve these questions and conflicts.  
3. Cranberry Mechanism of Action Hypotheses for UTI Prevention  
It was once hypothesized that cranberry juice acidified the urine, dropping the pH 
through the action of hippuric acid and thereby creating an unfavorable environment for 
bacterial growth in the bladder and the rest of the urinary tract (Bodel et al. 1959). This 
hypothesis was later disproven (Papas et al. 1968, Ofek et al. 1991) and has since been 
replaced by the hypothesis that certain high-MW constituents of cranberry prevent infections 
by inhibiting the adherence of uropathogenic bacteria to UECs (Sobota 1984, Zafriri et al. 
1989, Avorn et al. 1994, Ofek et al. 1996, Howell et al. 1998). Studies using AFM have shown 
that cranberry juice constituents have direct effects on the conformation E. coli P-fimbriae (Liu 
et al. 2006, Liu et al. 2008). The results of UPEC-UEC anti-adhesion assays validated with 
galabiose and globotriose provide strong evidence that cranberry constituents bind to microbial 
cells rather than to epithelial cells (Turner et al 2005). Cranberry juice and human urine 
produced after cranberry consumption both possess anti-adhesion activity (Howell et al. 2010, 
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Tao et al. 2011) and it has therefore been assumed that the compounds responsible for the 
activity of both materials are structurally related and present in both juice and urine. The active 
compounds present in urine are currently believed to be PACs or PAC-derived metabolites due 
to the reported in vitro anti-adhesion properties of A-type PACs isolated from cranberry 
(Howell et al. 1998, Foo et al. 2000a,b), and to the anti-adhesion activity of human urine 
produced after the consumption of cranberry powder standardized for PAC content (Howell et 
al. 2010), but PAC-related anti-adhesive metabolites have yet to be identified in mammalian 
urine.  
E. Anti-adhesive Urinary Metabolites of Cranberry Juice 
Many different digestive processes may apply to generate the anti-adhesive urinary 
metabolites of cranberry. Urinary metabolites are water soluble and chemical components are 
typically of medium to low MW. Many types of compounds are excreted into human urine, and 
urine metabolomics studies indicate that thousands of individual compounds are present in a 
given urine sample, many of which are unknown (Saude et al. 2007, Bouatra et al. 2013).  
Compounds with high polarity may be absorbed directly into the bloodstream and 
filtered through the kidneys into the urine within a relatively short period of time without 
metabolic modification (Brunton 2011, Rowland & Tozer 2011). Compounds with low polarity 
may be modified via enzymatic and nonenzymatic metabolic and catabolic pathways to yield 
more polar or lower MW metabolites, and may therefore take a longer period of time to reach 
the urine. Processes may include oxidation, hydroxylation, hydrolysis, and the addition of 
sulfate, glucose, glucuronic acid, or other polar groups via Phase I and Phase II metabolic 
pathways (Brunton 2011, Rowland & Tozer 2011). Phase I enzymes involved in these 
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processes typically include cytochrome P450 oxidases and reductases, and various esterases 
and hydrolases, among others. Phase II enzymes that conjugate low-polarity ingested 
compounds to more polar groups include glutathione S-transferases, glycosyl transferases, and 
acetyl transferases, among others. In general, lower-polarity and higher-MW compounds are 
more likely to be excreted through the fecal route. In the lower digestive tract, microbial 
enzymatic biotransformations can then occur to modify ingested compounds, yielding higher-
polarity and lower-MW metabolites that are then absorbed into the bloodstream and possibly 
excreted via urine.  
Little is currently known regarding in vivo PAC absorption and metabolism, but the 
chemical nature of PACs suggests that these compounds are unlikely to be directly excreted 
into urine. Many flavonoids are excreted into the feces, and may be derivatized or degraded by 
gut microflora before re-entering the bloodstream to be later excreted in the urine (Schneider & 
Blaut 2000, Braune et al. 2001, Rios et al. 2003, Blaut et al. 2003, Goldin 1986). A PAC-type 
drug has recently been approved by the U.S. FDA for the treatment of non-infectious diarrhea 
in HIV patients (Frampton 2013), further suggesting fecal elimination of PACs and similar 
compounds. It is also likely that ingested PACs bind to other food molecules and protein 
receptors along the digestive tract due to the tendency of PACs to form non-specific, covalent 
bonds with proteins (Zhu et al. 1997). Such protein binding may prohibit or delay absorption 
into the bloodstream. 
Flavonoids that have been identified in urine are typically glucuronated, sulfated, or 
glycosylated derivatives of ingested compounds with relatively low concentrations of free 
phenolic forms (Hollman et al. 1995, Hollman et al. 1999, Harada et al. 1999, Li et al. 2001, 
McGhie et al. 2003, Shimoi et al. 2003, Daykin et al. 2005, Kumazawa et al. 2004). If PACs 
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are excreted into urine, it would therefore likely be as either conjugated or derivatized forms of 
the known anti-adhesive PAC oligomers (Rechner et al. 2002). However, analytical studies that 
have specifically searched for the presence of flavonoids and related metabolites in urine after 
cranberry consumption have been unsuccessful at identifying PACs (Wang et al. 2012b, 
Iswaldi et al. 2013). Many urinary metabolite studies depend upon comparisons of unknown 
metabolites to reference compounds to confirm compound identifications, and the relative lack 
of PAC standards makes the identification of these structurally complex, high-MW compounds 
in urine impractical using typical, standards-based methods. 
F. Objectives  
The primary objectives of these studies were therefore (1) to isolate and identify the 
urinary metabolites of cranberry juice that are responsible for the prevention of UPEC 
adherence, and (2) to identify the compounds present in cranberry that are related to the anti-
adhesive urinary metabolites.  
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CHAPTER 2: PORCINE URINARY METABOLITES OF CRANBERRY 
A. Introduction 
Human volunteers who consume cranberry juice produce urine that has anti-adhesive 
properties (Howell et al. 2005, Howell et al. 2010, Tao et al. 2011). Anti-adhesion bioactivity 
appears shortly after consumption of the juice until about eight hours later, and maximum anti-
adhesion effects are observed within four to six hours after ingestion (Howell et al. 2010, Tao 
et al. 2011). This suggests rapid absorption and excretion of anti-adhesive cranberry 
metabolites into the urine. 
The identification of the anti-adhesive urinary compounds produced after cranberry 
consumption is essential for further studies regarding the efficacy and bioactive constituents of 
cranberry, but questions exist regarding whether PACs are the rapidly excreted urinary 
metabolites with anti-adhesion properties (Chapter 1, Section E). The primary objective of this 
study was therefore to isolate and identify the compounds responsible for the anti-adhesion 
properties of urine after the consumption of cranberry products. This objective was based on 
the hypothesis that the anti-adhesive urinary metabolites of interest were either PACs or 
metabolically derived from PACs (Howell et al. 1998, Howell et al. 2005). These hypothesized 
anti-adhesive metabolites were expected to be structurally related to the PACs previously 
identified from cranberry that have been shown to have in vitro UPEC-HRBC anti-
agglutination activity (Foo et al. 2000a,b). 
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Methods used for this study included the collection of urine after cranberry 
consumption, bioassay testing using a UPEC-HRBC anti-agglutination assay, and bioassay-
guided isolation of active fractions and metabolites, followed by structural characterization of 
putative active compounds using various methods. Sows were chosen to generate cranberry-
derived urinary metabolites due to their similar physiology and dietary adaptations to those of 
humans (Pond 1986, Tumbleson 1986, Tumbleson & Schook 1986), and because they can be 
fed a consistent diet supplemented with relatively large quantities of cranberry powder per day. 
Sows also generate the volumes of urine (~1–2 L/d) necessary to provide sufficient material for 
bioassay-guided fractionation and metabolite purification.  
B. Materials & Methods 
1. General Experimental Equipment 
Lyophilization was performed using a variety of Labconco FreeZone Systems housed in 
the NCNPR and Faser Hall at the University of Mississippi. All sample materials were stored at 
–20 or –60 oC. The centrifuge used was a Thermo IEC Centra CL3R instrument with 
exchangeable holders for different sizes of Falcon tubes. Early analytical and preparative 
HPLC separations of FA urine fractions were performed on a Waters Delta Prep 4000 system 
with #5 pump heads and a Prep LC Controller connected to a 2487 dual-wavelength UV 
detector. Analytical HPLC separations were later primarily performed on a Waters Alliance 
2695 Separations Module with a 996 photodiode array (PDA) UV detector connected in series 
to a Polymer Laboratories PL-ELS2100 analytical scale evaporative light scattering detector 
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(ELSD). Preparative HPLC separations for H and I urine fractions were performed on a Waters 
Delta Prep 4000 system with #5 pump heads and a Prep LC Controller connected in series to a 
2487 dual-wavelength UV detector and a Polymer Laboratories PL-ELS1000 ELSD. A Bruker 
MicroTOF-Agilent LC 1100 series instrument was used to acquire LC-MS data with a 
Phenomenex Luna C8 column (4.6 x 150 mm) at 27 oC, with a flow rate of 0.4 mL/min and a 
20 min gradient from 20–100% MeCN or MeOH with 0.1% formic acid. Additional equipment 
used by the CCRC is discussed in each respective section.  
Regular solvents, TLC plates, HPLC solvents, and most reagent chemicals were 
obtained from Fisher Scientific, Inc. Additional reagents, Sephadex LH-20, and Diaion and 
XAD resins were obtained from Sigma-Aldrich, Inc., and SPE sorbents were obtained from 
Phenomenex Inc. and Waters, Inc. Columns for HPLC were obtained from Waters, Inc., and 
HPLC sample filters were obtained from Millipore, Inc. Water used for all experiments was 
obtained from ultrafiltration systems located in Faser Hall or NCNPR. Water for HPLC was 
additionally filtered within two days prior to use. 
2. NMR Spectroscopy 
Two different Bruker Avance III 400 MHz NMR instruments were used to acquire 
NMR data. These instruments were housed in Faser Hall at the University of Mississippi, 
School of Pharmacy, and were equipped with UltrashieldTM and UltrashieldTM Plus magnets 
and 5 mm probes. Additional spectra were recorded on a Bruker Avance 700 MHz instrument 
equipped with a 5 mm CPTCI cryoprobe, housed in the Bruker facilities in Billerica, MD.  
Samples for NMR analysis were prepared by dissolving 2–10 mg of material in a 
minimal amount of high purity DMSO-d6 or D2O (Cambridge Isotope Laboratories, Inc.). 
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Selected samples were repeatedly lyophilized with D2O to avoid interference from the water 
resonance. Either DMSO-d6 (99.99%) or D2O (99.99%) was used for most sample preparations, 
and selected samples in NMR tubes were topped with argon gas to delay the absorption of 
atmospheric water prior to data acquisition. The use of pulse programs for water suppression 
during data acquisition was minimized to avoid resonance loss in this region. Spectra for most 
fractions were recorded at 400 MHz and additional high-resolution spectra were obtained at 
700 MHz for use in assigning the structure of 1.  
3. Source Material 
Research-grade, spray-dried cranberry (Vaccinium macrocarpon Ait., Ericaceae) juice 
powder (Ocean Spray Cranberries, Inc.) was supplied through NIH grant no. 1R21AT002076-
01 to both the University of Wisconsin, Madison, WI, (UWM) for the feeding of swine, and to 
the University of Mississippi, Oxford, MS, (UM) for preliminary separations and analytical 
studies. 
Five separate feedings produced the urine samples used for these studies, four of which 
(Table 1) are discussed in this chapter. Animal protocols were approved by the UWM Review 
Committee (approval number A3368-01, 04/25/2002). Adult female sows (~160 kg each, 1–2 
yrs of age) used in this study were housed in gestation crates at the Livestock Laboratory on the 
UWM campus and were offered a maintenance amount of a basal diet consisting of corn and 
soybean supplemented with tryptophan, methionine, lysine, and various vitamins and minerals 
as necessary to meet the recommended maintenance requirements of the National Research 
Council (National Research Council 1998).  
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Research-grade cranberry juice powder as described above was mixed with basal diet 
components at an administration rate of 800 g powder/d/sow (~5 g/kg body weight) for 3–5 d 
prior to collection of treatment urine. Feeding was continued through a collection period of 3–4 
d and urine was collected via Foley catheters (2–6.5 L per sow). Control urine (~2 L) was also 
collected via catheter prior to initiating the third feeding of cranberry powder. Urine was 
collected in containers placed over ice, containers were emptied at 4 h intervals, and collected 
urine was frozen. Animals were monitored two times per day and Foley catheters checked 
regularly by research staff during collection periods.  
The D and E urine materials were lyophilized as whole urine by UWM prior to 
shipment to UM for chemical analysis. The F, H and I urine samples were frozen at –20 oC 
immediately after collection, and were shipped to UM as frozen liquid on dry ice. Aliquots of 
each fresh urine (~5 mL each) were frozen and sent to the laboratory of Dr. Amy B. Howell at 
the Philip E. Marucci Center for Blueberry and Cranberry Research, Rutgers University, 
Chatsworth, NJ, (RU) for preliminary testing in the UPEC-HRBC anti-agglutination assay to 
confirm anti-adhesion activity (not shown) prior to materials being shipped to UM.  
Table 1. Details of swine urine collections used as source materials. 
Feeding 
Period Urine Collection Dates 
Received 
by UM 
Animal 
Number 
Urine 
Vol.a (L) 
Solute 
Conc.a 
(g/L) 
UM 
Sample 
Code 
1 2005/12/19b 2006/02 NAb 2.5 11 D 
3c 2006/10/27 (control, 1 day) 2006/12 5081 2.0 18 FC 
3 2006/10/31 – 2006/11/02 (3 days treatment) 2006/12 5081 7.0 20 F 
4 2008/06/24 – 2008/06/27 (4 days treatment) 2008/07 5023 3.5 17 H 
5 2008/06/24 – 2008/06/27 (4 days treatment) 2008/07 8401 2.5 18 I 
a Approximate values. b Incomplete information was provided for this material. c The second 
feeding, designated sample E, was used for numerous studies, but this parent material was 
ultimately found to have questionable UPEC-HRBC anti-agglutination activity. 
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4. Anti-agglutination Assay 
The anti-agglutination assay used for this study was performed at RU using methods 
described previously with minor modifications (Foo et al. 2000a,b). This assay has been used 
to identify PACs as anti-adhesive constituents of cranberry samples (Foo et al. 2000a,b) and to 
detect anti-adhesion properties of human urine samples after cranberry product consumption 
(Howell et al. 2005, Howell et al. 2010). The results of this assay have been accepted as as 
representative of the ability of UPEC to adhere to epithelial cells (see Chapter 1, Section C3). 
a. Bacterial Strains  
Clinical strains of uropathogenic P-fimbriated E. coli (UPEC) were isolated and 
cultured as described previously (Foo et al. 2000a,b) with the modifications that P-fimbriated 
bacteria were not washed to prevent fimbriae from breaking off and were suspended directly in 
phosphate buffered saline (PBS, pH 7.0) at a concentration of 5 x 108 bacteria/mL PBS for 
testing. Cultures were kept on agar slants at 4 oC for short-term use over several months and 
strains were kept frozen at –70 oC in tryptose broth (30% glycerol) for long-term storage. 
b. Hemagglutination Assessment 
Test samples were dissolved in different volumes of PBS based on the amount of 
sample provided (e.g. 150 μL for 10–30 mg, 200 μL for 40–70 mg, 400 μL for > 80 mg), and 
adjusted to neutral, physiologic pH (between 5.5 and 7.0) with 1 N NaOH. Serial two-fold 
dilutions of each test sample were prepared in PBS and were tested as described previously 
(Foo et al. 2000a,b). For ease of reference these methods are reproduced as follows:  
“A 30 µL drop of each dilution was incubated with 10 µL of bacterial 
suspension on the lid of a 24-well polystyrene plate for 10 min at room 
temperature on a rotary shaker. Freshly-drawn HRBCs (A1, Rh +) [donated 
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by human volunteers] were suspended (3%) in PBS and added separately 
(10 µL drops) to test suspensions. Suspensions were incubated for 20 min 
on a rotary shaker at room temperature and evaluated microscopically for 
the ability to prevent agglutination. The final dilution was recorded at 
which agglutination suppression by the test fraction occurred. Controls 
included wells containing bacteria + PBS, HRBC + PBS, bacteria + test 
fraction, HRBC + test fraction, and bacteria + HRBC.” (Foo et al. 2000b)  
This assay has been reported to detect PAC anti-adhesion activity at 25–50 µg/mL when 
performing two-fold serial dilutions with a starting amount of 1 mg purified PAC material (A. 
B. Howell 2006, personal communication). 
The microscopic evaluation for agglutination involved a visual assessment using a 0–4 
scale as established by RU (Table 2). For example, a visual agglutination score (VAS) of '0' 
represented 90–100% HRBC agglutination (Figure 2a) and therefore no inhibition of E. coli 
adhesion by the test sample, while a score of '4' represented 0–5% HRBC agglutination (Figure 
2b) and total inhibition of E. coli adhesion by the test sample. Dilution endpoints were reported 
as the lowest dilution concentration at which the sample received a VAS of ‘1’ or ‘2’ with the 
next dilution receiving a VAS of ‘0’ and having no anti-agglutination activity. Lower 
concentration dilution endpoints therefore indicated higher relative anti-agglutination activity.  
Table 2. Assignment criteria for visual agglutination score (VAS) values associated with 
UPEC-HRBC agglutination. 
VAS HRBC 
Agglutination (%) 
Inhibition of E. coli Adhesion 
by Test Sample (%) 
0 90–100 0 
1 60–90 10–40 
2 30–60 40–70 
3 5–30 70–95 
4 0–5 95–100 
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Figure 2. Light microscope image of HRBC agglutination by E. coli in the presence of inactive 
(a) and active (b) samples. 
The VAS value assigned to panel (a) would be ‘0’ as clumps of HRBCs have formed, while the 
VAS value assigned to panel (b) would be ‘4’ as no HRBC agglutination has occurred. 
Photographs provided by A. B. Howell. 
 
c. Test Samples  
Samples were submitted to RU as dry powders (~10–400 mg per sample) and were 
shipped overnight on cold packs or dry ice. Sample weights were provided, but sample 
identities were coded and samples were randomized within a set to avoid possible evaluation 
and test sequence biases. Duplicate or triplicate samples were submitted for parent materials 
and some fractions, but sample quantity limitations and the labor-intensive nature of the assay 
made it impractical to submit triplicate samples for every sample tested in every sample set. To 
account for assay variations over time, selected urine fractions were repeatedly tested with each 
set of samples submitted. These included control urine samples and fractions and the parent 
fractions for each separation step.  
d. Interpretations of Assay Raw Data  
Assay results were interpreted by UM using a qualitative scoring system similar to one 
previously published in association with this assay (Foo et al. 2000a). The scoring system used 
for this study assigned one of five scores (UM Scores) to each sample tested, based on four 
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different criteria (Table 3). The majority of UM Score assignments were made based primarily 
on dilution endpoint values, with secondary consideration given to the number of two-fold 
dilutions applied to each sample. The third and fourth criteria, involving the comparisons of 
fractions to parent materials or replicates, respectively, were considered but were given lower 
priority as they did not apply for all samples. The UM scores were used to determine whether a 
sample was or was not considered to be active and possibly able to prevent UPEC-epithelial 
cell adhesion. 
Table 3. Description of the qualitative scoring system developed by UM to interpret the results 
provided by the UPEC-HRBC anti-agglutination assay. 
The dilution endpoint values and number of two-fold dilutions for individual samples can be 
found in the tables of Appendix B-3. Samples were assessed within an individual sample set 
test date and then across test dates. Scoring criteria were applied in the order shown to 
determine the probable activity of individual samples and assign a UM Score. Replicates were 
not available for most samples. 
Scoring Criteria: First Second Third Fourth 
UM 
Score 
UM Assessment 
of Sample 
Activity 
Dilution 
Endpoint 
Range 
No. of 
Two-fold 
Dilutions 
Sample 
Compared to 
Parent Fraction: 
Replicates  
(if available): 
+ + active < 10 mg/mL 5+ more active  show activity 
+ probably active 10–30 mg/mL 4 more active show activity 
+/– may or may not be active  30–60 mg/mL 3 about the same  
may or may not 
show activity 
– probably not active 60–100 mg/mL 2 less active show no activity 
– – not active > 100 mg/mL 0, 1 less active show no activity 
5. Initial Characterization & Method Development 
The premise that the anti-adhesive metabolites of cranberry would be polyphenolic 
compounds such as PACs or related flavonoids was used to guide initial method development 
(Mabry et al. 1970, Porter 1988, Berhow 2002). Numerous methods were therefore applied in 
attempts to enrich for putative PAC metabolites. These included solvent-solvent extraction, gel 
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filtration with Sephadex LH-20 and G-10, column chromatography with silica or C18 packing, 
hydrophobic extraction resins (Diaion, XAD-8 and XAD-16), and many types of solid phase 
extraction (SPE) cartridges (Waters Oasis® and Phenomenx®) with sorbents including C8, C18, 
WAX, WCX, MAX, MCX, HLB, phenyl and others. Numerous TLC sorbents and solvent 
systems were also employed in efforts to visualize and characterize fraction components. The 
details of these methods have been omitted because they did not yield usable results.  
6. Enrichment for Active Urinary Components 
a. Urine Processing & Extractions 
Frozen liquid urine (F, H, & I) was thawed overnight at room temperature. The general 
processing and purification protocols shown in Figure 3 were applied to four batches of urine 
(FC, F, H, and I). Crude urine was centrifuged (5 min at 2500 RPM) or gravity filtered through 
filter paper (Whatman #1) to remove casts and solids. A portion of each clarified urine was 
removed and lyophilized to serve as pre-extraction control samples. Clarified urine aliquots (1 
L each) were partitioned with EtOAc (2–4 x 250 mL) or EtOAc:MeOH (2–4 x 50:250 
MeOH:EtOAc). After solvent partitioning, EtOAc and aqueous urine fractions were evaporated 
under reduced pressure with a water bath temperature of ~40 oC to remove organic solvents and 
decrease the total volume of aqueous samples. EtOAc fractions were re-dissolved in water, 
aqueous samples were diluted as necessary, and all samples were frozen and lyophilized. 
Repeated dilution and lyophilization was often necessary for highly hygroscopic samples. All 
samples were stored as dry powders or concentrated syrups (hygroscopic samples) in airtight 
containers at –20 oC. Selected samples were submitted to the anti-agglutination assay as dry 
powders. 
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Figure 3. General purification protocol used for isolation of active urine metabolites. 
 
Control urine (FC) was partitioned using the procedures developed for the active urine 
samples, but was processed only through to the stage of analytical reverse-phase HPLC 
analysis due to the absence of oligosaccharide components. Approximately 1.5 L raw urine was 
centrifuged and filtered and the clarified urine (1.5 L) was extracted with EtOAc (2 x 375 mL). 
Both fractions were concentrated, diluted, and lyophilized as before. The aqueous fraction 
could not be successfully dried by lyophilization and instead produced a concentrated, viscous, 
gooey material with about 90–95% of the original water removed. A portion of this material 
(FC1, 15–20 mL, resulting from 250 mL of the concentrated aqueous fraction) was separated 
on a Sephadex LH-20 column (4 x 33 cm) using an isocratic 75% EtOH solvent system, a flow 
rate of 0.8–1.2 mL/min, and a collection time of 5 min/tube (Appendix A color plates: Figure 
95). Fraction composition was compared by TLC on silica (MeOH:EtOAc:water, 8:1:1, 
sprayed with ninhydrin) and fractions were combined to give three fractions (FC1-1, 3.539 g; 
FC1-2, 3.065 g; and FC1-3, 0.233 g). Even with enrichment, control urine fraction FC1-1 
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lacked characteristic oligosaccharide components detectable by HPLC-ELSD or NMR 
spectroscopy, and further HPLC separation was not pursued. Control urine fractions were 
submitted to the anti-agglutination assay as negative controls. 
A portion of the raw I urine sample (~250 mL) was used for a rudimentary form of 
stability testing. This material was mixed with 60 mL MeOH and left covered in a 1 L 
Erlenmeyer flask at room temperature with ambient lighting for a period of three months. After 
three months, this solution (IZ) was centrifuged, filtered, extracted with EtOAc (150 x 4), and 
the resulting fractions lyophilized to yield IZ-A (3.573 g) and IZ-E (0.048 g). A portion of the 
IZ-A sample was submitted to the anti-agglutination assay to determine if activity remained in 
the aqueous fraction after the stability treatment described.  
b. Sephadex LH-20 Chromatography 
Aqueous urine fractions (10–50 g per column; various loading concentrations in eluting 
solvent) were loaded onto Sephadex LH-20 columns (various dimensions) and eluted with 50 
or 70% EtOH (isocratic) with gravity fed solvent and various flow rates (Tables 4–6; Appendix 
A color plates: Figures 96, 97). Fractions (5 to 25 mL each) were collected using an automated 
fraction collector and tubes were combined based on appearance and relative elution volume. 
Selected preliminary fractions and Sephadex LH-20 fractions were submitted to the anti-
agglutination assay for testing. Active and putatively active Sephadex LH-20 fractions were 
recombined and further purified as described below using additional Sephadex LH-20 columns 
(for the FA sample) and reverse and normal phase HPLC with UV and ELS detection.  
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Table 4. Details of multiple Sephadex LH-20 separations for the F aqueous urine sample. 
The total amount of active material (FA, 1.747 g) recovered from all five columns accounted 
for 1.3% of the total loaded samples (133 g) and contained both active and inactive 
components.  
Column Designation F1 F2 F3 F4 F5 
Amount of Loaded 
Material (g) 10.0 14.0 10.0 50.4 48.5
Loaded Volume & 
Concentration  
45 mL
222 mg/mL
36 mL
388 mg/mL
31.5 mL
317 mg/mL
120 mL 
417 mg/mL 
100 mL
485 mg/mL
Column Dimensions 
(cm; width x height) 5.5 x 32 7.5 x 5 5.5 x 34.5 10 x 24 10 x 24
Solvent Composition 50% EtOH 70% EtOH 50% EtOH 70% EtOH 70% EtOH
Solvent Flow Rate 
(mL/min) 1.8–2.0 1.0–1.2 1.2–1.4 2.0–4.0 3.0–5.0
Active Material 
Total Elution 
Volume (mL) 
150 50 114 456 572
Active Fractions 
F1-1
F1-2
F1-7a
F2-1
F2-2b
F3-1
F3-2
F4-1 
F4-2 
F5-1
F5-2b
Total Active 
Material per Column 
(g) 
0.239 0.287 0.138 0.356 0.727
Active % of Loaded 
Material 2.39% 2.05% 1.38% 0.71% 1.50%
a Activity in this sample was the result of contamination with part of fraction F1-2 during 
material transfers. 
b These samples did not show activity but were included in recombined FA sample to ensure 
full recovery of potentially active metabolites. 
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Table 5. Details of Sephadex LH-20 separation for the recombined, activity-enriched FA 
sample. 
The total amount of active material recovered from this column (0.917 g) accounted for 54.5% 
of the loaded FA sample contains primarily active components, and is equivalent to 0.7% of the 
total amount of separated F samples (133 g).  
Column Designation FA 
Amount of Loaded Material a  1.683 g 
Loaded Volume & Concentration  5 mL; 337 mg/mL
Column Dimensions (width x height) 2.5 x 40.5 cm
Solvent Composition 75% EtOH
Solvent Flow Rate  0.5–1.0 mL/min
Active Material Total Elution Volume  200 mL
Active Fraction FA1 (0.030 g)FA2 (0.887 g)
Total Active Material per Column 0.917 g
Active % of Loaded Material 54.5%
a Approximately 0.06 g of FA was reserved as a bioassay testing control. 
 
 
Table 6. Details of Sephadex LH-20 separations for the H and I urine samples. 
Combined oligosaccharide-containing fractions (1.334 g) comprised approximately 1–2% of 
the total amount of separated material (69 g) and contained oligosaccharides with putative 
activity as well as other, unrelated compounds. 
Column Designation HF1 HF2 IF1 IF2 
Amount of Loaded Material (g) 10 40 30 14
Loaded Volume & 
Concentration  
30 mL
333 mg/mL
125 mL
320 mg/mL
50 mL 
300 mg/mL 
50 mL
280 mg/mL
Column Dimensions 
(cm; width x height) 7 x 38
10 x 25 7 x 38 7 x 38
Solvent Composition 70% EtOH 70% EtOH 70% EtOH 70% EtOH
Solvent Flow Rate (mL/min) 1.0–1.5 1.5–2.0 1.0–1.5 1.0–1.5
Total Elution Volume for 
Oligosaccharide-containing 
Fractionsa (mL) 
350 450 380 200
Oligosaccharide-containing 
Fractionsa 
HF1-1
HF1-2
HF2-1
HF2-2
IF1-1 
IF1-2 
IF1-3 
IF2-1b 
IF2-2b 
Oligosaccharide Material per 
Column (g) 0.148 0.607 0.425 0.154
Activec % of Loaded Material 1.48% 1.52% 1.42% 1.10%
a HF1 fractions were tested in the Rutgers assay. HF2, IF1, and IF2 fractions were compared by 
HPLC to HF1, FA1, and FA2 fractions to direct isolation efforts while conserving material. 
b The IF2 fractions were combined with the respective IF1 fractions prior to later separations. 
c Putative activity based on composition comparisons using HPLC and NMR. 
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7. Isolation of Oligosaccharides by HPLC 
 Analytical scale HPLC was performed on a Waters 2695 separations module equipped 
with a Waters 996 PDA detector connected in series to a Polymer Laboratories PL-ELS2100 
ELSD. Preparative HPLC separations were performed using a Waters Delta Prep 4000 
chromatographic system equipped with an LC controller and a 2487 dual-wavelength UV 
detector connected in series to a Polymer Laboratories PL-ELS1000 ELSD. Preparative scale 
fractions were collected in parallel with ELSD monitoring through the use of a flow splitter 
installed in the output line after the UV flow cell. This device directed approximately 0.5–3 
mL/min of eluent to the ELSD, allowing the rest to be collected. For Polyamine semi-
preparative separations, the HPLC instrument was configured with analytical scale tubing, the 
analytical-scale UV detector flow cell, and split detection-collection with ~0.5–1 mL/min of 
eluent delivered to the ELSD and the remaining ~2–2.5 mL/min delivered to a collection 
vessel. For AtldC18 preparative separations, the HPLC instrument was configured with 
preparative scale tubing, the preparative-scale UV detector flow cell, and split detection-
collection with ~1–3 mL/min of eluent delivered to the ELSD and the remaining ~22–24 
mL/min to a collection vessel. System pressure data was acquired for all separations to monitor 
system and column performance. 
Analytical columns used included a Waters Atlantis dC18 (AtldC18) column (4.6 x 150 
mm, 5 µm particle size), a YMC Polyamine II (Polyamine) column (10 x 150 mm, 5 µm 
particle size, 12 nm pore size), and a Waters XTerra MS C18 (XTMSC18) column (4.6 x 150 
mm, 5 µm particle size). The AtldC18 and XTMSC18 analytical columns were both equipped 
with appropriate guard columns (4.6 x 20 mm). Analytical flow rates of 1–3 mL/min were 
typically used. The AtldC18 column was used with either water:MeCN or water:MeOH 
33 
 
gradients and a flow rate of 1 mL/min with a commonly used solvent systems of 100% water 
for 5 min, 100% water to 30% MeOH over 30 min, and 30 to 100% MeOH over 20 min. A 
commonly used solvent system for the Polyamine column consisted of 5 min at 65% MeCN, 
followed by a gradient from 65 to 45% MeCN over 25 min, with a flow rate of 2–3 mL/min for 
analytical separations. All columns were equilibrated in a minimum of 10 column volumes of 
the initial solvent for each separation. Reverse phase samples were dissolved in a minimum 
volume of water, while normal phase samples were dissolved in a minimum amount of either 
DMSO, water, or, at most, 60% MeOH. Samples were syringe filtered with 0.2 μm filters 
(PTFE or Nylon, 13 or 33 mm diameter) unless otherwise indicated, and various amounts of 
material were injected per separation depending on the nature of the sample, the column, and 
chromatographic conditions used. Typical ELSD settings for analytical AtldC18 and 
XTMSC18 separations were a gas flow rate of 0.8–1.2 SLM, an evaporator temperature of 100 
oC, and a nebulizer temperature of 50 oC, and those for the Polyamine column were a gas flow 
rate of 1.2–1.4 SLM, an evaporator temperature of 90 oC, and a nebulizer temperature of 50 oC. 
These values remained constant throughout each separation and the ELSD was allowed to 
equilibrate for at least 30 min at the desired settings prior to initial data acquisition.  
Columns used for preparative and semi-preparative separations included an AtldC18 
column (19 x 250 mm, 10 µm particle size), and a YMC Polyamine II column (10 x 150 mm, 5 
µm particle size, 12 nm pore size), respectively. Guard columns were not used. Instrument 
parameters, solvent systems, and sample preparation methods used for semi-preparative and 
preparative separations were based on analytical methods and were scaled appropriately to 
maintain chromatographic resolution. Commonly used solvent flow rates for the preparative 
AtldC18 and semi-preparative Polyamine columns were 20–25 and 4–6 mL/min, respectively, 
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with ~0.5–1 mL/min directed to the ELSD. Various amounts of material were injected per 
separation, depending on the nature of the sample, the column, and chromatographic conditions 
used (Tables 16, 20). An example method for the preparative AtldC18 column used 
MeOH:water, a flow rate of 25 mL/min, and 100% water for 5 min, 100% water to 20% MeOH 
over 30 min, 20% MeOH to 100% MeOH over 10 min, 3 min at 100% MeOH, followed by a 
17 min gradient from MeOH to 100% water with an equilibration of 10 min prior to the next 
separation. An example method for the Polyamine column used MeCN:water, a flow rate 4 
mL/min, and 65% MeCN for 5 min, 65–45% MeCN over 25 min, and a 3 min gradient to 65% 
MeCN, followed by equilibration in 65% MeCN. 
Typical ELSD settings for the AtldC18 preparative separations were a gas flow rate of 
0.8–1.2 SLM, an evaporator temperature of 100 oC, and a nebulizer temperature of 50 oC, while 
those for the Polyamine semi-preparative separations were a gas flow rate of 0.8–1.2 SLM, an 
evaporator temperature of 90 oC, and a nebulizer temperature of 45 oC. These values remained 
constant throughout each separation and the ELSD was allowed to equilibrate for at least 30 
min at the appropriate settings prior to initial data acquisition.  
Fractions collected by preparative or semi-preparative HPLC were recombined based on 
retention time and chromatographic profiles and were concentrated under reduced pressure 
with a water bath temperature of ~40 oC to remove solvent and decrease water content. 
Resulting samples were dissolved in water, frozen, and lyophilized.  Selected samples were 
analyzed by NMR and LC-MS.  
Residual material recovered after HPLC separations from putatively active H and I 
Sephadex LH-20 fractions was recombined based on HPLC profiles to give three fractions, 
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HI1, HI2 and HI3. These fractions were submitted to the anti-agglutination assay testing and 
examined by 1H NMR spectroscopy. 
8. Carbohydrate Derivatization Analyses 
The methods described above yielded a single sample, compound 1, in sufficient purity 
and quantity (~10 mg) for further structural characterization. This sample was determined to be 
a complex carbohydrate using preliminary NMR data and was therefore submitted to the 
Complex Carbohydrate Research Center (CCRC) at the University of Georgia, for specialized, 
professional, fee-for-service analysis. The majority of the structural characteristics for 1 were 
determined using a series of analyses that required derivatization of the sample and were 
therefore destructive. The results of these analyses provided information on (a) glycosyl 
composition, (b) glycosyl linkage positions, (c) high-resolution mass by MALDI-MS, (d) 
monomer configuration, and (e) glycosyl sequence. Details of the methods used by the CCRC 
are included below.  
a. Glycosyl Composition  
Glycosyl composition was determined using gas chromatography/mass spectrometry 
(GC-MS) of per-O-trimethylsilyl (TMS) derivatives of the sample. Monosaccharide methyl 
glycosides were produced by acidic methanolysis (1 M HCl in MeOH at 80 C, 18–22 h), 
followed by re-N-acetylation with pyridine and acetic anhydride in MeOH for detection of 
amino sugars.  The sample was then per-O-trimethylsilylated by treatment with Tri-Sil (Pierce) 
at 80 C (30 min) as previously described (Merkle & Poppe 1994, York et al. 1986). Inositol 
was added to the sample before derivatization as an internal standard (20 μg per sample). GC-
MS analysis of the TMS methyl glycosides was performed on an HP 6890 GC interfaced to a 
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5975b MSD, using an All Tech EC-1 fused silica capillary column (30 m  0.25 mm ID). 
Monosaccharides were identified by comparisons of retention times to those of standards, and 
mass spectra were used to authenticate the carbohydrate nature of the derivatives. 
b. Glycosyl Linkage (NaOH method)  
For glycosyl linkage analysis, the sample was permethylated, depolymerized, reduced, 
and acetylated. The resulting partially methylated alditol acetates (PMAAs) were analyzed by 
GC-MS (York et al. 1986). Initially, an aliquot of the sample after dialysis was suspended in 
about 200 µL of DMSO. The sample was then permethylated using treatment with NaOH and 
CH3I in dry DMSO (Ciucanu & Kerek 1984). The sample was subjected to NaOH base for 10 
min and CH3I was added and left for 20 min. This process was repeated to ensure complete 
methylation. Following sample workup, the permethylated material was reduced by 
superdeuteride to the methyl ester of uronic acid, hydrolyzed using 2 M TFA (2 h in a sealed 
tube at 121 C), reduced with NaBD4, and acetylated using Ac2O/TFA. The resulting PMAAs 
were analyzed on a Hewlett Packard 5890 GC interfaced to a 5970 MSD (mass selective 
detector, electron impact ionization mode). Separation was performed on a Supelco 2330 
bonded phase fused silica capillary column (30 m). 
c. MALDI-MS  
The sample was dissolved in deionized water (1 mg/mL) and 1 µL of the solution was 
deposited on a spot of 2,5-dihydroxybenzoic acid matrix dried from MeCN:water (1:1). This 
material was subjected to MALDI-MS on a Bruker MicroFlex Mass Spectrometer (+ mode).  
All masses were calibrated to malto-oligosaccharide controls separated immediately before the 
sample. 
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d. Monomer Configuration  
The absolute configuration of monomeric glycosyl units was determined by 
comparisons between derivatized compound substituents and derivatized standards. The sample 
was hydrolyzed in 2M TFA (500 μL) at 120 ºC for 1.5 h, the hydrolysate was dissolved in 200 
μL (S)-(+)-2-BuOH (Fluka 19025), 15 μL acetyl chloride (Aldrich 236691) was added, and N2 
was bubbled through the solution for 30 s. The mixture was capped tightly and incubated at 80 
ºC for 16 h. The mixture was dried under N2, and absolute MeOH was added to ensure sample 
dryness. To the dry sample, 250 μL TMS was added and derivatization was carried out at 121 
ºC for 20 min. The same procedure was applied to authentic standards D-Glc, L-Ara, and D-
Xyl; two sets of standards were derivatized to which either (S)-(+)-2-BuOH or (R)-(-)-2-BuOH 
was added separately. The sample and standard derivatives were analyzed on an Agilent 5975C 
GC interfaced with a 7890A MS detector. 
e. Glycosyl Sequence  
Glycosyl sequence was determined using per-O-methylated glycans analyzed by 
Nanospray Ionization-Linear Ion Trap Mass Spectrometry (NSI-MSn) (Anumula & Taylor 
1992). The sample was dissolved in DMSO, permethylated as described above (Anumula & 
Taylor 1992), extracted with DCM, and dried under N2. The resulting per-O-methylated glycan 
was dissolved in 1 mM NaOH in 50% MeOH and directly infused with a syringe flow rate of 
0.5 L/min into an LTQ Orbitrap Discoverer mass spectrometer (Thermo Scientific) equipped 
with a nanospray ion source. The capillary temperature was set to 210 C, and MS analysis was 
performed in positive ion mode with fragmentation by CID (25% collision energy) in MS/MS 
and MSn modes. Indicative partial-fragmentation patterns from NSI-MSn analysis of the per-O-
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methylated derivative of 1 were used to confirm side chain linkage positions and establish 
monomer connectivity. 
 
Compound 1: β-D-glucopyranosyl-(1→4)-[α-L-arabinofuranosyl-(1→2)-α-D-
xylopyranosyl-(1→6)]-β-D-glucopyranosyl-(1→4)-[α-L-arabinofuranosyl-(1→2)-α-D-
xylopyranosyl-(1→6)]-β-D-glucopyranosyl-(1→4)-β-D-glucopyranose (1); White amorphous 
powder; 1H NMR and 13C NMR data: Figure 4, Figures 59–68, Table 28; MALDI-MS (Figure 
42) (positive ion mode) [M+Na]+ at m/z 1218.117, to give a calculated molecular formula of 
C44H74NaO37+ for 1.  
 
 
Figure 4. Structure of the urinary octasaccharide (1) showing monosaccharide identities and 
absolute configuration. 
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C. Results & Discussion 
1. Anti-agglutination Properties of Urine Fractions 
a. Overview of Anti-agglutination Assay Results 
Cumulative results across test dates for selected urine samples and fractions are shown 
below (Tables 7–15). The raw assay data provided by RU (dilution endpoints) were interpreted 
by UM using a qualitative scoring system (Table 3) as discussed above (Section B4d). The raw 
data for these samples, organized by test date, are included in Appendix B-3 with some 
additional discussion points regarding assay limitations in Appendix B-2. Raw data include the 
same sample descriptions as shown below, the dilution endpoint values (mg/mL) provided by 
RU, the number of two-fold dilutions applied to each sample before loss of detectable anti-
agglutination activity, the amount of sample submitted by UM, the amount of PBS used to 
dilute each sample (dilution volume), and the starting concentration at which anti-agglutination 
properties were first assessed. The VAS values were reported by RU to UM for only some of 
the samples submitted and these scores are included in the raw data where available (Appendix 
B-3: Tables 46, 48, 50, 52). 
Although numerical dilution endpoint values were provided as the result for each 
sample, these values were, at best, qualitative assessments of sample activity due to the 
qualitative nature of the visual agglutination scoring system used. False negative results were 
also likely for many samples, as the reported dilution endpoints may have been affected by 
numerous sample, environmental, and methodological variables (See Appendix B-2 
discussion). In spite of the limitations of the UPEC-HRBC anti-agglutination assay, the results 
were determined to provide sufficient information to guide preliminary isolation efforts by 
40 
 
identifying which samples were or were not active. The results of these studies indicated, 
however, that this assay is not suitable for future quantitative assessments of the ability of test 
samples to prevent UPEC adhesion, especially for small quantities (< 10 mg) of material with 
unknown activity. Sample limitations therefore dictated that priority be given to the isolation 
and structure elucidation of putative active components in preference to further testing of urine 
fractions using this assay. 
b. Results for Urine Fractions 
The D urine fractions and DA Sephadex LH-20 fractions were tested across five 
different test dates and all samples were not tested for each test date (Table 7). Retesting of 
fractions DA1–DA8 yielded results with questionable reproducibility as some of samples that 
showed activity in the 05/2006 test set were inactive in the 03/2007 test set and vice versa. 
Retesting of fractions DA13–DA20 also yielded some results with questionable reproducibility, 
but some of these samples maintained activity. Samples within this set that were considered 
active included DA13, DA18, and DA19. A third retesting of fraction DA19 in the 07/2011 test 
set showed that this sample retained activity as a dry powder stored at –20 oC for at least five 
years. Insufficient amount of all DA materials were available for further isolation or structural 
characterization.  
The F urine fractions were tested across six different test dates (Table 8). The FF 
sample (the aqueous fraction of the F urine crude material) was tested repeatedly as a positive 
control for other urine samples. Although it was considered active, this sample did not always 
result in numerical dilution endpoints that fell within the defined ranges for activity, and 
dilution endpoints for replicate samples within a single test date were inconsistent. The 
variations in UM Scores reflect this variation in dilution endpoints. The observed variation in 
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sample activity may have been partly due to the complexity and heterogeneity of the sample 
and the hygroscopic nature of the material, as well as to other reasons (see Appendix B-2 
discussion). The FF sample was later submitted to preliminary versions of the UPEC-UEC 
assay used for cranberry studies (see Chapter 3) and it also showed anti-adhesion activity in 
this assay (data not shown). The FF sample retained activity for at least four to six years.  
The FF fraction was separated using five different Sephadex LH-20 columns (Table 4), 
and all fractions from these separations were submitted to the anti-agglutination assay (Table 9, 
10). Fractions that showed consistent activity were those that eluted early from each column, 
including F1-1, F1-2, F2-1, FF3-1, FF3-2, FF4-1, FF4-2, and FF5-1. These active FF fractions 
were combined to give the FA fraction which was also found to be active ( 
Table 11). The FA fraction was further separated by Sephadex LH-20 (Table 5) and the 
resulting fractions were tested on two different test dates ( 
Table 11). As before, early-eluting Sephadex LH-20 fractions (FA1 and FA2) showed 
highest activity (09/2007 test date). Retesting of the FA fractions in the 06/2008 sample set 
yielded negative activity for the FA1 and FA2 fraction. This apparent lack of activity was most 
likely due to the submission of less than 10 mg of each sample (Appendix B-3: Tables 51, 54). 
Control urine fractions were primarily inactive, as expected (Table 12), and the FC1 
fractions were tested repeatedly as negative controls for other urine samples. Similar separation 
methods were applied to the FC material as were used for active urine materials (Section B5a); 
the fraction FC1 was analogous to fractions FF, HF and IF, and FC1-1 was analogous to FA1 
and HF1-1. Fraction FCE showed possible activity and this activity may indicate the presence 
of innate or other dietary-derived urine components that can interfere with HRBC agglutination 
by E. coli. Limited FCE material was available for further analyses. 
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The H urine material and H fractions were tested across three different test dates (Table 
13). The HF fraction showed activity and fractionation of HF by Sephadex LH-20 (Table 6) 
yielded early-eluting fractions with highest activity. This pattern of activity was similar to that 
observed with the F urine material, with active components being retained in the aqueous 
fraction after organic solvent extraction and eluting early from a Sephadex LH-20 column. The 
HCE fraction also showed possible activity but a limited amount of this material was available 
and attempts at isolating the constituents present were unsuccessful. Combination of selected 
HF and IF fractions (see below) produced the three HI fractions shown, and the combined 
fraction derived from early-eluting Sephadex LH-20 fractions (HI1) had the best activity. 
The I urine material was tested across two different test dates and I fractions showed a 
pattern of activity similar to that observed with H and F samples (Table 14). The IF fraction 
was separated using Sephadex LH-20 (Table 6) but the resulting fractions were not tested. 
Combinations of selected HF and IF Sephadex LH-20 fractions were, however, tested as HI 
samples, confirming the activity of early eluting IF fractions (Table 13). The ICE fraction also 
showed activity but a limited amount of this material was available. The I urine material was 
subjected to a stability test followed by solvent-solvent extraction to yield the IZ and IZA 
materials. Both of these IZ samples showed activity, indicating that the active constituents were 
stable in 20% MeOH solution with other crude urine components for up to three months. 
c. Results for Standards 
Carbohydrate standards were submitted with the last two sets of test samples (Table 15) 
with the objective of assessing assay specificity for different monosaccharides. Of the 
submitted carbohydrate standards, D-glucose showed reproducible activity, suggesting that the 
presence of this compound in urine fractions may be a cause for false-positive results. While 
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glucose may be present in crude urine materials, it would have been removed from later, 
enriched fractions (such as FA1 and HF1-1) by the chromatographic methods used (See 
Appendix B-5: Figure 105). It also could not be detected in cranberry fractions that were later 
collected and shown to be active in a different anti-adhesion assay (See Chapter 3, Sections 
B5b, C2d, and C4b). A possible reason for the positive result obtained with glucose relates to 
the fact that this compound can serve as a growth substrate for E. coli. The presence of this 
compound in test media may cause E. coli to alter gene expression profiles associated with 
adhesion (A. B. Howell personal communication). Glucose may therefore inhibit HRBC 
agglutination by E. coli, but this inhibition may be due to an indirect mechanism of action that 
is not clinically relevant. Additional studies would be necessary to fully investigate this 
phenomenon. 
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Table 7. Anti-agglutination assay results for D urine fractions and DA Sephadex LH-20 
fractions tested in three different test date sets. 
Samples within this set that were considered active included DA13, DA18, and DA19. Fraction 
DA19 retained activity as a dry powder stored at –20 oC for at least five years. 
Sample Description UM Scorea 
Test 
Dateb 
UM 
Score
Test 
Date 
UM 
Score 
Test 
Date 
D (crude urine) – – 03/2006 
DE (D EtOAc fraction – – 03/2006 
DS (D sec-BuOH fraction) – – 03/2006 
DA (D aqueous fraction) +/– 03/2006 
DA1 (Sep LH-20 fraction) – 05/2006 + + 03/2007 
DA2 (Sep LH-20 fraction) – 05/2006 + 03/2007 
DA3 (Sep LH-20 fraction) +/– 05/2006 + 03/2007 
DA4 (Sep LH-20 fraction) +/– 05/2006 – – 03/2007 
DA5 (Sep LH-20 fraction) – – 05/2006 – – 03/2007 
DA6 (Sep LH-20 fraction) – – 05/2006 – – 03/2007 
DA7 (Sep LH-20 fraction) – – 05/2006 – – 03/2007 
DA8 (Sep LH-20 fraction) – – 05/2006 + + 03/2007 
DA9 (Sep LH-20 fraction) – – 05/2006 
DA10 (Sep LH-20 fraction) – – 05/2006 
DA11 (Sep LH-20 fraction) – – 05/2006 
DA12 (Sep LH-20 fraction) – – 05/2006 
DA13 (Sep LH-20 fraction) + + 05/2006 + + 08/2006 
DA14 (Sep LH-20 fraction) + + 05/2006 – 08/2006 
DA15 (Sep LH-20 fraction) + + 05/2006 – 08/2006 
DA16 (Sep LH-20 fraction) + + 05/2006 +/– 08/2006 
DA17 (Sep LH-20 fraction) – – 05/2006 + + 08/2006 
DA18 (Sep LH-20 fraction) + + 05/2006 + + 08/2006 
DA19 (Sep LH-20 fraction) + + 05/2006 + + 08/2006 + + 07/2011 
DA20 (Sep LH-20 fraction) – – 05/2006 – – 08/2006 
a The evaluation criteria for assigning the qualitative UM Scores are described in Table 3. 
b Samples with the same test date were submitted as part of the same shipment to RU but may 
not have been tested on the same day or in the same batch. See Appendix B-2 for additional 
discussion. 
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Table 8. Anti-agglutination assay results for F urine fractions. 
The FF sample (the aqueous fraction of the F urine sample) was tested repeatedly as a positive 
control for other urine samples. The variations in UM Scores reflect the variation in dilution 
endpoints both within and across test dates. These data indicate that the FF sample retained 
activity for at least four years. Later testing in preliminary versions of the UPEC-UEC 
indicated that anti-adhesion activity was still retained in the FF sample for at least six years.  
Sample Description UM Score Test Date 
FB (F EtOAc fraction) – 09/2007 
FG (F solids) – – 03/2007 x3a 
FF (aqueous fraction) +/– 03/2007 
FF (aqueous fraction) +/– 03/2007 
FF (aqueous fraction) + + 05/2007 
FF (aqueous fraction) + 05/2007 
FF (aqueous fraction) – 05/2007 
FF (aqueous fraction) +/– 06/2007 
FF (aqueous fraction) +/– 06/2007 
FF (aqueous fraction) – 06/2007 
FF (aqueous fraction) – 09/2007 
FF (aqueous fraction) – 09/2007 
FF (aqueous fraction) + 07/2011 
FF (aqueous fraction) + 07/2011 
a This sample was submitted and tested in triplicate for this test date. 
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Table 9. Anti-agglutination assay results for FF Sephadex LH-20 fractions, columns 1 and 2. 
The FF Sephadex LH-20 fractions that showed consistent activity were those that eluted early 
from the columns: F1-1, F1-2, and F2-1. F2-2 – F2-4 may also have been active. Fraction FF1-
7 was contaminated with a small amount of FF1-1 during sample transfers. 
Sample Description UM Score Test Date 
FF1-1 (Sep LH-20 fraction) + + 03/2007 
FF1-2 (Sep LH-20 fraction) + + 03/2007 
FF1-3 (Sep LH-20 fraction) – – 03/2007 
FF1-4 (Sep LH-20 fraction) – – 03/2007 
FF1-5 (Sep LH-20 fraction) – 03/2007 
FF1-6 (Sep LH-20 fraction) +/– 03/2007 
FF1-7 (Sep LH-20 fraction) + + 03/2007 
FF1-8 (Sep LH-20 fraction) – – 03/2007 
FF1-9 (Sep LH-20 fraction) – – 03/2007 
FF2-1 (Sep LH-20 fraction) + + 05/2007 
FF2-2 (Sep LH-20 fraction) + 05/2007 
FF2-3 (Sep LH-20 fraction) + 05/2007 
FF2-4 (Sep LH-20 fraction) + 05/2007 
FF2-5 (Sep LH-20 fraction) – – 05/2007 
FF2-6 (Sep LH-20 fraction) +/– 05/2007 
FF2-7 (Sep LH-20 fraction) +/– 05/2007 
FF2-8 (Sep LH-20 fraction) – – 05/2007 
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Table 10. Anti-agglutination assay results for FF Sephadex LH-20 fractions, columns 3, 4, and 
5. 
The FF Sephadex LH-20 fractions that showed consistent activity were those that eluted early 
from the columns: FF3-1, FF3-2, FF4-1, FF4-2, and FF5-1. 
Sample Description UM Score Test Date 
FF3-1 (Sep LH-20 fraction) + + 05/2007 
FF3-2 (Sep LH-20 fraction) + + 05/2007 
FF3-3 (Sep LH-20 fraction) – – 05/2007 
FF3-4 (Sep LH-20 fraction) – – 05/2007 
FF3-5 (Sep LH-20 fraction) – – 05/2007 
FF3-6 (Sep LH-20 fraction) +/– 05/2007 
FF4-1 (Sep LH-20 fraction) + 06/2007 
FF4-2 (Sep LH-20 fraction) + 06/2007 
FF4-3 (Sep LH-20 fraction) – 06/2007 
FF4-4 (Sep LH-20 fraction) – – 06/2007 
FF4-5 (Sep LH-20 fraction) – – 06/2007 
FF4-6 (Sep LH-20 fraction) – – 06/2007 
FF4-7 (Sep LH-20 fraction) – – 06/2007 
FF4-8 (Sep LH-20 fraction) – – 06/2007 
FF5-1 (Sep LH-20 fraction) + + 06/2007 
FF5-2 (Sep LH-20 fraction) – – 06/2007 
FF5-3 (Sep LH-20 fraction) – – 06/2007 
FF5-4 (Sep LH-20 fraction) – – 06/2007 
FF5-5 (Sep LH-20 fraction) – – 06/2007 
FF5-6 (Sep LH-20 fraction) – – 06/2007 
FF5-7 (Sep LH-20 fraction) – – 06/2007 
FF5-8 (Sep LH-20 fraction) – 06/2007 
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Table 11. Anti-agglutination assay results for FA urine fractions. 
In the 09/2007 sample set, the FA sample showed probable activity and the early-eluting 
Sephadex LH-20 fractions (FA1 and FA2) showed highest activity, as before. When all FA 
samples were retested in the 06/2008 sample set, however, FA1 and FA2 showed no activity. 
This result is probably a false negative due to the submission of less than 10 mg of each sample 
(see Appendix B-3: Tables 50, 53). 
Sample Description UM Score Test Date 
UM 
Score Test Date 
FA (combined active FF samples) +/– 09/2007 +/– 06/2008 
FA1 (Sep LH-20 fraction) + + 09/2007 – – 06/2008 
FA2 (Sep LH-20 fraction) + 09/2007 – – 06/2008 
FA3 (Sep LH-20 fraction) – – 09/2007 – – 06/2008 
FA4 (Sep LH-20 fraction) +/– 09/2007 +/– 06/2008 
FA5 (Sep LH-20 fraction) – – 09/2007 +/– 06/2008 
 
 
Table 12. Anti-agglutination assay results for FC urine fractions. 
The FC1 fractions were tested repeatedly and were inactive each time, as expected. Fraction 
FCE showed possible activity, but limited material was available for further analyses. The 
presence of possible activity in the FCE fraction indicated that other innate or dietary-derived 
urinary components may be present in this fraction that can inhibit agglutination. 
Sample Description UM Score Test Date 
FC (control urine) – – 09/2007 
FCE (FC EtOAc fraction) +/– 09/2007 
FC1 (aqueous fraction) – 07/2011 x2, 09/2007 x3, 12/2008 
FC1-1 (Sep LH-20 fraction) – – 06/2008, 12/2008, 07/2011 x2 
FC1-2 (Sep LH-20 fraction) – – 06/2008, 07/2011 
FC1-3 (Sep LH-20 fraction) – – 06/2008 
 
  
49 
 
Table 13. Anti-agglutination assay results for H urine fractions. 
The H crude urine material and the HF aqueous fraction both showed activity. The HCE 
fraction also showed possible activity. Fractionation of HF by Sephadex LH-20 yielded early-
eluting fractions with activity: HF1-1 and HF1-2. Combination of HF and IF Sephadex LH-20 
fractions produced the HI fractions shown, and the fraction derived from early-eluting H and I 
Sephadex LH-20 fractions (HI1) had the best activity of the HI fractions. 
Sample Description UM Score Test Date 
H (crude urine) +/– 08/2008, 12/2008, 07/2011 
HG (H solids) – – 08/2008 
HCE (H EtOAc extract, water soluble) + 08/2008 
HCM (H EtOAc fraction, MeOH soluble) – – 08/2008 
HD (H EtOAc:MeOH fraction, water soluble) – – 08/2008, 12/2008 
HF (H aqueous fraction) + 08/2008, 12/2008 
HF1-1 (Sep LH-20 fraction) + + 12/2008 
HF1-2 (Sep LH-20 fraction) +/– 12/2008 
HF1-3 (Sep LH-20 fraction) – 12/2008 
HF1-4 (Sep LH-20 fraction) – 12/2008 
HF1-5 (Sep LH-20 fraction) – – 12/2008 
HF1-6 (Sep LH-20 fraction) – 12/2008 
HF1-7 (Sep LH-20 fraction) – – 12/2008 
HI1 (combined H & I active fractions,  
HF2-1 + IF1-1) + + 07/2011 
HI2 (combined H & I active fractions,  
HF1-1 + HF2-2 + IF1-2) + 07/2011 
HI3 (combined H & I active fractions,  
HF1-2 + IF1-3 + HF2-3) – – 07/2011 
 
 
  
50 
 
Table 14. Anti-agglutination assay results for I urine fractions. 
The I urine material and the IF fraction both showed activity. The ICE fraction also showed 
activity but a limited amount of this material was available. The Sephadex LH-20 fractions of 
IF were not tested. The IZ and IZA materials derived from the stability test both showed 
activity, indicating that active components of the urine are not degraded under the conditions 
used. 
Sample Description UM Score Test Date 
I (crude urine) +/– 12/2008 
ICE (I EtOAc:MeOH fraction, water soluble) + + 12/2008 
ICM (I EtOAc:MeOH fraction, EtOAc soluble) – – 12/2008 
ID (EtOAc:MeOH fraction, water soluble) – – 12/2008 
IF (I aqueous fraction) +/– 12/2008 
IZ (I stability test) + 12/2008 
IZA (IZ aqueous fraction after stability test) + + 07/2011 
 
 
Table 15. Anti-agglutination assay results for submitted reference compounds. 
Of the submitted carbohydrate standards, D-glucose showed reproducible activity, suggesting 
that the presence of this compound in test samples may cause false-positive results. Queries 
directed at RU regarding the activity of glucose in the assay led to the proposal that glucose 
may inhibit agglutination of HRBCs by E. coli via an indirect mechanism of action that is not 
clinically relevant for UTI prevention. 
Sample Description UM Score Test Date 
D-Glucose (Sigma Aldrich 99.5%) +/– 12/2008 
D-Glucose (Sigma Aldrich 99.5%) + + 07/2011 x2 
Glucose Tabs (ReliOn Glucose Tablets 
commercial product, powdered) + + 07/2011 x2 
D-Glucuronic Acid – – 12/2008 
D-Galacturonic Acid – – 12/2008 
D-Sorbitol – – 12/2008 
D-Fructose (CalBioChem) – 07/2011 x2 
Sucrose (Great Value Brand) – – 12/2008, 07/2011 
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2. Initial Results with Early (D, E, & F) Source Materials 
The first shipment of active urine material (D) provided information relevant to method 
development but did not provide sufficient material from which to purify the active 
components. This material was handled under the premise that the target metabolites were 
PACs or PAC-derived. Methods that would normally be used for PAC isolation, such as those 
previously applied to cranberry materials (Foo et al. 2000a), were therefore attempted, 
including EtOAc and sec-BuOH extraction and Sephadex LH-20 chromatography with 100% 
EtOH. The use of SPE cartridges (Oasis® HLB) and hydrophobic extraction resins (Diaion, 
XAD-8 and XAD-16) was also attempted based on the premise that PACs would be retained by 
such sorbents.  
The fractions from solvent-solvent extraction using EtOAc and sec-BuOH were sent to 
the anti-agglutination assay, and the aqueous fraction (DA) yielded the best activity (Table 7). 
The DA material was therefore the focus of additional work. Of the methods attempted, the 
Sephadex LH-20 column yielded the most useful information for further method development. 
This column was packed in 100% EtOH but the sample would only partially dissolve in 75% 
EtOH and fell out of solution upon loading. The eluting solvent subsequently used was a 
gradient, with gradual 10% decreases in EtOH concentration in 1–2 L increments so as to 
redissolve the sample without overexpanding the Sephadex and breaking the glass column. 
This gradient method resulted in elution of anti-adhesive constituents at ~70–75% EtOH, as 
fractions DA13-DA19. Low amounts of material were recovered and half of the material for 
most fractions collected was sent for initial testing in the anti-agglutination assay (Table 7, 
Appendix B-3: Tables 42–44). Later retesting of the DA column fractions confirmed activity 
for fractions DA13, DA18 and DA19. Unexpectedly, D fractions that showed activity gave 
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negative results for an anthocyanidin test, indicating that PACs were not present in these 
fractions (Ofek et al. 1996). The active D fractions from this separation were analyzed by 1H 
NMR spectroscopy and LC-MicroTOF-MS, but data quality was poor and the spectra obtained 
could not be reliably interpreted. The low-quality 1H NMR spectra for fractions DA18 and 
DA19 (Appendix B-5: Figures 106, 107) were later determined to have similar features as 
spectra obtained for other active urine fractions (FA1 and HF1-1). 
Early studies also indicated that active fractions of unknown composition were soluble 
in water, dimethyl sulfoxide, and water-alcohol mixtures (EtOH or MeOH) of up to 80% 
alcohol with diluted material. Active metabolites were found to be stable after exposure to 
moderate heat (up to 60 oC), light, alcohols (EtOH, MeOH, sec-BuOH), EtOAc, DMSO, ether, 
and acid at room temperature (titrated to pH 2.5 using 1 M HCl). Activity also remained after 
freezing in powder or liquid form for long periods of time (up to 5 years or more) in both 
complex mixtures and in more purified active fractions. 
The second shipment of active urine material (E) was used for further attempts at 
method development using numerous approaches. Many fractions of this material were sent for 
assay testing and the results indicated that the material supplied to UM may have lost activity. 
Issues with this apparent loss of activity prompted consideration of mechanisms by which the 
unknown (at that time) metabolites could be degraded or inactivated. The E urine samples had 
been lyophilized as crude urine by the UWM group prior shipment to UM and issues during 
this stage of processing could have contributed to the degradation of active components. Raw 
urine material is difficult to lyophilize due to relatively high solute concentrations, the presence 
of fats and surfactants, and the logistics of processing large volumes of liquid via 
lyophilization. Of the possible scenarios, crude urine material could have been subjected to 
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extended periods of time in untreated aqueous solution and to multiple freeze-thaw cycles. 
During such times, active metabolites could have been degraded by native enzymes present in 
crude active urine or could have chemically reacted with other crude urine components (Saude 
et al. 2007). Enzymatic degradation can be prevented by mixing crude urine samples with 
MeOH or other alcohols to denature proteins, but alcohol addition would have interfered with 
lyophilization, freezing, and shipping. The alternative addition of common urine stabilizing 
agents, such as sodium azide, may have interfered with the unknown active metabolites and the 
assay results (Saude et al. 2007). Degradation can also be avoided, and lyophilization 
efficiency improved, by filtering and extracting urine samples with organic solvents prior to an 
initial lyophilization step. Later urine samples were therefore kept frozen for the entire time 
between collection and extraction, including during shipping, and up to 20% of MeOH was 
added to urine samples immediately upon thawing. 
The stability test later performed using the crude I urine sample confirmed that the 
active constituents were stable at room temperature in a 20% MeOH solution in the presence of 
crude urine constituents. During the three month incubation time, a precipitate formed, the 
color of the material changed from amber yellow to dark chocolate brown, and the smell of the 
material changed. All of these observations indicated the presence of oxidation and other 
chemical changes that were not prevented by the presence of MeOH. When tested in the anti-
agglutination assay, the IZ-A material showed higher activity than the analogous aqueous 
material (IF) prepared without the room temperature incubation. These data suggested that 
additional enrichment for the active constituents may have occurred, possibly through 
degradation of non-active urinary components or assay-confounding materials. As MeOH 
denatures proteins, it is likely that enzymatic mechanisms may have been responsible for the 
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loss of activity in the E urine material. Additional testing and analyses would be required to 
profile the chemical and biological changes that could affect the stability of active urinary 
components, but such studies were not feasible during the present project. 
3. Enrichment for Active Components 
Active urinary components were consistently present in aqueous fractions after 
extraction with organic solvents (using EtOAc, EtOAc-MeOH mixtures, sec-BuOH, or ether) 
or with the use of solid phase extraction (SPE) cartridges, or XAD resins. Low anti-
agglutination activity was present in some EtOAc fractions (HCE, ICE; Tables 13, 14) but not 
others (FB; Table 8). Attempts were made to isolate components from HCE, but insufficient 
amounts of this and similar materials were available to pursue further purification. The control 
urine EtOAc fraction (FCE; Table 12) also displayed low anti-agglutination activity, indicating 
that constitutive urinary metabolites or dietary sources other than cranberry may be responsible 
for the activity observed in some EtOAc fractions. Efforts were therefore focused on the 
isolation of possible active components from aqueous fractions (FF, HF, IF). 
The anti-agglutination assay data for the FF sample Sephadex LH-20 fractions (Tables 
9, 10) provided certainty as to methods that allowed for satisfactory enrichment of the active 1–
2% of total urine material. Active fractions consistently eluted within the first 1–3 fractions of 
each Sephadex LH-20 column regardless of variations in column dimensions or EtOH 
percentages (50–70%). The total amount of active material enriched from the F urine samples 
accounted for ~0.7% of the starting material by weight, giving an estimated starting urine 
concentration for active metabolites of less than 0.14 mg/mL. Some of this material was used 
for method development and fraction characterization without success. Remaining anti-
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adhesive urine fractions from the five separate Sephadex LH-20 columns of the FF material 
were combined to give F Actives (FA; 1.75 g). This material was separated on Sephadex LH-
20 (Table 5), to give two anti-adhesive fractions (FA1 and FA2). Half of each FA1 and FA2 
sample was submitted to the anti-agglutination assay ( 
Table 11), and fraction FA1 was used primarily for analytical HPLC separations and 
comparative analyses due to its limited quantity. Method development with FA1 and FA2 used 
HPLC-UV with HILIC and XCMSC18 sorbents and various solvent systems (see analytical 
HPLC example in Appendix B-5: Figure 108). All fractions isolated from FA2 using UV 
detection, however, gave inconclusive or negative assay results, and LC-MicroTOF-MS of both 
FA1 and FA2 gave inconclusive results (not shown) regarding possible fraction composition.  
4. Characterization of Active Components 
Comparisons between the 1H NMR data of active urine fractions FA1 and FA2 (Figure 
5), commercial fruit pectin (Figure 6), and galacturonic acid (Figure 7), a monomeric 
component of pectin, indicated that the active fractions could contain complex carbohydrates. 
While the 1H NMR spectra of active urine fractions and pectin appeared similar, the urine 
fractions had significantly different characteristics in aqueous solution than pectin. The 
composition of the FA1 sample could also not be sufficiently distinguished from that of other, 
inactive, FA fractions by NMR (Figure 5).  
Analysis of FA1 via analytical HPLC-ELSD/UV indicated that the major components 
of this fraction lacked chromophores and therefore required the use of ELSD or other 
chromophore-independent detection methods to monitor and guide HPLC separations (see 
Appendix B-4: overview of ELSD principles). Purification and structure elucidation of the 
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compounds present in the FA1 fraction was impractical, however, due to material limitations. 
The observation that active fractions with the highest anti-agglutination activity lacked UV-
detectable components was later supported by HPLC-ELSD/UV analysis of HF1-1 (Figure 8).  
Further guidance regarding the possible composition of the FA and HF1-1 active 
mixtures was obtained from additional 1H NMR data. Comparisons between the 1H NMR 
spectra of FA1 and HF1-1 (Figure 9) indicated a similar composition. Comparisons of these 
spectra with the 1H NMR spectra of synthetic trimeric and tetrameric PACs (Figure 10), 
however, indicated that the active urine fractions did not contain these compounds. This was 
established by the lack of characteristic overlapping aromatic resonances from the A- & B-
rings of different PAC monomer units that would correspond to PACs or possible PAC-related 
metabolites. Although NMR spectra of crude active urine fractions (HF; Figure 11) did contain 
resonances in the aromatic region (Figure 12), these resonances were also present in the 
inactive enriched control urine fraction (FC1-1), and in inactive fraction HI3 (Figures 13, 14). 
Aromatic resonances were present only at trace levels in enriched fractions with higher anti-
agglutination activity (FA, HF1-1, HI1; Figures 11–14).These aromatic region resonances were 
therefore likely due to the presence of simple aromatic acids commonly found in mammalian 
urine (Saude et al. 2007, Bouatra et al. 2013).  
The dominant 1H NMR resonances present in all active fractions were indicative of 
carbohydrates even though the possible presence of monosaccharides within these fractions had 
been eliminated through chromatography (see Appendix B-5: Figure 105) and comparisons to 
various carbohydrates and other standards (galacturonic acid, apple pectin, D-glucose, sucrose, 
fructose, corn starch, sodium citrate, and epicatechin) using multiple TLC spray reagents (e.g. 
ninhydrin, p-anisidine, bromocresol green) (not shown). The use of TLC spray reagents that 
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produced color reactions indicative of flavonoids (e.g. vanillin, p-anisaldehyde) further 
indicated that PACs and other flavonoids were not present in the active fractions (not shown). 
Inactive Sephadex LH-20 fractions also lacked the characteristic profile present in the HPLC-
ELSD spectra of active urine fractions (Figures 15, 16). It was therefore concluded that the 
active components of interest in enriched samples were complex oligosaccharides. 
 
Figure 5. Comparison of the 1H NMR spectra for FA and fractions FA1–FA5, 400 MHz, D2O. 
Fraction FA1 and FA2 exhibited the best anti-agglutination activity but could not be 
significantly distinguished from the other FA fractions using NMR data alone. The FA1 
fraction also resulted in a low resolution NMR spectra.  
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Figure 6. The 1H NMR spectrum of pectin (from apples) reference sample, 400 MHz, D2O. 
The overlapping resonances between 3–5.5 ppm are indicative of numerous monomeric 
carbohydrate substituents with similar chemical shift values. 
 
 
 
 
Figure 7. The 1H NMR spectrum of galacturonic acid reference sample, 400 MHz, CDCl3. 
Pure galacturonic acid, one of the monomer components of pectin yields an NMR spectrum 
with distinct resonances. This spectrum has little similarity to that of pectin or urine samples of 
interest.  
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Figure 8. HPLC of HF1-1 visualized by ELS and UV (max plot). 
Comparison of the ELS and UV chromatograms for the active urine fraction HF1-1 indicates 
that a set of major fraction components (box) is not visible by UV detection methods. Similar 
UV-transparent components were present in the active FA1 fraction without the presence of 
additional UV-absorbing components (see Appendix B-5: Figure 108). The semi-quantitative 
nature of ELSD makes it possible to determine that the UV-visible component of HF1-1 is of 
relatively low concentration (arrows) (see Appendix B-4: ELSD overview).  
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Figure 9. Comparison of the 1H NMR spectra for active fractions FA1 and HF1-1, 400 MHz, 
D2O. 
The FA1 and HF1-1 materials both had activity in the anti-agglutination assay and produced 1H 
NMR spectra with similar profiles even though the parent material was collected from different 
source animals. The HF1-1 spectrum showed improved resolution over that of FA1 but still 
provided insufficient information for structural assignments.  
 
 
 
 
Figure 10. The 1H NMR spectra of synthetic PAC oligomers, 400 MHz, Acetone-d6. 
Spectra for the proanthocyanidin trimer and pentamer both contained sets of complex 
multiplets in the 6.2 – 8.5 ppm region corresponding to the multiple aromatic protons present in 
these compounds.  
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Figure 11. Comparison of the 1H NMR spectra for FC1-1, HF, FA and HF1-1 samples, 400 
MHz, D2O. 
Fraction 1H NMR profiles changed as samples increased in anti-agglutination activity, from 
inactive (FC1-1), to probably active (HF), to active (FA), to highly active (HF1-1).  
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Figure 12. Comparison of the 1H NMR spectra for FC1-1, HF, FA and HF1-1 samples, 
expansion of the aromatic region, 400 MHz, D2O. 
Samples with a higher degree of activity (FA1 and HF1-1), and, presumably, a corresponding 
higher degree of enrichment for active components, lacked aromatic resonances, while inactive 
samples and samples with lower or no activity (HF and FC1-1, respectively) contained these 
resonances. 
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Figure 13. Comparison of the 1H NMR spectra for HI1, HI2, and HI3, D2O, 400 MHz. 
Fraction HI1 had the highest activity, fraction HI2 had moderate activity and fraction HI3 
lacked activity.  
 
 
 
 
Figure 14. Comparison of the 1H NMR spectra for HI1, HI2, and HI3, expansion of the 
aromatic region, D2O, 400 MHz. 
The fraction with highest activity, HI1, lacked distinct resonances in the aromatic region. 
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Figure 15. Analytical HPLC-ELSD of Sephadex LH-20 fractions HF1-1, HF1-2, and HF1-3 
(AtldC18).  
The UV transparent components of interest (box) identified in the active fraction HF1-1 are 
detectable at low concentrations in the moderately active fraction HF1-2 and absent from the 
inactive fraction HF1-3. All three of these samples were injected at the same concentration. 
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Figure 16. Analytical HPLC-UV (Max Plot) of Sephadex LH-20 fractions HF1-1, HF1-2, and 
HF1-3 (AtldC18). 
The ELS-detectable components present at 18-22 min (box) in Figure 15 are not detectable by 
UV spectroscopy using wavelengths of 210-400 nm (Max Plot).   
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5. Isolation of Urine Oligosaccharides from H & I Source Materials 
a. Sephadex LH-20 Fractionation 
The H and I urine samples were separately extracted with EtOAc and fractionated 
following the Sephadex LH-20 protocols developed for F urine samples (Figure 3; Tables 4–6). 
As with the F urine fractions, the major active constituents remained in the aqueous layer after 
EtOAc extraction and eluted early from a Sephadex LH-20 column, with fractions HF1-1, HI1, 
and HI2 giving the best anti-agglutination assay results of the enriched samples tested (Tables 
13, 14). All fractions were not tested to conserve material, and comparisons of the HPLC-
ELSD profiles of active and inactive fractions were used to guide isolation efforts (Figures 17–
21). Comparative analysis via HPLC-ELSD indicated that a series of UV-transparent 
compounds with a distinct profile, eluting between 17–25 min (Figure 17) with optimized 
HPLC methods, was consistently present in all active samples and absent from inactive 
samples. The HF2-2 fraction series (Figures 19–21) is representative of the HPLC-ELSD 
fraction profiles observed for the HF and IF Sephadex LH-20 column fractions.  
Method development for HPLC separations was pursued under the new paradigm that 
the target compounds were carbohydrates. Purification for all components of the UV-
transparent mixture was attempted, but these efforts were complicated by many factors related 
to the structural nature of the compounds, the complexity of the mixture, and the 
chromatographic systems used. 
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Figure 17. Comparison of the HPLC-ELSD data for active fraction HF1-1 and untested samples 
IF1-2, IF1-3, HF2-2, showing a similar profile of ELS detectable peaks. 
The profile of peaks eluting in the region of interest for each sample was similar. The gradient 
used for the HF1-1 sample was slightly different than that used for the other samples, resulting 
in shifts of retention times but a similar overall profile.  
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Figure 18. Analytical HPLC-ELSD of IF1-1, IF1-2, and IF1-3 (AtldC18). 
The components of interest (18–24 min) were readily detectable in Sephadex LH-20 fractions 
IF1-2 and IF1-3 but could only be detected at trace levels in fraction IF1-1.  
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Figure 19. Analytical HPLC-ELSD of HF2-1, HF2-2, and HF2-3 (AtldC18). 
The components of interest (18–24 min, box) were predominantly present in Sephadex LH-20 
fraction HF2-2 with trace amounts present in fractions HF2-1 and HF2-3.  
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Figure 20. Analytical HPLC-ELSD of HF2-2, HF2-3, HF2-4 and HF2-5 (AtldC18). 
The components of interest (22–28 min) present in Sephadex LH-20 fraction HF2-2 were 
detected at trace levels in fraction HF2-3, and were not detected in fractions HF2-4, and HF2-5.  
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Figure 21. Analytical HPLC-UV (Max Plot) of HF2-2, HF2-3, HF2-4 and HF2-5 (AtldC18). 
The components of interest (22–28 min) present in Sephadex LH-20 fraction HF2-2 were not 
detectable by UV and the HF2-2 fraction could not be readily distinguished from the other 
fractions using only UV detection.  
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b. Preparative AtldC18 HPLC-ELSD  
Reverse phase HPLC separations were performed with H and I Sephadex LH-20 
fractions that contained UV-transparent oligosaccharides by ELSD and 1H NMR spectroscopy, 
starting with those fractions that were available in the highest quantity (Table 16). These 
included HF1-1, HF1-2, HF1-3, HF2-1, HF2-2, IF1-1, IF1-2 and IF1-3 (Table 6).  
The majority of the HF1-1, HF1-2, and HF1-3 samples were used for method 
development. Attempts were made to resolve the components of these fractions using direct 
injection onto both XTMSC18 and Polyamine semi-preparative columns with both PDA and/or 
ELS detection, but were unsuccessful at yielding pure compounds. The fractions collected from 
these separations were not combined with later materials due to the differences in the 
chromatographic methods used. Efforts were also made to isolate compounds from the inactive 
fraction HF2-6 and the compounds isolated were found to be known urinary metabolites (not 
shown).  
Once an acceptable method was obtained, the same or highly similar methods were used 
for all subsequent separations and the results are included below (Tables 18, 19; Figures 22–
24). H and I fractions were initially kept separate with the goal of identifying and comparing 
the components from both source animals. As isolation efforts proceeded, chromatographic 
profiles indicated that the components of both samples were similar and selected fractions from 
both materials were therefore combined. Aliquots of fractions that were available in lower 
quantities were co-injected with samples from more abundant fractions to aid in the alignment 
of peaks, to account for instrument variations between separations, and to account for possible 
sample matrix effects.  
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Attempts at method optimization during preparative separations led to several method 
variations. The method for HF2-2 R1 used 5 min at 100% water, a 30 min gradient to 30% 
MeOH, and a 20 min gradient to 100% MeOH. The ELSD conditions were adjusted for HF2-2 
R1. Initial conditions were an evaporator temperature of 100 oC, a nebulizer temperature of 50 
oC, and a gas flow rate of 1.0 SML. At 40 min into the separation, corresponding to 50% 
MeOH, the evaporator temperature was changed to 90 oC to account for the increase in the 
percentage of organic solvent. This modification did not improve detector resolution and 
changes to the evaporator temperature were not made in subsequent separations. The method 
for HF2-2 R2–R6, IF1-2 R1, IF1-3 R1–R3, and HF2-1+IF1-1 R1 used 5 min at 100% water, a 
30 min gradient to 20% MeOH, and a 10 min gradient to 100% MeOH. The method for HF2-
1+IF1-1 R2 used modified gradient times with 5 min at 100% water, a 10 min gradient to 20% 
MeOH, and a 30 min gradient to 100% MeOH. The ELSD conditions were maintained at an 
evaporator temperature of 100 oC, a nebulizer temperature of 50 oC, and a gas flow rate of 1.0 
SML. 
Selected fractions of the AtldC18 preparative separations were combine across different 
parent materials: HF2-2P1t20, IF1-3P1t20, H/IF2/1-1P1t20 were combined into fraction HF2-
2P1t20, and HF2-2P1t22 + IF1-3P1t22 were combined into fraction HF2-2P1t22 (17.1 mg). 
Both 1D and 2D NMR data were acquired for HF2-2P1t20 and HF2-2P1t22 combined samples 
(Figures 25–27). 
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Table 16. Details of preparative-scale sample preparations for AtldC18-based separations of 
oligosaccharide-containing Sephadex LH-20 fractions. 
Samples were assessed by analytical HPLC-ELSD to determine their composition prior to 
preparative separation. All of the fractions show below were determined to contain the 
components of interest. 
Parent 
Fraction 
Amount 
(mg) 
Sample 
Dissolved In 
Water (µL) 
Filter 
Wash 
(µL) 
Sample 
Vol. 
(µL) 
Injected per Run 
(mg/µL) 
Separation 
Dates 
IF1-1 12 200 200 400 R1: 6 mg/200 µL 2009/06/24
HF2-2 122 675 500a 775 
R1: 50/250 
R2: 50/275 
25/150a + IF1-2R1 
2009/07/09
HF2-2 208 800 200 1000 
R3: 50/250 
R4: 50/250 
R5: 50/250 
R6: 50/250 
2009/07/10
IF1-2 53.3 250 (HF2-2 wash)b 100 250 
R1: 53.3+/250  
(contained small 
amount of HF2-2) 
2009/07/10
IF1-3 182 600 (+ IF1-2 wash)b 
150 
(IF1-2 
wash)b 
750 
R1: 60/250 
R2: 60/250 
R3: 60/250 
2009/07/10
HF2-1 + 
IF1-1c 
67.5 + 
59.7 300 200 500 
R1: 60/250 
R2: 60/250 2009/07/14
a This material was combined with the sample shown. 
b The filter wash collected from the fraction shown was used as the dilution solvent for this 
material 
c These fractions were determined to be sufficiently similar by analytical HPLC-ELSD to 
justify combining them. 
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Table 17. Combined preparative HPLC fractions resulting from HF2-2 and IF1-2 separations, 
designated HF2-2P1. 
Fractions t20 and t22 were analyzed by NMR spectroscopy and the results are discussed below. 
Retention 
Time (min)a 
Fraction mg Notes 
1.7–3.7 03 92.9  
3.7–4.57 04 14.4  
4.57–5.52 05 10.4  
5.52–9 06-09 13.1  
18.3–19.4 19 10.6  
19.4–20.0 20 * 11.9 Major fraction of interest
20.0–20.8 21 8.0  
20.8–22.0 22 * 17.1 Major fraction of interest
22.0–24.0 24 14.7  
24.0–25.0 25 -  
25.0–26.0 26 5.1  
Baselineb B -  
a Time points for fraction numbers were based on HF2-2 R4 and R5. 
b Baseline contains all peaks not accounted for by other time points. 
 
 
Table 18. Combined preparative HPLC fractions resulting from IF1-3 separations, designated 
IF1-3P1. 
Fractions t20 and t22 from these separations appeared to have the same composition as 
analogous fractions from the HF2-2 and IF1-2 parent materials. 
Retention 
Time (min) 
Fraction  mg Notes 
1.7–3.7 03 77.6  
3.7–5.0 04 10.1  
5.0–8.3 05-08 14.2  
8.3–11 08-11 8.0  
18.5–19.4 19 4.3  
19.4–20.0 19.5 2.4  
20.0–20.5 20 * 4.3 Major fraction of interest
20.5–21.4 21 16.4  
21.4–22.0 22 * 3.5 Major fraction of interest
22.0–22.8 22.5 2.7  
22.8–23.5 23 2.1  
23.5–24.1 24 2.3  
24.1–25.0 25 1.7  
25.0–60 B 25.4  
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Table 19. Combined preparative HPLC fractions resulting from HF2-1 and IF1-1 separations, 
designated H/IF2/1-1P1. 
The HF2-1 and IF1-1 fractions were determined to be of similar composition and the 
subfractions from these separations were therefore combined.  
Retention Time (min) Fraction mg Notes 
R1 R2 R1 + R2   
1.5–7.0 1.5–8.5 02 24.2  
7.0–14 8.5–11.5 B - Part of baseline  
14–22.6 11.5–15.0 20 12.6 Major fraction of interest
22.6–37.7 15.0–17.5 25 17.0  
37.7–48.0 17.5–30.0 40 32.9  
48.0–70.0 30.0–60.0 B - Part of baseline 
 
 
 
Figure 22. Preparative HPLC-ELSD of HF2-2, R1 (AtldC18). 
The gradient used for this separation varied from that used for subsequent separations. ELSD 
parameters were also changed during this separation in an effort to improve ELSD resolution, 
but resulted in no apparent improvement. The parameters used for subsequent separations 
(below) were preferred for later separations. 
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Figure 23. Preparative HPLC-ELSD of HF2-2, R2-6 (AtldC18). 
Retention times were similar across preparative separations and chromatographic resolution 
was not significantly affected by slight variations in injection volumes or sample amounts.  
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Figure 24. Preparative HPLC-ELSD of IF1-2 and IF1-3 R1–3 (AtldC18). 
Retention times were similar across preparative separations and chromatographic resolution 
was not significantly affected by slight variations in injection volumes or sample amounts. 
Fractions from the IF1-2 separation (top pane) were combined with those of HF2-2 to give 
HF2-2P1 subfractions, and fractions from the IF1-3 separations were combined to give IF1-3P1 
subfractions. 
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Figure 25. Comparison of the 1H NMR spectra for HF2-2P1t20 and HF2-2P1t22 showing 
highly similar composition, DMSO-d6, 400 MHz. 
The HF2-2P1t20 sample was later determined to be relatively pure while HF2-2P1t22 was 
determined to be a mixture of three major components in approximately equal amounts. 
Resonances were not present in the regions of the spectra that are not displayed. 
 
 
 
 
Figure 26. Comparison of the 13C NMR spectra for HF2-2P1t20 and HF2-2P1t22 showing 
highly similar composition, DMSO-d6, 400 MHz. 
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Figure 27. Comparison of the HMQC spectra for HF2-2P1t20 and HF2-2P1t22 showing the 
similarity of composition for these fractions, DMSO-d6, 400 MHz. 
The anomeric, methylene, and glycosyl ring regions are indicated for the HF2-2P1t22 
spectrum. Integration of the anomeric region of the 1H NMR spectrum and consideration of the 
data shown here led to the refined working hypothesis that the carbohydrates of interest were 
oligosaccharides with 7-9 monomeric units. It was later determined that a reducing glucosyl 
unit was responsible for two of the anomeric resonances shown and that the two high intensity 
resonances indicated for the HF2-2P1t20 spectrum were duplicated anomeric resonance sets 
corresponding to two Xyl and two Ara residues.  
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c. Semi-Preparative Polyamine HPLC-ELSD 
Methods for semi-preparative separations were developed using the refined working 
hypothesis that the compounds of interest were oligosaccharides. Fractions eluting from the 
AtldC18 column were combined based on retention time and profile and were further analyzed 
by normal-phase analytical HPLC-ELSD (Figures 28–30). Selected fractions were further 
purified using the Polyamine column (Figures 31– 34, Table 20). Resulting Polyamine fractions 
were cautiously combined across parent materials in an effort to obtain sufficient material for 
detailed structural analysis. Analytical scale HPLC-ELSD data (Figures 28–30) and 
considerations of the results of sample co-injections (Table 20) were both used to aid in 
comparisons and sample fraction combinations (Tables 21–26).  
Fraction HF2-2P1t24 was used to evaluate the effects of changes in starting solvent 
percentages and gradient length on the resolution of semi-preparative separations. A consistent 
flow rate of 4 mL/min was used for all separations. The method for HF2-2P1t24 R1 used 
MeCN:water, with 10 min at 70% MeCN, a 30 min gradient to 40% MeCN, and a 3 min 
gradient to 70% MeCN. The method for HF2-2P1t24 R2 used MeCN:water, with 5 min at 65% 
MeCN, a 30 min gradient to 40% MeCN, and a 3 min gradient to 65% MeCN. The method for 
HF2-2P1t24 R3–R5 (Figure 31) used MeCN:water, with 5 min 65% MeCN, a 25 min gradient 
to 45% MeCN, and a 3 min gradient to 65% MeCN. This last method was also used for HF2-
2P1t21 R1–R5 and later separations.  
Initial ELSD conditions used for HF2-2P1t24 were an evaporator temperature of 90 oC, 
a nebulizer temperature of 45 oC, and a gas flow rate of 1.0 SLM. The instrument configuration 
and ELSD conditions were modified for HF2-2P1t21 and later separations with changes in the 
ELSD inlet tubing to give 3.9 mL/min to collection and 0.1 mL/min to ELS detection. These 
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changes dictated that the ELSD gas flow rate be decreased to 0.8 SLM to maintain sensitivity; 
other temperature conditions remained the same.  
Fractions from Polyamine separations were minimally combined due to minor shifts in 
retention times between samples and the difficulties of obtaining NMR data on small quantities 
of material. The three major components of the HF2-2P1t22 fraction (A17, A18 and A19; 
Figure 33; Table 25) were of interest, but the 1H NMR (Figure 35) and LC-MS data for these 
fractions could not be reliably interpreted and insufficient material was available for further 
analyses at the time.  
All fractions that corresponded to HF2-2P1t20A17 (Table 26) were combined and the 
resulting material was further purified using the same Polyamine method as before to yield a 
single major component. This material was submitted for CCRC derivatization analyses and for 
high resolution NMR data at 700 MHz.  
Fraction 02 and baseline elutions (B) were combined across all HF and IF separations. 
These materials had low solubility in either DMSO or water, yielding precipitate and cloudy 
solutions. Preliminary 1H NMR data was acquired for these samples in an attempt to determine 
the nature of these fractions but provided little useful information. 
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Figure 28. Analytical HPLC-ELSD comparisons of AtldC18 fractions HF2-2P1t19, IF1-
3P1t19, and IF1-3P1t23 showing the composition of these fractions in support of preparative 
combinations (Polyamine). 
Fractions HF2-2P1t19 and IF1-3P1t19 were combined for semi-preparative separations while 
IF-3P1t23 was combined with IF1-3P1t22.5 (Figure 30) based on the results of additional 
analytical analyses (not shown). 
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Figure 29. Analytical HPLC-ELSD comparisons of AtldC18 fractions HF2-2P1t19, IF1-
3P1t20, and IF1-3P1t25, and showing the composition of these fractions in support of 
preparative combinations (Polyamine). 
The parent fractions shown here were determined to be distinct enough to warrant independent 
separations and fraction recombinations. Fraction IF1-3P1t20 appears to contain the same 
major component as HF2-2P1t20. 
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Figure 30. Analytical HPLC-ELSD comparisons of AtldC18 fractions HF2-2P1t21, IF1-
3P1t22, IF1-3P1t22.5 and HF2-2P1t24, and showing the composition of these fractions in 
support of preparative combinations (Polyamine). 
The parent fractions shown here were determined to be distinct enough to warrant independent 
separations and fraction recombinations. 
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Table 20. Details of semi-preparative-scale sample preparations used for Polyamine-based 
separations of HF and IF AtldC18 fractions. 
Samples were separated in the sequential order shown (Separation Date) and chromatographic 
separations with the same date were often performed back-to-back within a single session. 
Parent 
Fraction 
Amount 
(mg) 
Sample 
Dissolved 
In (µL) 
Filter 
Wash 
(µL)a 
Sample 
Vol. 
(µL) 
Injected per Run 
(mg/µL) 
Separation 
Date 
HF2-2P1t24 14.7 150 0 150 
R1: 2/20 
R2: 4/40 
R3: 4.5/45 
R4, R5: 3.5/35b 
2009/10/04
IF1-2P1t24 + 
HF2-2P1t24c 6.8 45
b 25 70 Added to HF2-2P1t24 R4 & R5 2009/10/04
HF2-2P1t21 + 
IF1-3P1t21c 
8.0 
16.4 200 0 200 
R1: 4.3/35 
R2: 5.5/45 
R3: 4.9/40 
2009/10/04
 
 
HF2-2P1t21 + 
IF1-3P1t21c (9.76)
d 80 (prev. 
sample) 40 120 
R4: 5/60 
R5: 5/60 2009/10/11
HF2-2P1t19 10.6 75 0 80 
R1: 4.0/30 
6.6/50 added to 
MixR1–R2 
2009/10/11
IF1-3P1t19 + 
IF1-3P1t19.5c 
4.3 + 
2.4 60 20 80 
R1: 3.3/40 
3.4/40 added to 
MixR1–R2 
2009/10/11
HF2-2P1t19 
IF1-3P1t19c 
(6.6)d 
(3.4)d 50 + 45 25 120 
MixR1: 4.2/50 
MixR2: 5.8/70 2009/10/12
IF1-3P1t20 4.3 30 0 30 R1: 4.3/30 2009/10/12
IF1-3P1t22 3.5 25 45 70 
R1: 2.5/50  
1.0/20 added to 
IF1-3P1t23 R2 
2009/10/12
IF1-3P1t23 + 
IF1-3P1t22.5c 
2.1 + 2.7 
+ (1.0)d 50 40 90 
R1: 3.2/60 
R2: 2.6/50a 2009/10/12
HF2-2P1t22 17.1 100 50 130 
R1: 5.3/40 
R2: 4/30 
R3e: 5.3/40 
R3: 5.0/40b 
2009/10/14
HF2-2P1t20 11.9 50 90 140 
R1: 4/50 
R2: 2/25 
R3, R4: 2.4/30 
1.1/10 added to 
HF2-2P1t22 R3 
2009/10/14
a Samples for which the filter wash amount is 0 µL were not filtered. b Contained material from 
an additional parent fraction. c These fractions were determined to be sufficiently similar by 
analytical HPLC-ELSD to justify combining them during separations. d Material from a 
previously prepared sample. e Sample and data were lost due to instrument/operator 
malfunction.  
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Table 21. Combined semi-preparative HPLC fractions resulting from HF2-2P1t24 separations, 
designated HF2-2P1t24A. 
Fractions eluting at t16, t18, t20 and t22 were assessed by 1H NMR spectroscopy and were 
found to contain-closely related oligosaccharides, but full structural assignments could not be 
made. 
Retention 
Time (min)a 
Fraction mg Notes 
1.2–15 02  1.2 few compounds between 0–6, low % of sample 
15.0–16.0 15 0.5  
16–16.8 16 * 0.8 Major component of interest 
16.8–17.6 17 0.6  
17.6–18.7 18 * 1.6 Major component of interest 
18.7–19.8 19 0.9  
19.8–20.8 20 * 1.7 Major component of interest 
20.8–21.5 21 0.3  
21.5–22.5 22 * 0.8 Major component of interest 
22.5–24.0 23 0.4  
a Time points for fraction numbers were based on R2, as R1 had an extended gradient time. 
 
Table 22. Combined semi-preparative HPLC fractions resulting from HF2-2P1t21 and IF1-
3P1t21 separations, designated HF2-2P1t21A. 
Fractions eluting at t15, t17, and t21 were assessed by 1H NMR spectroscopy and were found to 
contain closely-related oligosaccharides, but full structural assignments could not be made. 
Retention 
Time (min)a 
Fraction mg Notes 
0–2.5 02  - large peak, inconsistent profile, large % of sample 
2.5–14 04 2.9 multiple peaks between start and 8 min – 
inconsistent retention times 
14–15 14 1.2  
15–16 15 * 1.1 Major component of interest 
16–17 16 0.9  
17–18 17 * 1.2 Major component of interest 
18–18.5 18  0.5  
18.5–19.2 19  0.9 first of 19–20 double peak 
19.2–20 20  1.0 second of 19–20 double peak 
20–21 21 * 1.2 Major component of interest 
21–21.5 21.5  0.4 shoulder of 21 
21.5–23 22 0.6  
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Table 23. Combined semi-preparative HPLC fractions resulting from HF2-2P1t19, IF1-3P1t19 
and IF1-3P1t19.5 separations, designated HF2-2P1t19A. 
Retention 
Time (min)a 
Fraction mg Notes 
0–3 2 4.6  
3–4 4 0.5  
4–13 B 3.0 flat line before eluting peak set 
13–14.5 14  0.2 first minor peak 
14.5–16.5 15 0.6 baseline peaks between 14 and 17 
16.5–17.5 17 * 1.9 major peak for t19 fractions, possibly same as 
HF2-2P1t20A17 
17.5–18.5 18 0.5 side peak of 17 (minor component) 
18.5–20 19 0.4 last minor peak of set 
20–22 21 0.3 baseline peaks tailing off end of separation 
a Time points for fraction numbers were based on HF2-2t19R1 & IF1-3t19R1. 
 
Table 24. Combined semi-preparative HPLC fractions resulting from IF1-3P1t22 and IF1-
3P1t23 separations, designated IF1-3P1t23A. 
Fractions eluting at t15, t16, and t18 were assessed by 1H NMR spectroscopy and were found to 
contain closely-related oligosaccharides, but full structural assignments could not be made. 
Retention 
Time (min)a 
Fraction mg Notes 
1.3–4.0 2 -  
4.0–13.5 B - baseline between early eluting 
impurity and major peak set 
14.5–16 15 * 0.6 Major component of interest 
16–17 16 * 0.5 Major component of interest 
17–18 17  0.5  
18–19 18 * 1.0 Major component of interest 
19–20 19 0.9  
20–21.5 21 0.9 mix of baseline minor components 
21.5–22.5 22 0.8 mix of baseline minor components 
a Times points for fraction numbers were based on IF1-3P1t23 R1. 
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Table 25. Combined semi-preparative HPLC fractions resulting from HF2-2P1t22 separations, 
designated HF2-2P1t22A. 
Fractions eluting at t17, t18, and t19 were assessed by 1H NMR spectroscopy and were found to 
contain closely-related oligosaccharides, but full structural assignments could not be made. 
Fraction t17 from this separation appears to be the same compound as HF2-2P1t20A17 based 
on co-injection of the HF2-2P1t20 and HF2-2P1t22 samples. 
Retention 
Time (min)a 
Fraction mg Notes 
1.3–4.0 2 -  
4.0–13.5 B - baseline between early eluting impurity and major peak set 
13.5–14.5 14 0.9  
14.5–15.5 15 0.4 minor – almost baseline relative percent 
15.5–16.5 16 0.5  
16.5–17.5 17 * 1.9 same compound as major component of HF2-2t20 
17.5–18.5 18 * 1.8 first major peak of set found in HF2-2t22 sample 
18.5–20.0 19 *  1.9 second major peak of set found in HF2-2t22 sample 
20.0–22 21 0.4 minor baseline peak set 
a Times points for fraction numbers were based on HF2-2P1t22 R2 as this sample contained a 
portion of the HF2-2Pt120 sample. 
 
Table 26. Combined semi-preparative HPLC fractions resulting from HF2-2P1t20 and IF1-
3P1t20 separations, designated HF2-2P1t20A. 
Fraction t17 was the primary source of compound 1; other fractions with similar retention times 
were combined with this sample and the resulting material was re-purified to yield the sample 
of 1 that was submitted to the CCRC for analysis and analyzed by NMR spectroscopy at 700 
MHz. 
Retention 
Time (min)a 
Fraction mg Notes 
1.3–4.0 02 3.2  
4.0–12.5 B 1.1 baseline between early eluting impurity and major peak set 
12.5–13.5 13 1.0  
13.5–14.5 14 1.6  
14.5–15.8 B - baseline peaks just before major component – perhaps one 
primary component 
15.8–17.8 17 * 8.8 major peak/major component of sample mass 
17.8–19 18 0.8 baseline minor peak (mixture) 
19–21 20 0.9 baseline minor peak set (mixture) 
a Time points for fraction numbers were based on HF2-2P1t20 R2 & R3. 
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Figure 31. Semi-preparative HPLC-ELSD of HF2-2P1t24 R2–5 (Polyamine). 
Fractions eluting at t16, t18, t20 and t22 were assessed by 1H NMR spectroscopy and were 
found to contain closely-related oligosaccharides. 
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Figure 32. Semi-preparative HPLC-ELSD of HF2-2P1t21 R1–5 (Polyamine). 
Fractions eluting at t15, t17, and t21 were assessed by 1H NMR spectroscopy and were found to 
contain closely-related oligosaccharides. (% MeCN shown) 
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Figure 33. Semi-preparative HPLC-ELSD of HF2-2P1t22 R1–3 (Polyamine). 
Fractions eluting at t17, t18, and t19 were assessed by 1H NMR spectroscopy and these data are 
discussed further below. The t17 peak for the third separation (R3) is of increased intensity 
presumably due to co-injection of a small amount of HF2-2P1t20. If the same compound is 
indeed present in the HF2-2P1t22 sample, this data indicates the low resolution obtained with 
the AtldC18 separations. The increased intensity of t17 may also indicate, however, similar 
retention times for two different components as resulted with many of these fractions (see 
Section C5d). Although fraction t17 from this separation appears to be the same compound as 
HF2-2P1t20A17 these materials were kept separate. 
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Figure 34. Semi-preparative HPLC-ELSD of HF2-2P1t20 R1–4 (Polyamine). 
Fraction t17 was the primary source of compound 1. The fraction of IF1-3Pt20 with similar 
retention time was combined with this sample. The resulting material was re-purified to yield 
the sample of 1 that was submitted to the CCRC for analysis and analyzed by NMR 
spectroscopy at 700 MHz. (% MeCN shown) 
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Figure 35. Comparison of the 1H NMR spectra for HF2-2P1t22A fractions eluting at 17, 18, 
and 19 min, D2O, 400 MHz. 
No resonances were present in the spectra regions not displayed. Characteristic resonances 
were present at 4.5, 5.0, 5.1 and 5.15 ppm (arrows) in all three spectra shown. These 
resonances could not be interpreted at the time these spectra were collected but were later 
determined to potentially correspond to the anomeric protons for arabinoxyloglucan type 
oligosaccharides. All three spectra are similar to that of 1. HF2-2P1t22A17 may be the same 
compound as 1 based on the results of co-injection during preparative separations. 
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d. Challenges of HPLC-ELSD-Based Oligosaccharide Isolation 
Carbohydrates such as oligosaccharides are often purified using amino or polyamine 
stationary phases. Multiple attempts were therefore made to directly separate the components 
of HF1-1 using amino, polyamine, and other normal phase sorbents with various solvent 
systems and conditions. These efforts did not yield sufficient resolution for the compounds of 
interest (Figure 36). Attempts at reverse phase separations with more nonpolar sorbents, such 
as the XTMSC18 column, and with sorbent appropriate starting solvents of 10% or more 
MeOH or MeCN, were also unsuccessful for retaining and resolving the oligosaccharide 
components (Figure 37). The method that yielded the best results employed a reverse phase 
AtldC18 column but still did not yield baseline resolution of the components of interest. The 
AtldC18 sorbent has polar groups embedded into the silica-bound C18 stationary phase, 
allowing complete wetting with water without the need for an organic modifier such as MeOH 
or MeCN. The ability to equilibrate and use the column in 100% water appears to have 
contributed to the resolution that was achieved with this sorbent.  
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Figure 36. Examples of the analytical HPLC-ELSD chromatograms produced during HF1-1 
method development with an amino HPLC sorbent.  
These HPLC chromatograms correspond to variations in solvent systems (changes in solvent 
%, use of MeOH or MeCN) using a YMC NH2 column (4.6 x 150 mm, 5 µm) and a flow rate 
of 1 mL/min. 
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Figure 37. Examples of the analytical HPLC-ELSD chromatograms produced during HF1-1 
method development attempts using a C18 HPLC sorbent. 
These HPLC chromatograms correspond to variations in solvent systems (changes in solvent 
%, use of MeOH or MeCN) using an XTMSC18 column (4.6 x 150 mm, 5 µm) and a flow rate 
of 1 mL/min. 
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The enriched fractions obtained from the AtldC18 separations could be further resolved 
by amino, polyamine, or other normal phase sorbents. Multiple sorbents and solvent systems 
were tested and the polyamine sorbent yielded the best resolution with MeCN as the solvent. 
The lack of resolution previously observed for attempts at direct, normal phase separation of 
oligosaccharide components could be explained by observations made with AtldC18 fractions. 
Fractions collected from a single AtldC18 separation (e.g. IF1-3; Figure 24) were separated 
sequentially using the polyamine sorbent with an optimized analytical instrument and 
controlled, repeated conditions. Comparisons of the resulting analytical HPLC-ELSD spectra 
showed that fractions eluting with different AtldC18 retention times, and therefore different 
major components, contained compounds that had similar retention times on the polyamine 
sorbent (Figures 38–40). For example, during semi-preparative separation, the IF1-3P1t20 
subfraction collected from the AtldC18 column contains a major compound that appears at 16–
17 min on the Polyamine column (Figure 41). This component overlaps in retention time with 
compounds in the t22 and t23 subfractions even though they are derived from different parent 
AtldC18 fractions and are unlikely to contain the same components. Peaks that appear to 
contain single or major components in the AtldC18 chromatogram (e.g. the peak at 22 min; 
Figure 24) were also found to contain multiple components when examined on the Polyamine 
stationary phase (Figure 39). In non-enriched parent fractions, all such compounds would have 
overlapped and led to the observed poor resolution. These phenomena also made the 
recombination of fractions from multiple separations especially challenging, as there was little 
guarantee, based solely on retention time data, that any two peaks from related fractions 
represented the same compounds.  
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Figure 38. Analytical Polyamine HPLC-ELSD comparisons of IF1-3 AtldC18 fractions t03, 
t05-08, 08-11, 19, and B, showing the changes in elution profile associated with the change in 
sorbent. 
The fractions shown here eluted at distinct times on the AtldC18 sorbent, but the major 
components of each all had similar retention times on the Polyamine sorbent (~18 min). The 
lack of distinct components in the IF1-3P1B fraction indicates that the major components of the 
IF1-3 parent material have been collected as parts of other fractions.  
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Figure 39. Analytical Polyamine HPLC-ELSD comparisons of IF1-3 AtldC18 fractions t19.5, 
t20, t21, t22, and t22.5, showing the changes in elution profile associated with the change in 
sorbent. 
The fractions shown here eluted at distinct times on the AtldC18 sorbent, but the major 
components of each all had similar retention times on the Polyamine sorbent. 
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Figure 40. Analytical Polyamine HPLC-ELSD comparisons of IF1-3 AtldC18 fractions t122.5, 
t23, t24, and t25, showing the changes in elution profile associated with the change in sorbent. 
The fractions shown here eluted at distinct times on the AtldC18 sorbent, but the major 
components of each all had similar retention times on the Polyamine sorbent. 
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Figure 41. Semi-preparative HPLC-ELSD separations for IF1-3P1 subfractions (Polyamine). 
The IF1-3P1t20 subfraction was similar in ELSD profile to the HF2-2P1t20 subfraction and 
both were collected at 20 min from the AtldC18 column (Figure 24). This fraction contains a 
major compound that appears at 16-17 min (indicated as t17) on the Polyamine column. This 
component overlaps in retention time with compounds in the t22 and t23 subfractions (box) 
even though these fractions are derived from different parent AtldC18 fractions and are 
unlikely to contain the same components. 
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A factor that further detracted from efforts to isolate sufficient quantities of pure 
oligosaccharides was the requirement for destructive, ELSD-based detection and collection. 
The preparative HPLC configuration involved the placement of a flow splitter after the UV 
detector but before the ELSD. This splitter directed the majority of the flow to collection 
vessels, with a smaller portion directed to the detector. Typically, 2–4% of the eluting solvent 
entered the detector for the flow rates of 20–25 mL/min used with the preparative AtldC18 
column, but this percentage may have been as high as 10% for the slower flow rates (5–10 
mL/min) used with the semi-preparative Polyamine column. At the time, a larger, preparative-
scale, polyamine column was not available. This arrangement meant that as much as 10% of a 
given sample would be lost to the detector with every injection and separation. All attempts 
were made with available resources to decrease this percentage of sample loss but such efforts 
were limited by the sensitivity and configuration of the detector and by the flow dynamics of 
the system. 
The issue of poor baseline resolution combined with the need for split detection and 
collection further hindered isolation efforts. Steps were taken to design the system in such a 
way as to ensure that the sample would reach the detector and the collection vessel at the same 
time, but as little as a ten second delay or shift could change the composition of the collected 
fraction from that observed on the chromatogram. This phenomenon further contributed to the 
need for multi-step purification protocols involving more than one chromatographic sorbent.  
Multiple, instrument-related issues could also interfere with the re-combination of 
fractions from different samples based on retention times. These were typically due to (a) 
alterations in HPLC instrument configuration due to clogged tubing or leaks, (b) changes in 
HPLC instrument performance due to inappropriate methods of switching between normal and 
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reverse solvent systems, and (c) decreased detector sensitivity or response due to the deposition 
of unknown, insoluble sample materials on the ELSD nebulizer, within the evaporator tube, or 
on the detection optics. Most of these issues were due to abuse of the instruments by other 
individuals.  
Numerous efforts were therefore made to ensure the stability of the chromatographic 
system to achieve repeatable retention times and to maintain the highest possible detector 
sensitivity. For the majority of samples, material was divided into portions that were 
intensively separated over a series of back-to-back preparative separations. Instrument 
performance was checked with known samples prior to batches of separations and instrument 
back-pressure data was acquired with every separation to monitor instrument and column 
performance. Sets of separations were also typically performed over a period of several days 
when the instrument was not accessible to other users.  
The amounts of material obtained for AtldC18-Polyamine purified fractions (0.5–5 mg) 
were typically insufficient to obtain quality 1H NMR data. This was likely due partly to the 
high-MW of the compounds in question and partly to the high resonance overlap inherent to 
oligosaccharides. The oligosaccharide nature of many purified compounds could be established 
by 1H NMR, but the data obtained could often not reliably distinguish two components that 
were known to have different retention times and originated from different parent fractions. 
These issues further contributed to the difficulty of recombining samples to obtain higher 
quantities and additional data. For most samples, sufficient purity could not be assured for the 
pursuit of chemically based structure elucidation approaches, and the limited quantities 
available made additional ELSD-based separations impractical due to the losses inherent to the 
system.  
105 
 
Many of these factors did provide useful information even though they made isolation 
and structural characterization challenging. The difficulty of obtaining baseline resolution 
between the components of the series indicated that the compounds present possessed similar 
chromatographic properties, most likely due to similar structures. Similarities in the NMR data 
that could be obtained indicated that many of the distinct compounds present have structures 
closely related to that subsequently established for 1.  
6. Structure Elucidation  
The primary and secondary structure of 1 was established using standard carbohydrate 
derivatization and analysis procedures, MSn fragmentation data, and 1D and 2D NMR 
experiments as discussed below. 
a. Results of Carbohydrate Derivatization Analyses 
Glycosyl composition analysis by GC-MS of the TMS methyl glycosides of 1 indicated 
it was composed of arabinose, xylose and glucose with a molar ratio of 1:1:2 (Table 27). Mass 
fragments of the TMS methyl glycosides at m/z 204 and 217 (not shown) indicated that 1 
contained neutral sugars. MALDI-TOF-MS (Figure 42) analysis showed an [M+Na]+ ion of  
1218.117 for the highest intensity molecular ion, consistent with an octasaccharide composed 
of two arabinosyl, two xylosyl and four glucosyl residues.  
GC-MS analysis of the (S)-(+)-butyl glycoside TMS derivatives of 1 as compared to 
standards (Figure 43) indicated that the absolute configurations of these residues were D-Glc, 
D-Xyl, and L-Ara, consistent with the natural abundances of these monosaccharides.  
The linkage positions on each monomer were determined using partially methylated 
alditol acetate derivatives of 1 (Jahfar & Azadi 2004). These data, when evaluated in 
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conjunction with the molar ratio and mass results, indicated that 1 contained two terminally-
linked arabinofuranosyl residues, two 2-linked xylopyranosyl residues, one terminally-linked 
glucopyranosyl residue, one 4-linked glucopyranosyl residue, and two 4,6-linked 
glucopyranosyl residues. The 2-linked xylopyranosyl residues, the 4-linked glucopyranosyl 
residue, and the 4,6-linked glucopyranosyl residues could also be linked through the anomeric 
position. 
Further MS and NMR analyses were used to confirm glycosyl linkages, to confirm 
connectivity through anomeric positions, and to assign anomeric configurations.  
 
Table 27. Results of the glycosyl composition analysis for 1. 
Arabinose, xylose, and glucose were determined to be the monosaccharides present in 1 in a 
ratio of 1:1:2. 
Residue  Weight (µg)  Mole%  
Arabinose (Ara)  26.5  22.0  
Ribose (Rib)  0.0  0.0  
Rhamnose (Rha)  0.0  0.0  
Fucose (Fuc)  0.0  0.0  
Xylose (Xyl)  30.4  25.1  
Glucuronic Acid (GlcUA)  0.0  0.0  
Galacturonic Acid (GalUA)  0.0  0.0  
Mannose (Man)  0.0  0.0  
Galactose (Gal)  0.0  0.0  
Glucose (Glc)  76.7  52.9  
N-Acetyl Galactosamine (GalNAc)  0.0  0.0  
N-Acetyl Glucosamine (GlcNAc)  0.0  0.0  
Heptose (Hep)  0.0  0.0  
3 Deoxy-2-Manno-2-Octulsonic Acid (KDO)  0.0  0.0  
Sum  100  
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Figure 42. Results of the MALDI-MS analysis for 1 showing an m/z of 1218.117 corresponding 
to the sodium adduct of the compound in the (+) ionization mode. 
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Figure 43. Results of the GC-MS analysis of the TMS derivatives of (S)-(+)-butyl glycosides of 
authentic standards D-Glc, L-Ara, D-Xyl and 1.  
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b. Partial Fragmentation Pattern Analysis for Linkage Positions 
A pure sample of 1 was derivatized via per-O-methylation and then subjected to NSI-
MS with fragmentation by CID in MS/MS and MSn modes using direct infusion of the sample. 
As the only material in the sample was the compound of interest, resulting fragment ions were 
presumed to have been generated from this material. The derivative produced from 1 was 
detected as singly and doubly (2+) charged species (Figure 44) and selected ions were 
subjected to additional fragmentation (Figures 44–58).  
Two possible structures for 1 were consistent with the data from previous analyses 
(Figure 45). These could be distinguished using the results of the fragmentation pattern 
analysis, even though mass fragments were only generated at unit resolution due to the nature 
of the method used. Methylation patterns and knowledge of typical fragmentation sites 
(glycosidic bonds) and fragmentation sequences for oligosaccharides made it possible to 
distinguish between different mass fragments and associate the resulting mass losses with the 
two putative structures for 1 (Domon et al. 1990, Costello & Vath 1990, Hisamatsu et al. 1992, 
York et al. 1996). Terminal, internal, and reducing glucopyranosyl residues could be 
distinguished based on unit mass differences of 218 (terminal), 190 (internal), and 236 
(reducing) amu. Arabinofuranosyl and xylopyranosyl residues could also be distinguished 
based on mass losses of 174 and 160 amu, respectively, or 334 amu for an Ara-Xyl side chain.  
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Figure 44. Results of the NSI-MS-based glycosyl linkage analysis showing mass fragments for 
the per-O-methylated derivative of 1.  
The per-O-methylated derivative of 1 was detected as singly and doubly (2+) charged species. 
The parent ion at m/z 1526 was selected for further fragmentation. 
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Figure 45. Possible structures for 1 showing alternate placements of a Xyl-Ara side chain on 
either Glcp-B (a) or Glcp-A (b). 
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The NSI-MS2 fragmentation at m/z = 1526 for the per-O-methylated derivative of 1 
(Figure 46) gave indicative mass fragments of m/z 1352, 1308, 1290, 1192, and 784. The mass 
fragment of m/z 1352 is consistent with the loss of a terminal arabinose (∆m/z = 174), m/z 1308 
is consistent with the loss of terminal glucose (∆m/z = 218), m/z 1290 is consistent with the loss 
of reducing end glucose (∆m/z = 236), m/z 1192 is consistent with  the loss of a terminal 
arabinose and an internal xylose (∆m/z = 334), and m/z 784 is consistent with the loss of a 
terminal arabinose, an internal xylose, an internal glucose and a terminal glucose (∆m/z = 742). 
These mass fragments were consistent with structure (a) (Figure 47), as structure (b) (Figure 
48) did not result in the production of an m/z 1290 fragment corresponding to the loss of a 
reducing end glucose (∆m/z = 236).  
 
Figure 46. The NSI-MS2 fragmentation at m/z = 1526 for the per-O-methylated derivative of 1.  
Mass losses of ∆m/z 174, 218, 236, and 334 were indicative of key putative fragments 
consistent with structure (a). Ions at m/z 1308 and 1352 were selected for further fragmentation. 
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Figure 47. Structure (a) putative mass fragments produced from the m/z = 1526 parent ion of 
per-O-methylated 1. 
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Figure 48. Structure (b) putative mass fragments produced from the m/z = 1526 parent ion of 
per-O-methylated 1. 
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The NSI-MS3 fragmentation at m/z = 1526 → 1308 for the per-O-methylated derivative 
of 1 (Figure 49) gave indicative mass fragments of m/z 1134, 1072, 974, and 784. The mass 
fragment of m/z 1134 is consistent with the loss of a terminal arabinose (∆m/z = 174), m/z 1072 
is consistent with the loss of a reducing end glucose (∆m/z = 236), m/z 974 is consistent with 
the loss of a terminal arabinose and an internal xylose (∆m/z = 334), and m/z 784 is consistent 
with the loss of a terminal arabinose, an internal xylose, and an internal glucose (∆m/z = 524). 
These mass fragments were consistent with structure (a) (Figure 50), as the putative m/z 1308 
fragment of structure (b) (Figure 51) did not produce a fragment at m/z 1072 corresponding to 
the loss of a reducing end glucose (∆m/z = 236).  
 
Figure 49. The NSI-MS3 fragmentation at m/z = 1526 → 1308 for the per-O-methylated 
derivative of 1.  
This spectrum was generated using CID = 30%. Mass losses of ∆m/z 174, 236, 334, and 524 
were indicative of key putative fragments consistent with structure (a). 
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Figure 50. Structure (a) putative mass fragments produced from the m/z = 1308 fragment of 
per-O-methylated 1. 
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Figure 51. Structure (b) putative mass fragments produced from the m/z = 1308 fragment of 
per-O-methylated 1. 
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The NSI-MS3 fragmentation at m/z = 1526 → 1352 for the per-O-methylated derivative 
of 1 (not shown; see Figures 47, 48 for putative structures of the m/z 1352 ion) yielded a high 
intensity, indicative fragment at m/z 1192, with additional low intensity mass fragments of m/z 
1178, 1017, 955, 857, and 784. The m/z 1178 fragment was consistent with the loss of a 
terminal arabinose (∆m/z = 174), and the m/z 1192 fragment was consistent with the loss of an 
internal xylose (∆m/z = 160). The fragmentation pattern for the m/z 1352 ion was of minimal 
utility in distinguishing between the two putative structures for 1, and the highest intensity ion 
at m/z 1192 was therefore selected for further fragmentation. 
The NSI-MS4 fragmentation at m/z = 1526 → 1352 → 1192 for the per-O-methylated 
derivative of 1 (Figure 52) gave indicative mass fragments of m/z 1017, 974, 955, 857, and 784. 
The mass fragment of m/z 1017 is consistent with the loss of a terminal arabinose (∆m/z = 174), 
m/z 974 is consistent with the loss of a terminal glucose (∆m/z = 218), m/z 955 is consistent 
with the loss of a reducing end glucose (∆m/z = 236), m/z 857 is consistent with the loss of an 
internal xylose and a terminal arabinose (∆m/z = 334), and m/z 784 is consistent with the loss of 
a terminal and an internal glucose (∆m/z = 408). These mass fragments were consistent with 
structure (a) (Figure 53), as the putative m/z 1192 fragment of structure (b) (Figure 54) did not 
produce a fragment at m/z 955 corresponding to the loss of a reducing end glucose. The m/z 
1192 fragment of structure (b) would also have been expected to result in a fragment at m/z 579 
corresponding to the loss of a terminal glucose and two internal glucose units (∆m/z = 612). 
This fragment was not present in the NSI-MS4 data at m/z 1192. 
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Figure 52. The NSI-MS4 fragmentation at m/z = 1526 → 1352 → 1192 for the per-O-
methylated derivative of 1.  
Mass losses of ∆m/z 174, 218, 236, 334, and 408 were indicative of key putative fragments 
consistent with structure (a). The ion at m/z 1192 was selected for further fragmentation.  
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Figure 53. Structure (a) putative mass fragments produced from the m/z = 1192 fragment of 
per-O-methylated 1. 
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Figure 54. Structure (b) putative mass fragments produced from the m/z = 1192 fragment of 
per-O-methylated 1. 
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The NSI-MS5 fragmentation at m/z = 1526 → 1352 → 1192 → 784 for the per-O-
methylated derivative of 1 (Figure 55) gave indicative mass fragments of m/z 609, 565, 547, 
and 449. The mass fragment of m/z 609 is consistent with the loss of a terminal arabinose (∆m/z 
= 174), m/z 565 is consistent with the loss of a reducing end glucose minus an oxygen (∆m/z = 
219), m/z 547 is consistent with the loss of a reducing end glucose (∆m/z = 236), and m/z 449 is 
consistent with the loss of an internal xylose and a terminal arabinose (∆m/z = 334). These 
mass fragments were consistent with structure (a) (Figure 56), as the putative m/z 784 fragment 
of structure (b) (Figure 57) did not produce fragments at m/z 547 or 565 corresponding to the 
loss of a reducing end glucose. The m/z 784 fragment of structure (b) would also have been 
expected to result in fragments at m/z 579, corresponding to the loss of an internal glucose 
(∆m/z = 204), and at m/z 563, corresponding to the loss of an internal glucose minus an oxygen 
(∆m/z = 221). These fragments were not present in the NSI-MS5 data. 
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Figure 55. NSI-MS5 fragmentation at m/z = 1526 → 1352 → 1192 → 784 for the per-O-
methylated derivative of 1. 
Mass losses of ∆m/z 174, 219, 236, and 334 were indicative of key putative fragments 
consistent with structure (a). 
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Figure 56. Structure (a) putative mass fragments produced from the m/z = 784 fragment of per-
O-methylated 1. 
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Figure 57. Structure (b) putative mass fragments produced from the m/z = 784 fragment of per-
O-methylated 1. 
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Structure (a) was therefore confirmed as the structure of 1 through the presence of key 
putative fragments produced from partial and sequential fragmentation of the m/z 1526 parent 
ion. These data supported the presence of a reducing, unsubstituted glucosyl moiety connected 
via a single glycosidic bond to the remainder of the compound, and allowed placement of the 
two Xyl-Ara side chains on the two internal glucosyl residues of the tetrameric backbone. 
Alternative placement of one of the side chains on the reducing glucosyl unit (structure b) 
would have resulted in a different pattern of MSn fragments. A key indicator of the presence of 
the 4-linked glucosyl unit was a mass loss of ∆m/z = 236 from all fragment ions analyzed (m/z 
1526, 1308, 1192, and 784). If the reducing glucosyl unit had instead been substituted with a 
side chain on C-6, the mass loss of ∆m/z = 236 would not have been detected. Additional 
fragments indicative of C-6 substitution on the reducing glucosyl unit would instead have been 
detected. Placement of the Xyl-Ara side chains was further confirmed using NMR analyses. 
All data obtained from the CCRC analyses were used to assign the structure of 1 as 
shown (Figure 58), with a D-glucopyranosyl-(1→4)-D-glucopyranosyl backbone and two L-
arabinofuranosyl-(1→2)-D-xylopyranosyl side chains connected to the internal glucosyl 
residues via D-xylopyranosyl-(1→6)-D-glucopyranosyl linkages. Configurations at the C-1 
positions were determined using NMR analyses. 
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Figure 58. The structure of 1 as determined by the CCRC analyses. 
Anomeric configurations could not be assigned using the data collected from the CCRC 
analyses, but all other structural features shown could be conclusively determined. 
 
 
 
c. NMR Spectroscopy 
The complexity of the compound and the extensive degree of overlap for monomer ring 
resonances made it necessary to assign putative NMR values based on comparisons with 
reference compounds and previously determined knowledge of compound structure. This 
approach is considered appropriate as the majority of the structure had been previously 
determined using chemical derivatization and associated analyses. The NMR data was 
primarily used to confirm or refute previously made assignments and to assign anomeric 
configuration (York et al. 1990, Hisamatsu et al. 1992, York et al. 1996). Spectra were 
therefore compared to those of purified cranberry oligosaccharides (Auker 2013, Auker et al. 
2014) as the oligosaccharides isolated from both cranberry and urine sources were determined 
to be similar.  
The NMR spectra indicated the presence of minor impurities, but sufficient resolution 
could be obtained to assign putative 1H and 13C values for 1 (Figure 59–Figure 62, Table 28). 
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These assignments were supported by HMQC (Figure 64), COSY (Figure 65), and TOCSY 
(Figure 66) data, and by comparisons to reference values for monomer units, cellotetraose, and 
cranberry oligosaccharides (Auker 2013, Auker et al. 2014). Duplicate resonance sets were 
detectable for the two pairs of Ara and Xyl units, but could not be assigned independently. 
These duplicated resonance sets indicated a high degree of structural symmetry for the local 
environment of each side chain. These observations were consistent with the structural 
assignments made using the partial-fragmentation pattern analyses. 
The anomeric positions of Glc-B, Glc-C, and Glc-D were assigned β-orientation based 
on their downfield (δH < 4.70) chemical shifts and coupling constants of JH1,H2 > 5 Hz, while 
Xyl-E, and Xyl-F were assigned α-orientation due to their upfield (δH > 4.70) chemical shifts 
and coupling constants of JH1,H2 < 5 Hz (Duus et al. 2000). The anomeric positions of the Ara-
G and Ara-H residues were assigned α-orientation due to their JH1,H2 ≈ 1–2 Hz, although the 
exact J-value for these residues could not be assigned as a result of resonance overlap (Duus et 
al. 2000, Islam et al. 2011). The reducing glucosyl residue indicated by MSn-fragmentation 
patterns was assigned to Glc-A and its presence confirmed by duplicate resonances for the α- 
and β-anomers of this monomer (Table 28).  
Numerous COSY, TOCSY, and HMBC correlations further confirmed the identities and 
connectivity of the units indicated by the CCRC analyses and the MSn fragmentation patterns 
(Figures 63–66). Key HMBC correlations between H-1 of Araf-G and H (δH 4.93) and C-2 of 
Xylp-E and F (δC 78.9), and between H-2 of Xylp-E and F (δH 3.21) and C-1 of Araf-G and H 
(δC 109.9), supported the assignment of α-L-arabinofuranosyl-(1→2)-α-D-xylopyranosyl side 
chains. These side chains were linked to C-6 of the two internal glucose residues Glcp-B and C 
through HMBC correlations between H-1 of Xylp-E and F (δH 4.79), and δC 67.1. Key HMBC 
129 
 
correlations also further confirmed the connectivity of the glucose backbone with a correlation 
between H-1 of Glcp-C (δH 4.27) and C-4 of Glcp-B (δC 81.0). The structure of the resulting 
octasaccharide (1) was assigned as β-D-glucopyranosyl-(1→4)-[α-L-arabinofuranosyl-(1→2)-
α-D-xylopyranosyl-(1→6)]-β-D-glucopyranosyl-(1→4)-[α-L-arabinofuranosyl-(1→2)-α-D-
xylopyranosyl-(1→6)]-β-D-glucopyranosyl-(1→4)-β-D-glucopyranose. 
 
  
130 
 
 
Figure 59. The 1H NMR spectrum of 1 in DMSO-d6, 700 MHz, showing sufficient resolution to 
obtain structural information. 
 
 
Figure 60. Expansions of the 1H NMR spectrum of 1, DMSO-d6, 700 MHz, showing 
integration and chemical shift assignments. 
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Figure 61. The 13C NMR spectrum of 1 in DMSO-d6, 175 MHz, showing sufficient resolution 
to obtain structural information. 
 
 
Figure 62. Expansions of the 13C NMR spectrum of 1, DMSO-d6, 175 MHz, showing chemical 
shift assignments. 
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Table 28. Proposed 1H and 13C NMR assignments for 1, DMSO-d6, 700/175 MHz. 
Duplicate resonance sets were observed for the two sets of Xyl and Ara residues. The same 
chemical shift values were therefore assigned to the two sets of Xyl and Ara residues. Values 
for the Glc residues were assigned using the aid of reference compounds including glucose, 
cellotetraose, and the two oligosaccharides of similar structure isolated from cranberry 
materials. The majority of these assignments were supported by 2D correlations. Numerical 
assignments for the 2- and 3-positions of the glucosyl residues are tentative. 
 Monomer Position δC δH (multa; 
JHH) 
  Monomer Position δC δH (multa; 
JHH) 
Glcp-A 1 92.2 4.92 (3.9)  Glcp-D 1 103.5 4.36 (8.0) 
α-anomer 2 72.0 3.59    2 73.2 3.12 
  3 72.3 3.24    3 75.1 3.37 
  4 81.7 3.32    4 73.7 3.63 
  5 77.3 3.21    5 81.5 3.38 
  6 61.5 3.61, 3.71    6 61.0 3.55, 3.75 
Glcp-A 1 96.9 4.35 (6.8)  Xylp-E 1 99.1 4.79 (3.3b)
β-anomer 2 73.7 3.01    2 78.9 3.21b
  3 70.9 3.29    3 71.9 3.76 
  4 81.6 3.28    4 70.9 3.29 
  5 76.9 3.16    5 62.0 3.42 
  6 61.1 3.44, 3.72  Xylp-F 1 99.1 4.79 (3.3b)
Glcp-B 1 102.9 4.43 (8.1)    2 78.9 3.21 
  2 73.1 3.15    3 71.9 3.76 
  3 74.7 3.01    4 70.9 3.29 
  4 81.0 3.36    5 62.0 3.42 
  5 79.0 3.20b  Araf-G 1 109.9 4.93c
  6 67.1 3.70, 3.85    2 82.1 3.91
Glcp-C 1 103.8 4.27 (7.8)    3 77.6 3.63 
  2 73.5 3.66    4 83.9 3.81 
  3 75.2 3.40    5 61.7 3.42, 3.59 
  4 82.1 3.91  Araf-H 1 109.9 4.93c
  5 79.0 3.20    2 82.1 3.91 
  6 67.1 3.75, 3.83    3 77.6 3.63 
       4 83.9 3.81 
       5 61.6 3.42, 3.59 
a All protons appeared as overlapping multiplets. b Approximate J value  
c A reliable numerical J value assignment could not be made due to resonance overlap. 
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Figure 63. The structure of 1 with putative 1D NMR numerical assignments shown.  
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Figure 64. The HMQC spectrum for 1, DMSO-d6, 700/175 MHz. 
Anomeric correlations and methylene correlations have been indicated on the spectrum. 
Remaining correlations were assigned to ring carbons and protons. Two resonances 
corresponding to C-1/H-1 of the Glc-A moiety were present due to the reducing nature of this 
moiety.  
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Figure 65. The COSY spectrum for 1, DMSO-d6, 700 MHz. 
These correlations were used to confirm HMQC assignments for ring protons and are shown 
below on the structure of 1 (Figure 68). 
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Figure 66. The TOCSY spectrum for 1, DMSO-d6, 700 MHz.      
These correlations were used to provide further support for the assignment of ring protons and 
associated carbons. 
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Figure 67. The HMBC spectrum for 1, DMSO-d6, 700 MHz. 
Key HMBC correlations (arrows) supported the assignments of connectivity between monomer 
units and were consistent with the structure determined by the CCRC analyses.  
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Figure 68. Structure of the urinary octasaccharide (1) showing putative COSY and HMBC 
correlations.  
 
D. Conclusions 
This project was initiated on the premise that the active compounds present in treated 
swine urine would be A-type PACs or metabolically-transformed PACs (Chapter 1). Such 
compounds would be expected to retain aromatic protons detectable by 1H NMR spectroscopy, 
even in complex mixtures and regardless of metabolic transformations such as polymer 
hydrolysis or glycosidic conjugation. As the project progressed, it became evident that active 
fractions contained no indication of PACs, flavonoids, or related compounds. These results did 
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not support the original PAC-based hypothesis. The isolation and purification approach was 
therefore changed to focus on the isolation and characterization of unknown compounds from 
active aqueous fractions. During the subsequent method development it was determined that 
the major components of the active fractions lacked chromophores, making them undetectable 
by conventional UV-based methods.  
The use of ELSD made it possible to detect and characterize a group of urinary 
compounds from active fractions that were not PAC-derived and were instead determined to be 
complex carbohydrates, specifically oligosaccharides. A single compound from the series of 
oligosaccharides detected by HPLC-ELSD was purified in sufficient quantity for full structural 
elucidation. This compound (1) was found to be an octasaccharide composed of a tetrameric, β-
(1→4)-linked glucose backbone with two xylose-arabinose side chains. Preliminary NMR data 
and chromatographic characteristics of the other purified compounds indicates that 1 is 
representative of the complex pool of oligosaccharides that is present.  
The structure of 1 is similar to that of arabinoxyloglucans isolated from solanaceous 
plants (York et al. 1996). Such compounds are believed to be derived from the hemicellulose 
polymers that serve as structural components of plant primary cell walls. These hemicellulose 
polymers are enzymatically cleaved and solubilized during the process of fruit ripening (York 
et al. 1996, Brummell et al. 2004, Goulão & Oliveira 2008). The presence of similar 
compounds in cranberry would support the hypothesis that the oligosaccharides present in 
swine urine originate from cranberry hemicelluloses, but little is known about the composition 
of cranberry hemicelluloses or cranberry oligosaccharides.  
Oligosaccharide urinary metabolites were consistently present in active urine collected 
from three different swine after cranberry consumption and were present in active fractions but 
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not in inactive fractions, control urine, or control urine fractions. Retrospective examination of 
NMR data from the first active D fractions also confirmed the evidence of oligosaccharides, but 
this evidence was discounted at the time it was collected as it did not indicate the presence of 
PACs. The concentration range estimates for the urinary metabolites isolated during this study 
are within a reasonable range for bioactivity, with single components being present at ~1–5 
µg/mL urine (Saude et al. 2007, Bouatra et al. 2013).  These data strongly indicated that 
arabinoxyloglucan oligosaccharides are a component that may be responsible for the anti-
adhesion properties of urine and urine fractions following cranberry consumption, but E. coli 
anti-adhesion properties had not been previously reported for this class of compounds. 
At the conclusion of this study, insufficient amounts of urinary oligosaccharides were 
available for testing in the UPEC-HRBC anti-agglutination assay and the reproducibility of the 
assay had been questioned. The source of the urinary oligosaccharides was also unknown, as 
arabinoxyloglucan oligosaccharides had not been previously reported from cranberry or other 
Vaccinium species. The information available suggested a major paradigm transition regarding 
the mechanism by which cranberry juice prevents UTIs, but, alone, provided insufficient direct 
evidence to support such a proposition with certainty. Additional studies using cranberry 
materials were therefore pursued (Chapter 3). 
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CHAPTER 3: CRANBERRY COMPOSITION 
A. Introduction 
The majority of previous cranberry juice chemical composition studies have focused on 
the low-MW, relatively nonpolar compounds of cranberry which are responsible for the aroma, 
flavor, color, and anti-oxidant properties of the juice (Pappas & Schaich 2009, Singh et al. 
2012, Vu et al. 2012, Su et al. 2010). Compounds previously investigated include terpenoids, 
aromatic acids, monosaccharides, simple phenolics, polyphenols, and a wide variety of 
flavonoids (Chapter 1, Section B).  
The compounds believed to be responsible for the anti-adhesion properties of cranberry 
juice are PAC oligomers of epicatechin units containing at least one A-type linkage (Foo et al. 
2000a,b). Cranberry PACs are typically isolated from the EtOAc fraction of acetone-extracted 
whole cranberry fruit (Howell et al. 1998, Foo et al. 2000a,b) and make up a relatively small 
percentage of whole cranberry starting material (Gu et al. 2004, Santos-Buelga & Scalbert 
2000, Gu et al. 2003). Studies examining the anti-adhesion properties of cranberry-derived 
PACs and whole cranberry juice have indicated that additional compounds may be present that 
could contribute to the anti-adhesion properties of the juice (Turner et al. 2007, Pinzón-Arango 
et al. 2009, Holguin et al. 2008, Mathison et al. 2013, Kimble et al. 2014). 
Studies investigating the anti-adhesive components of urine after cranberry 
consumption (Chapter 2) have indicated that arabinoxyloglucan oligosaccharides with anti-
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adhesion properties may be present in cranberry materials, but relatively little is known 
regarding the oligosaccharide components of cranberry fruit or juice products. The gel-forming 
characteristics of cranberries, as exhibited by the classic cranberry sauce, led to early structural 
investigations of complex carbohydrates including pectins and other cell wall-associated 
insoluble polysaccharides (Holmes & Rha 1978), but other complex carbohydrates including 
oligosaccharides have received limited attention. In addition, studies on soluble cranberry 
carbohydrates are typically limited to known mono- and di-saccharide components using 
comparisons to standards (Marlett & Vollendorf 1994).   
The objectives of these studies were therefore to characterize additional components of 
cranberry that could contribute to anti-adhesion activity and to determine if cranberry is 
potentially the source of the oligosaccharides found in active urine fractions. This objective was 
based on the outcome of the studies discussed in Chapter 2 and on the newly formed hypothesis 
that complex carbohydrates with anti-adhesion properties are present in cranberry materials and 
are related to the identified urinary metabolites.  
These studies used primarily chemically-guided fractionation methods to focus on the 
isolation of compounds that could be similar to putative active urinary metabolites. Cranberry 
fractions were submitted to the previously used UPEC-HRBC anti-agglutination assay and to a 
newly-developed assay that assessed the ability of uropathogenic P-fimbriated E. coli (UPEC) 
to adhere to uroepithelial cells (UECs). 
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B. Materials & Methods 
1. General Experimental Equipment 
Lyophilization was performed using a variety of Labconco FreeZone Systems housed in 
the NCNPR and Faser Hall at the University of Mississippi. All sample materials were stored at 
–20 or –60 oC. The centrifuge used was a Thermo IEC Centra CL3R instrument with 
exchangeable holders for different sizes of Falcon tubes. Preparative and analytical HPLC 
separations for CJE fractions were performed on a Waters Delta Prep 4000 system with #5 
pump heads and a Prep LC Controller connected to a 2487 dual-wavelength UV detector. 
Analytical HPLC separations for most samples were performed on a Waters Alliance 2695 
Separations Module with a 996 PDA connected in series to a Polymer Laboratories PL-
ELS2100 analytical scale ELSD. Preparative HPLC separations for CJ-P1 samples were 
performed on a Waters Delta Prep 4000 system with #5 pump heads and a Prep LC Controller 
connected in series to a 2487 dual-wavelength UV detector and a Polymer Laboratories PL-
ELS1000 ELSD. Additional analytical and preparative HPLC separations were performed on a 
Waters Delta Prep 600 with a Waters 600 Controller and a Waters 996 PDA detector connected 
in series to a Softa 300S ELSD. Two different Bruker Avance III 400 MHz NMR instruments 
were used to record NMR spectra and both were housed in Faser Hall at the University of 
Mississippi, School of Pharmacy. They were equipped with UltrashieldTM and UltrashieldTM 
Plus magnets and 5 mm probes.  
Regular solvents, TLC plates, HPLC solvents, and most reagents were obtained from 
Fisher Scientific, Inc., Sephadex LH-20 and additional reagents and were obtained from Sigma-
Aldrich, Inc., and HPLC sample filters and Amicon Ultra MW cut-off filters were obtained 
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from Millipore, Inc. Water used for all experiments was obtained from ultrafiltration systems 
located in Faser Hall or the NCNPR. Water for HPLC was additionally filtered within two days 
prior to use. 
2. Materials 
Spray-dried cranberry juice powder (CJ) was supplied by Ocean Spray Cranberries, Inc. 
through NIH grant no. 1R21AT002076-01. This same material was used for swine feeding to 
generate the urine samples discussed in Chapter 2. Cranberry juice concentrate (CC) was also 
supplied by Ocean Spray Cranberries, Inc. This material is used in the cranberry industry for 
preparation of various cranberry juice products. Commercially produced cranberry dietary 
supplements (Table 29) and juices (Table 30) were purchased at local grocery stores. Color 
images and additional label and product information for these materials can be found in 
Appendices A & C (color plates: Figures 98–101; Appendices C-2 – C4). 
Table 29. Descriptions of cranberry dietary supplements obtained from local grocery stores. 
The information included in this table was derived from the label information provided with 
each product. Examples of these labels and associated dietary supplement product literature can 
be found in Appendix C. Images of these products can be found in Appendix A color plates: 
Figure 98. 
Brand 
Name Form 
Cranberry 
Ingredient Label Description Observations 
Finest 
Natural 
(FN) 
softgel 
capsule 
fruit 
powder 
concentrate 
140 mg/capsule from 12:1 
concentrate: equivalent to 
1680 mg fruit powder/capsule 
Dark purple-mauve 
goo  
Nature’s 
Bounty  
(NB) 
softgel 
capsule 
fruit 
powder 
concentrate 
40 mg/capsule from 50:1 
concentrate: equivalent to 
2000 mg fruit powder/capsule 
Dark pink goo 
Sundown 
Naturals  
(SN) 
powder 
capsule 
fruit 
powder 475 mg/capsule 
Dry, bright pink 
powder  
Nature 
Made 
(NM) 
softgel 
capsule fruit extract
450 mg/capsule from 15:1 
concentrate of a fruit extract 
Undescribed 
extraction method; 
pinkish-mauve goo  
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Table 30. Descriptions of cranberry juices obtained from local grocery stores. 
The information shown below was derived from the label of each product. These labels and 
images of the juice material can be found in Appendix A color plates: Figures 100, 101. 
Brand Name Label Name Total Juice Content (%) Ingredients Listed
a 
Best Choiceb 
(BCB) “Cranberry Blend” 100 
grape juice, cranberry juice, apple juice, 
natural flavors, ascorbic acid, citric acid 
Great Valueb 
(GVC) 
“Cranberry Juice 
Cocktail” 30 cranberry juice, sugar, ascorbic acid 
Great Valueb 
(GVNS) 
“No Sugar Added 
Cranberry Juice 
Blend” 
100 grape juice, cranberry juice, apple juice, natural flavors, ascorbic acid 
Ocean Spray 
(OSC) 
“Cranberry Juice 
Cocktail” 27 
cranberry juice, cane or beet sugar, 
ascorbic acid 
Langers 
(LCP) 
“Cranberry Plus” 
(with vitamins A, C 
& E and Calcium 
100 
apple juice, cranberry juice, calcium 
gluconate, calcium lactate, natural 
flavors, citric acid, fruit and vegetable 
juice for color, ascorbic acid, vitamin E 
acetate, vitamin A palmitate 
Northland 
(NL) 
“Cranberry 
Flavored Blend” 100 
apple juice, cranberry juice, pear juice, 
grape juice, citric acid, natural flavor, 
vegetable color, fruit extracts (grape skin, 
blueberry, pomegranate, cranberry, red 
grapes and apple), ascorbic acid, vitamin 
A palmitate, vitamin E acetate 
a Water was an ingredient for all products, and all juices were listed as juice concentrates. 
Ingredients are listed here in the order they are shown on product labels. 
b These products were store brands specific to the grocery store company. 
 
3. Characterization of Cranberry Material 
a. Molecular Weight Cut-Off Filtration 
Cranberry juice powder (CJ) was dissolved in water (5 mg/mL) and subjected to 
centrifugal filtration using Amicon Ultra regenerated cellulose centrifugal filters with MW cut-
off sizes of 3, 10 and 30 kDa. Samples (4 mL each; 20 mg/filter tube insert) were centrifuged 
(4000 x g, 20 min), filtrate and retentate were transferred to separate vials, and filter inserts and 
centrifuge tubes were washed with water (3–4 x 0.5 mL, combined with their respective 
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fractions). Samples were lyophilized, weighed, analyzed by 1H NMR, and submitted to the 
UPEC-HRBC anti-agglutination assay for testing.  
b. Acid/Base Incubation 
Aliquots (98–104 mg) of cranberry juice powder (CJ) were dissolved in water (7–10 
mL) in 4 dram glass vials and titrated to pH 2, 6, or 8 using 10–100 mM NaOH, 100 mM HCl, 
and an electronic microscale pH meter. The final volume per sample was adjusted after titration 
to give final concentrations of 10 mg/mL. Samples were incubated at 37 oC with shaking for 2, 
4, or 8 h. After incubation, samples were directly frozen, lyophilized, weighed, and analyzed by 
1H NMR spectroscopy and C18 HPLC-PDA. Aliquots (20–25 mg) of each sample were 
submitted to the UPEC-HRBC anti-agglutination assay for testing. 
4. Detection & Isolation of Cranberry Oligosaccharides 
a. Analytical HPLC-ELSD of Cranberry Material 
Cranberry juice powder (CJ) and the aqueous fraction of this material (CJA) were 
examined by analytical HPLC using the same column and a similar method as used for 
detection of oligosaccharides in active urine fractions (AtldC18, 4.6 x 150 mm, 5µm). The 
method was as follows: 100% water for 5 min, 100% water to 30% MeOH over 30 min, 30% 
MeOH to 100% MeOH over 20 min, and 100% MeOH for 5 min, followed by a 10 min 
gradient from MeOH to 100% water with 20 min of re-equilibration with 100% water before 
injection of the next sample. Chromatograms were collected using ELS/PDA detection, with 
ELS conditions of a gas flow rate of 1.0 SLM, an evaporator temp of 100 oC, and a nebulizer 
temp of 50 oC. Max plot chromatograms (200–400 nm) were extracted from PDA data for 
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detection of UV-active metabolites. Samples were prepared in a single session, were not 
filtered due to low sample volumes, and were sequentially separated using a single method and 
without flow interruptions between injections. Different sample concentrations and column 
load volumes were used (Table 31) to preserve enriched reference materials (HF1-1 and HF2-
2) and to ensure the detection of putative oligosaccharides in crude cranberry materials (CJ and 
CJA). 
Table 31. Sample details for analytical HPLC-ELSD comparisons between CJ and HF 
materials. 
Sample Code Amount (mg) 
Water 
(µL) 
Conc. 
(mg/mL) 
Injection Amount 
(µL; mg/inj) 
CJ 6.5 300 21.7 50; 1.09 
CJA 6.0 200 30.0 40; 1.20  
HF2-2 1.6 160 10.0 25; 0.25 
HF1-1 2.6 100 26.0 20; 0.52 
 
 
b. Preparative HPLC-ELSD of Cranberry Juice Powder 
Cranberry juice powder (CJ) was directly separated using the same methods and 
preparative instrument configuration as used previously for urinary fraction HF2-2 separations 
(Chapter 2, Section B7). These methods used a preparative AtldC18 column (19 x 250 mm, 10 
µm particle size) with a flow rate of 25 mL/min as follows: 100% water for 5 min, 100% water 
to 20% MeOH over 30 min, 20% MeOH to 100% MeOH over 10 min, 3 min at 100% MeOH, 
followed by a 17 min gradient from MeOH to 100% water with an equilibration of 10 min at 
100% water prior to the next separation. The ELSD settings for this separation were a gas flow 
rate of 0.8 SLM, an evaporator temperature of 100 oC, and a nebulizer temperature of 50 oC. 
These ELSD values remained constant throughout the course of each separation, and the ELSD 
was allowed to equilibrate for at least 30 min at the appropriate settings prior to initial data 
acquisition.  
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Two batches of CJ (99.2 mg for R1 and R2, and 250 mg for R3) were dissolved in water 
(800 µL and 1 mL), filtered (0.2 µm nylon filter), and separated over three separations with 
different amounts of material injected per separation (R1: 200 µL, R2: 500 µL and R3: 1 mL). 
Fractions from these separations (Table 32) were combined based on chromatographic profile 
and time points (Figures 69–71), and were concentrated under reduced pressure with a water 
bath temperature of ~40 oC to remove solvent and decrease water content. Resulting samples 
were dissolved in water, frozen, and lyophilized. Fractions CJ-P1t22, CJ-P1t23, CJ-P1t25, and 
CJ-P1t38 were analyzed by 1H NMR.  
 
 
Table 32. Fractions collected from direct HPLC separation of cranberry juice powder (CJ-P1). 
Time points for fraction recombination were compared to those of urinary fractions and 
materials were combined across three separate injections. 
Retention 
Time (min)a Fraction
 mg Notes 
0–6 01 82.7 early eluting mass majority – mixture, UV active 
6–21.5 16 9.5 no peaks – blank area before next set – some minor peaks by UV 
21.5–22.7 22b 3.3 first short peak set in area of interest – no UV 
22.8–23.7 23b 4.0 tallest peak of set in area of interest – no UV 
23.8–25.8 25b 7.3 low peaks before and second tallest peak in area of interest – no UV 
25.8–30 28 7.6 low peaks after three primary eluting peaks of set – mixture – no UV 
30–37.7 35 12.8 wash between peak set of interest and final gradient peak  
37.7–39.1 38b 6.5 final peak – elutes with gradient to MeOH – no or low UV – mixture 
39.1–47 40 6.1 end wash – UV chromophores (pink) 
a Time points for fraction numbers were based on CJP-crude R1. 
b These fractions were analyzed by 1H NMR spectroscopy. 
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Figure 69. Preparative HPLC-ELSD chromatograms of CJ-P1 separations, R1–3. 
Different amounts of material were injected over the three separations, resulting in the differing 
intensities of the ELSD chromatograms shown. All eluting material was collected as fractions 
and fractions t22, t23, t25 and t38 were analyzed by NMR spectroscopy.  
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Figure 70. Preparative HPLC-UV (215 nm) chromatograms of CJ-P1 separations, R1–3. 
Comparison of these chromatograms to those in Figure 69 shows the absence of chromophores 
for the compounds eluting from 18–38 min and the presence of weak chromophores for 
compounds eluting from 0–8 min. The profile of compound chromophores visible between 38 
and 46 min does not appear to correlate to the profile of the fraction eluting at 38 min, 
suggesting that fraction CJP1t38 lacks a chromophore. The components eluting from 39–47 
min showed a visible pink color in solution suggesting the presence of known anthocyanins. 
151 
 
 
Figure 71. Preparative HPLC-UV (254 nm) chromatograms of CJ-P1 separations, R1–3. 
The characteristics for the chromatographic profile of the CJ-P1 separations at 254 nm were 
similar to the chromatographic profile visible at 210 nm (Figure 70) and further supported the 
lack of chromophores for the compounds eluting from 18–38 min. The low intensity 
absorbance for the components eluting from 39–47 min further supported the conclusion that 
this fraction contained anthocyanins. 
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5. Enrichment for Cranberry Oligosaccharides 
a. Cranberry Juice Powder Separations 
Cranberry juice powder (CJ) (1.24 kg, in 80–120 g aliquots) was dissolved in water 
(450 mL/100 g) and extracted with EtOAc (10 x 1:3 v/v EtOAc:water). The EtOAc extracts 
(CJE) were combined (12.706 g; 1.02% w/w of CJ), solvent removed under reduced pressure 
and the residual amorphous burgundy solid was resuspended in a minimum amount of water 
and lyophilized. Aqueous material (CJA) was combined, residual solvent removed under 
reduced pressure, and the resulting burgundy liquid was diluted, frozen and lyophilized in 1–2 
L batches.  
The CJA and CJE fractions were both assessed using an anthocyanidin test: 1 mg of 
material was combined with 5 mL of isopropanol: 3 N HCl (4:1) (test samples) or 
isopropanol:water (4:1) (control samples) and heated for 30 min at 96 oC under pressure. Both 
CJE and CJA materials were used for further separations. The CJE fraction was investigated by 
TLC, PLC, Sephadex LH-20, HPLC with reverse phase sorbents, and derivatization via 
methylation and acetylation. Purified components were characterized using UV, LC-MS, and 
NMR. The further characterization of CJ and CJA materials will be discussed below. 
The CJ aqueous residue (CJA) was fractionated on Sephadex LH-20 using protocols 
similar to those developed for urine samples (Table 33). The CJA samples were dissolved in 
water and EtOH (100%) was added gradually with intermittent sonication to give a final 
concentration of 70% EtOH (v/v). The sample was briefly centrifuged to remove precipitate 
and samples in 70% EtOH were loaded onto Sephadex LH-20 and eluted with 70% EtOH 
(isocratic) (Appendix A color plates: Figure 102). Columns were washed with 80% EtOH and 
60–100% acetone after the majority of the fractions eluted. Fractions were combined based on 
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appearance and elution volume, concentrated under reduced pressure to remove EtOH, 
dissolved or diluted in water, frozen, and lyophilized. Selected CJA fractions were submitted 
for bioassay testing and further characterized by 1H NMR and HPLC-ELSD/UV. 
 
Table 33. Details of Sephadex LH-20 separations for CJA samples 1 & 2. 
The recombination of fractions collected from columns CJA1 and CJA2 differed slightly and 
fractions were labeled with different numbers, but both columns yielded similar percentages of 
oligosaccharide-containing material. 
Column Designation CJA1 CJA2a 
Amount of Loaded Material (g) 25.6 25.3
Loaded Volume &  
Sample Concentration 
100 mL
256 mg/mL
100 mL
253 mg/mL
Column Dimensions  
(cm; width x height) 7 x 37 7 x 37
Solvent Composition 70% EtOH 70% EtOH
Solvent Flow Rate (mL/min) 1.5–1.7 1.5–1.7
Total Elution Volume for 
Oligosaccharide Fractions (mL) 300 450
Oligosaccharide-containing  
Fractions (g) 
CJA1-02 (3.619) 
CJA1-02B (1.280) 
CJA1-03B (1.669) 
CJA2-03 (2.090) 
CJA2-04 (3.980) 
CJA2-05 (1.740) 
Total Oligosaccharide-containing 
Material per Column (g) 6.568 7.810
Oligosaccharide % of Loaded Material 25.6% 30.8%
a Some information for this separation is also reported in Auker 2013 and Auker et al. 2014. 
 
 
b. Cranberry Juice Concentrate Separations 
Cranberry juice concentrate (CC) syrup was also used as starting material for the 
isolation of cranberry oligosaccharides via protocols similar to those used for urine and CJ 
samples. Syrup (500 mL) was diluted with water (300 mL) and exhaustively extracted with 
EtOAc (8 x 200 mL; CCE). Aqueous residue (CCA) was lyophilized and portions were 
separated by Sephadex LH-20 (Appendix A color plates: Figures 103, 104). As before, CCA 
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samples were dissolved in water and 100% EtOH was added gradually, with sonication, to 
yield concentrated material in column solvent (70% EtOH). This material was briefly 
centrifuged to remove precipitate and separated on two different Sephadex LH-20 columns 
(Table 34). The columns were washed with 80% EtOH and 60–100% acetone after the majority 
of the fractions eluted. Fractions were concentrated under reduced pressure, dissolved or 
diluted with water, frozen, and lyophilized. Selected CCA fractions were submitted for 
bioassay testing and further characterized by 1H NMR and HPLC-ELSD. 
 
Table 34. Details of Sephadex LH-20 separations for CCA samples 1 & 2. 
The recombination of fractions collected from columns CCA1 and CCA2 differed and fractions 
were labeled with different numbers, but both columns yielded similar percentages of 
oligosaccharide-containing material. The elution flow rate for column CCA2 was higher than 
that of column CCA1 to account for the larger diameter of this column. The CCA2 fractions 
yielded higher resolution between different oligosaccharide components than the CCA1 
fractions. 
Column Designation CCA1 CCA2 
Amount of Loaded Material (g) 50.53 151.33
Loaded Volume &  
Sample Concentration 
200 mL
250 mg/mL
500 mL
303 mg/mL
Column Dimensions  
(cm; width x height) 7 x 37 10 x 49
Solvent Composition 70% EtOH 70% EtOH
Solvent Flow Rate (mL/min) 1.2–1.5 1.5–2.0
Total Elution Volume for 
Oligosaccharide Fractions (mL) 520 1500
Oligosaccharide-containing  
Fractions (g) 
 
CCA1-01 (0.377) 
CCA1-02 (0.913) 
CCA1-03 (0.733) 
CCA1-03 (0.026) 
CCA2-01 (0.032) 
CCA2-02 (0.215) 
CCA2-03 (1.686) 
CCA2-04 (3.158) 
CCA2-05 (1.739) 
Total Oligosaccharide-containing 
Material per Column (g) 2.05 6.83
Oligosaccharide % of Loaded Material 4.06% 4.51%
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6. Preliminary Characterization of Commercial Cranberry Products 
Aliquots of commercial cranberry dietary supplements (Table 29) were removed from 
their gel capsules (one capsule per product) dissolved in water, sonicated, and left to sit for 
about 4 h to yield aqueous solutions (Appendix A color plates: Figure 98). Dissolved material 
was removed from insoluble matter with a pipette, filtered with glass wool in a glass pipette 
and then filtered with a 20 µm syringe filter (30 mm). Samples of CJ and CJA were prepared in 
a similar manner (0.2 µm filter) and analyzed at the same time for comparison. Filtered samples 
(Table 35) were injected as part of a single analysis set onto an analytical HPLC column 
(AtldC18, 4.6 x 150 mm, 5 µm, with 4.6 x 20 mm guard cartridge) and separated using a 
method similar to that used for enriching and detecting oligosaccharides in active urine 
samples. This method was as follows: 5 min 100% water, 30 min gradient to 30% MeOH, 10 
min gradient to 100% MeOH, 10 min at 100% MeOH, 10 min gradient to 100% water, with 20 
min of re-equilibration with 100% water before injection of the next sample. Chromatograms 
were collected using ELS/PDA detection with ELS conditions of a gas flow rate of 1.0 SLM, 
an evaporator temp of 100 oC, and a nebulizer temp of 50 oC. Max plot chromatograms (200–
400 nm) were extracted from PDA data for detection of UV-active metabolites.  
Samples of each commercially obtained juice were directly injected onto the HPLC-
ELSD instrument with injection volumes of 50 µL each. The dry weights of each juice material 
corresponding to the 50 µL injection volumes are not known. All juice samples were analyzed 
within a single sample set using automated sample handling to avoid changes in instrument 
performance and retention times between injections. The same HPLC-ELSD method was used 
for the analysis of juice samples as was used for the dietary supplement samples and urine 
samples (see above). 
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Table 35. Sample details for analytical HPLC-ELSD comparisons of cranberry dietary 
supplement products. 
Multiple injection amounts were used for the commercial product samples in an attempt to 
detect minor components. Data was not available to assess the “fruit equivalents” of the CJ 
materials. 
Sample 
Code 
Amount 
(mg) 
Fruit Powder 
Equivalenta 
(mg) 
Water 
(mL) 
Sample 
Conc. 
(mg/mL)
Injection Amount 
(µL; mg/inj) 
Injected Fruit 
Equivalent 
(mg) 
Commercial Products  
FN 140 1680 10 14.0 25; 0.35 & 50; 0.70 4.2–8.4 
NB 40 2000 5 8.0 50; 0.40 & 100; 0.8 20.0–40.0 
SN 475 475 10 47.5 25; 1.20 & 50; 2.40 1.2–2.4 
NM 450 6750 10 45.0 25; 1.13 & 50; 2.25 16.9–33.8 
Reference Cranberry Juice Powder 
CJ 2.9 N/A 0.2 14.5 50; 0.73 N/A 
CJ 6.5 N/A 0.3 21.7 50; 1.08 N/A 
CJA 6.1 N/A 0.3 20.3 50; 1.02 N/A 
CJA 6.0 N/A 0.2 30.0 50; 1.50 N/A 
a Based on manufacturer labeling.  
 
7. Bioassay Testing 
a. Anti-agglutination Assay 
The UPEC-HRBC anti-agglutination assay used for cranberry-derived samples was the 
same as that used for urine samples (Chapter 2: Section B4). Several CJ-derived samples 
(Sections B3) and selected CJA1 and CJA2 fractions (Section B5) were submitted to this assay. 
b. Anti-adhesion Assay 
Selected CJA1 and CJA2 fractions were submitted to an early version of the 
uroepithelial cell-uropathogenic E. coli (UPEC-UEC) anti-adhesion assay developed at 
Washington State Univ. (WSU). This early version of the assay used radiolabeled E. coli, and 
the number of E. coli that adhered to uroepithelial cells were quantified using scintillation 
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counts (Mathison et al. 2013). Samples were tested in duplicate at different dilutions (Auker 
2013).  
The CCA1 fractions (~10 mg each) were submitted to a later version of the UPEC-UEC 
anti-adhesion assay that used fluorescent-labeled E. coli and uroepithelial cells according to 
previously established protocols (Kimble et al. 2014). Samples were tested using serial dilution 
and each sample was tested in duplicate. Duplicate results were corrected for baseline 
fluorescence and averaged to give fluorescence values for each dilution tested. Samples were 
tested using five to eight serial dilutions and IC50 values were calculated.  
c. Antimicrobial Assays 
Selected cranberry samples (CJ: 35.6 mg, CJE: 12 mg, CJA: 24.7 mg) were submitted 
to the antibacterial, antifungal, and antiprotozoal screening programs available at the UM 
National Center for Natural Products Research (NCNPR). Samples were tested according to 
previously reported methods (Zhang et al. 2012, Rahman et al. 2011) modified from the 
methods of the Clinical and Laboratory Standards Institute (CLSI), formerly the National 
Committee for Clinical and Laboratory Standards (NCCLS 2002a,b, NCCLS 2003, NCCLS 
2006). Samples were tested against a panel of pathogens: five fungi (Candida albicans ATCC 
90028, C. glabrata ATCC 90030, C. krusei ATCC 6258, Cryptococcus neoformans ATCC 
90113, and Aspergillus fumigatus ATCC 204305), five bacteria (Staphylococcus aureus ATCC 
29213, methicillin-resistant Staph. aureus ATCC 33591, E. coli ATCC 35218, Pseudomonas 
aeruginosa ATCC 27853, and Mycobacterium intracellulare ATCC 23068), and two protozoa 
(Leishmania donovani and Plasmodium falciparum D6 Clone) 
In the antibacterial and antifungal assays, samples were tested at concentrations of 50 
µg/mL. In the antiprotozoal assays, samples were tested at a concentration of 15.9 µg/mL 
158 
 
against Plasmodium falciparum and at 80 µg/mL against Leishmania donovani. Amphotericin 
B served as the positive control for the Leishmania donovani assay and resulted in 100% 
inhibition under the parameters used. Percent growth inhibition for each organism was 
calculated relative to positive and negative controls. 
C. Results & Discussion 
1. Characterization of Cranberry Material 
The EtOAc soluble CJE fraction composed 1% w/w of the starting CJ material and the 
results of the anthocyanidin test indicated that PACs were present primarily in this fraction. 
The CJE test sample, but not the control sample or the CJA samples, produced an intense 
fuchsia color. This color indicated the formation of anthocyanins resulting from acid-catalyzed 
cleavage of leucoanthocyanidins and PACs (Berhow 2002, Fletcher et al. 1977). The CJE 
fraction also showed similar TLC Rf values when compared to PAC reference dimers, 
procyanidins A2 and B1 (benzene:acetone, 4:6, v/v), indicating the presence of these 
compounds. Sephadex LH-20 of CJE yielded 20 fractions that were further separated by PLC 
and HPLC and derivatized via methylation and acetylation. Purified components were 
characterized using UV, LC-MS, and NMR. These separations yielded a series of known 
flavonoids and phenolic compounds (not shown).  
The CJ and CJA materials were the focus of the remaining studies discussed below. 
Selected samples from these studies were submitted to the UPEC-HRBC anti-agglutination 
assay in conjunction with the urine samples discussed in Chapter 2. The results of this assay for 
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the cranberry samples were evaluated using the same methods described in Chapter 2, Section 
B4d, to provide relative activity scores (UM Scores; Table 3). The results of the MW cut-off 
filtration and acid/base incubation assessments are shown below (Table 36). Additional anti-
agglutination assay results for CJA Sephadex LH-20 fractions are discussed below (Section 
C4a). The raw data for these evaluations can be found in Appendix B-3: Tables 52, 58. 
 
Table 36. Anti-agglutination assay results for experiments characterizing cranberry (CJ) 
material. 
The CJ material consistently showed UPEC-HRBC anti-agglutination activity. Use of MW cut-
off filters indicated that low-MW components of CJ were unlikely to contribute to the observed 
anti-agglutination activity. 
Sample Description UM Scorea Test Date 
CJ (cranberry juice powder) + + 06/2008 x2b
CJ-MA3a (3 kDa retentate) + + 06/2008 
CJ-MB3a (10 kDa retentate) + + 06/2008 
CJ-MC3a (30 kDa retentate) + + 06/2008 
CJ-MA3b (3 kDa filtrate) – – 06/2008 
CJ-MB3b (10 kDa filtrate) – – 06/2008 
CJ-MC3b (30 kDa filtrate) – – 06/2008 
CJ pH 2.0, 2 h + 06/2008 
CJ pH 2.0, 4 h + 06/2008 
CJ pH 2.1, 8 h + 06/2008 
CJ pH 5.9, 2 h + + 06/2008 
CJ pH 6.0, 4 h + + 06/2008 
CJ pH 6.1, 8 h + + 06/2008 
CJ pH 7.9, 2 h + + 06/2008 
CJ pH 8.0, 4 h + + 06/2008 
CJ pH 8.2, 8 h + + 06/2008 
CJ Native pH (2.7), 2 h + + 06/2008 
CJ Native pH (2.7), 4 h + + 06/2008 
CJ Native pH (2.7), 8 h + + 06/2008 
a The criteria used to assign the UM Score can be found in Table 3. Raw data for these samples 
can be found in Appendix B-3: Table 52.  
b Sample was tested in duplicate for this test date. 
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a. Molecular Weight Cut-off Filtration 
CJ material partitioned in similar ratios across the three sizes of centrifugal filters used, 
with 3.25–3.5 mL of filtrate recovered from each separation. After lyophilization, the filtrate 
accounted for 70–75% of the total recovered sample mass. Both retentate and filtrate fractions 
did not lyophilized to powders, instead producing viscous goo. Filtrate samples were bright 
pink in color, similar to the starting material, while retentate samples were tan in color. Filter 
inserts also retained a slight pinkish tinge after washing. The anti-agglutination assay results 
indicated that the active constituents from the cranberry juice powder were concentrated into 
the retentate portion of the filtered samples (Table 36). 
The active components of cranberry juice powder were retained and enriched by 3, 10 
and 30 kDa regenerated cellulose centrifuge filters under the conditions used. Retention could 
have been the result of molecular size, sample concentration and filtration time, or repellant 
interactions between the active compounds and the filter material. The physics of centrifugal 
filtration dictates that the smallest molecules will pass through the filter matrix before larger 
molecules in solution, and the filter matrix of regenerated cellulose can bind to certain 
compounds (pink color) while repelling others. Hydrogen bonding between compounds in 
solution, yielding larger apparent MW complexes, may also have contributed to the retention of 
the active constituents.  
b. Acid/Base Incubation 
Cranberry juice powder in solution has a native pH of about 2.7. The adjusted pH of 
each sample remained the same from the beginning to the end of the incubation periods. All 
samples had anti-agglutination activity (Table 36). The pH 6 and pH 8 samples showed slightly 
higher activity than the non-incubated reference material, while the pH 2 samples showed 
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slightly lower activity. Incubation time did not appear to have any effects on the anti-
agglutination activity profile.  
Cranberry juice powder samples were incubated at human body temperature for three 
time periods and three different pH values similar to those that could be experienced by 
cranberry juice components during digestive processes (Evans et al. 1988). The presence of 
anti-agglutination activity after incubation under these conditions is consistent with the 
presence of active metabolites in both cranberry and urine materials. These data indicate that 
the active constituents are relatively stable to moderate acid/base chemical degradation and to 
moderate heat and would be likely to remain intact when subjected to non-enzymatic digestive 
conditions. 
2. Detection & Isolation of Cranberry Oligosaccharides 
a. Analytical HPLC of Cranberry Materials 
Analytical scale HPLC-ELSD analysis of cranberry starting material in comparison to 
active urine fractions showed that cranberry contains the same HPLC-ELSD/UV profile in the 
region of interest as active urine fractions (18–24 min; Figure 74). The chromatographic 
behavior of the cranberry material suggested that these compounds were also oligosaccharide in 
nature with chromophores absent for all cranberry peaks, as was seen with urine fractions 
(Figure 73). The elution times for the cranberry profile could be directly overlaid with those of 
the urine fractions and the relative ratios of the components of the mixture were similar (Figure 
74). As ELSD is a semi-quantative, mass-sensitive method (see Appendix B-4: ELSD 
overview), this observation further supports the hypothesis that similar components are present. 
Although the cranberry material was injected at 2–4 x higher concentrations than the urine 
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fraction material (Figure 74) retention times and relative peak ratios remained similar further 
suggesting that the compounds present in cranberry material and urine were similar, and that 
the compounds present were unaffected by the cranberry sample matrix. The cranberry profile 
appears to be more complex than that found in urine samples, but this could be due to higher 
concentrations of individual metabolites present in the cranberry sample. Overall, it appears 
that many of the oligosaccharides present in the urine sample are directly derived from 
oligosaccharides present in the cranberry material, even at the same approximate concentration 
ratios.  
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Figure 72. Analytical HPLC-ELSD comparison of cranberry material (CJ and CJA) and urine 
fractions (HF2-2 and HF1-1). 
The same profile of oligosaccharide components was present in both urine- and cranberry-
derived materials. Additional complexity was apparent in the CJ and CJA materials, possibly 
due to higher sample concentrations. The higher intensities of the peaks for the cranberry 
material also likely reflect higher sample concentrations and higher injection amounts.  
 
 
164 
 
 
Figure 73. Analytical HPLC-ELSD/UV of CJA compared to HF1-1 confirming the absence of 
chromophores for cranberry oligosaccharides. 
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Figure 74. Analytical HPLC-ELSD of CJA compared to HF1-1 and HF2-2 (overlay). 
This comparative profile indicated that urine and cranberry fractions have similar relative 
quantities of what appear to be the same set of components. Several of these components have 
been highlighted (arrows) and other components present also appear to vary in similar ratios.  
 
b. Preparative HPLC of Cranberry Juice Powder 
Direct preparative HPLC separation of 349.2 mg of crude cranberry juice powder (CJ) 
resulted in a total fraction weight of 139.8 mg from the starting amount to give 40% recovery 
(w/w). It is possible that most of this loss was due to split-ELSD detection-collection, with 
additional material being retained by the sample filter, lost during transfers, lost due to loop 
overflow during injection, or lost due to irreversible retention on the HPLC column. From the 
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fractions collected, 22.2 mg of material eluted in the oligosaccharide region of interest (21.5–30 
min, Figure 69) to give 15.9% of the total recovered CJ material (139.8 g) as being composed 
of oligosaccharides. Most of the CJ-P1 fractions contained mixtures of compounds, but the 
fraction at 22.8–23.7 min, designated CJ-P1t23 (4.0 mg), had similar HPLC-ELSD 
characteristics as 1 isolated from urine samples (Chapter 2). Comparison of this sample to that 
of the enriched fraction HF2-2P1t20, containing primarily 1, via 1H NMR spectroscopy 
confirmed the similar chemical composition of the two materials (Figure 75). Insufficient pure 
material of CJ-P1t23 was available for full structural characterization, but resonances in the 
anomeric region indicated the probable presence of an arabinoxyloglucan with eight monomer 
units. The presence of a series of oligosaccharides with structural composition similar to each 
other and to the previously isolated urinary compounds was further supported by 1H NMR data 
of the other enriched cranberry oligosaccharide fractions (Figure 76). In particular, fractions 
CJ-P1t22 and CJ-P1t25 also contained resonances in the anomeric region indicative of 
arabinoxyloglucans. Fraction CJ-P1t38, however, yielded a 1H NMR spectrum unique from 
those of the other CJ-P1 fractions. This spectrum indicated that CJ-P1t38 is also probably a 
complex carbohydrate but not an arabinoxyloglucan. Larger quantities of cranberry 
oligosaccharides were needed for further structural studies and bioactivity assessments, and 
direct preparative HPLC separations were not necessarily an optimum method for obtaining 
this material. 
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Figure 75. Comparison of the 1H NMR spectra for the enriched cranberry oligosaccharide 
fraction CJ-P1t23 and the urinary fraction HF2-2P1t20, enriched for compound 1, DMSO-d6, 
400 MHz. 
The spectra for both fractions were highly similar indicating similar chemical composition. 
These data suggested that the cranberry fraction was also an arabinoxyloglucan 
oligosaccharide.  
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Figure 76. Comparison of the 1H NMR spectra for major CJ-P1 oligosaccharide fractions, 
DMSO-d6, 400 MHz. 
Fractions CJ-P1-22, CJ-P1-23, and CJ-P1-25 all contained resonances similar to those of 
arabinoxyloglucan oligosaccharides. The spectrum of CJ-P1-38 was distinct and is probably not 
an arabinoxyloglucan, but is likely to be another type of oligosaccharide.  
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c. Cranberry Juice Powder Separations 
The CJ material was processed and separated using Sephadex LH-20 via methods 
similar to those applied to urine samples. The color of fractions can be used to track the 
progressive elution of compounds and shows that the majority of the pigmented components of 
the juice elute at later retention times (Appendix A color plates: Figure 102). Later fractions 
(CJA1-04 – CJA1-06) are also more hygroscopic, probably due to the presence of high 
concentrations of simple sugars such as fructose. Fractions of CJA that eluted early, at similar 
retention times as active urine fractions (e.g. CJA2-03), were found to contain oligosaccharide 
mixtures of similar composition as active urine fractions by HPLC-ELSD (Figures 77–79) and 
NMR spectroscopy (Figure 80). The appearance of CJA oligosaccharide fractions was cloudy 
white to pale lavender in appearance in 70% EtOH, and these fractions eluted just before or in 
conjunction with the visible lavender band that appeared on the column (CJA1 column; 
Appendix A color plates: Figure 102). Changes in both the HPLC system and the ELS detector 
resulted in lower-resolution chromatography and different retention times for some fractions 
than obtained previously, but UV-transparent oligosaccharides could still be detected (20–30 
min; Figure 79).  
Fraction CJA2-03 served as part of the source material for the further isolation of two 
oligosaccharides in sufficient purity and quantity to assign structures (Auker 2013) (Figure 81). 
Methods used to make these assignments included NMR and carbohydrate derivatization 
methods similar to those discussed in Chapter 2 Methods.  
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Figure 77. Analytical HPLC-ELSD comparison HF1-1, CJ, CJA, and CJA2-03 (AtldC18) 
showing the similarity of oligosaccharide profiles present in all four samples.  
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Figure 78. Analytical HPLC-ELSD of CJA2 fractions 02, 03, 04, 05, and 06 (AtldC18) 
showing the resolution and composition of these Sephadex LH-20 fractions. 
Oligosaccharide components of interest are present in fractions 03, 04, and 05. 
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Figure 79. Analytical HPLC-ELSD of CJA1 and CJA2 oligosaccharide-containing fractions in 
comparison to SN-04 (% MeOH shown). 
These fractions were analyzed using an HPLC instrument that produced lower chromatographic 
resolution and the Softa ELS detector. This instrument configuration was sufficient for 
detecting oligosaccharide content by comparisons to fractions with previously known 
oligosaccharide content, but instrument parameters and the chromatographic system shown 
here would need to be further optimized for preparative separations.  
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Figure 80. Comparison of the 1H NMR spectra for fractions CJA1-02 and CJA2-03, D2O, 400 
MHz. 
These spectra show the similarity of composition for the oligosaccharide-enriched fractions 
from both CJA1 and CJA2 columns. These spectra do not contain resonances in the regions that 
are not displayed.  
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Figure 81. Structures of the two oligosaccharides isolated from fraction CJA2-03 (Auker 2013). 
These compounds are highly similar in structure to that of 1, discussed in Chapter 2. 
 
 
d. Cranberry Juice Concentrate Separations 
The aqueous fraction of CC material (CCA) yielded early eluting sub-fractions from 
both CCA1 and CCA2 Sephadex LH-20 columns that were composed of oligosaccharides. As 
with the CJA separations, these fractions were cloudy white to pale lavender in appearance in 
70% EtOH, and eluted just before the visible lavender band that appears on the column (CCA2 
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column; Appendix A color plates: Figure 103). Fractions 1–3 from column CCA1 (CCA1-01, 
CCA1-02, CCA1-03) contained mixtures of penta- to octameric oligosaccharides as determined 
by the number and integration of anomeric resonances observed in 1H NMR spectra (Figure 
84). The components of these three fractions are similar in structure and have similar HPLC 
retention times and profiles as those isolated previously from CJ cranberry materials (CJ and 
CJA) and CJ-derived urine samples (Figure 82). Fraction CCA1-04 also contained 
oligosaccharides, but 1H NMR and HPLC-ELSD data suggest differences in monosaccharide 
composition and branching patterns as compared to fractions CCA1-01 – CCA1-03. Fractions 
CCA1-05 – CCA1-12 contained a variety of other classes of compounds and lacked the 
oligosaccharide components of interest. Fractions CCA1-01 – CCA1-03 accounted for a total 
of ~2 g of material and ~4% w/w of the loaded aqueous cranberry extract. Column 2 (CCA2) 
yielded 19 fractions with improved resolution of oligosaccharide components across fractions 
CCA2-01 – CCA2-05 as determined by 1H NMR spectroscopy. The oligosaccharide fractions 
of interest from CCA2 separations accounted for ~7 g of material and ~5% w/w of the loaded 
CCA sample.  
Changes in both the HPLC system and the ELS detector resulted in lower resolution 
chromatography than obtained previously for the CCA1 fractions (Figures 82, 83). Use of the 
same HPLC column and method, and comparisons to other fractions with previously 
established oligosaccharide composition still made it possible, however, to detect the presence 
of the UV-transparent oligosaccharides of interest, eluting between 12–18 min, in CCA 
fractions (Figures 82, 83). 
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Figure 82. Analytical HPLC-ELSD of CCA1 fractions 01, 02, and 03, compared to CJA2-04 
showing a similar elution profile (AtldC18, % MeOH shown). 
The chromatographic resolution for these separations is lower than that shown previously due 
to changes in the instruments used. These materials were highly enriched for oligosaccharides 
as evidenced by the lack of other compounds that eluted during the full gradient. From previous 
chromatographic analyses, glucose, fructose and sucrose were determined to elute at < 5 min 
with the conditions used (See Appendix B-5: Figure 105). The minimal quantity of compounds 
eluting at this retention time for fractions CCA1-01 – CCA1-03 indicates that these samples are 
unlikely to contain monosaccharide contaminants such as glucose. 
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Figure 83. Analytical HPLC-ELSD of CCA1-03, 04, 04P, 05, and 06 showing the absence of 
oligosaccharide components in the CCA1-04 and later Sephadex LH-20 fractions (AtldC18, % 
MeOH shown). 
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Figure 84. Comparison of the 1H NMR spectra for fractions CCA1-01, CCA1-02, CCA1-03, 
and CCA1-04, D2O, 400 MHz. 
Fractions CCA1-01, CCA1-02 and CCA1-03 were determined to probably contain 
arabinoxyloglucan oligomers based on the presence of indicative resonances at 4.4, 5.0, 5.1, 
and 5.2 ppm. These arabinoxyloglucan mixtures are likely composed of penta- to octameric 
oligosaccharides as determined by the number and integration of these observed anomeric 
resonances. Fraction CCA1-04 does not contain the indicative anomeric resonances and instead 
appears to contain only a reducing glucose moiety based on the presence of α- and β-anomeric 
resonances at 5.15 and 4.55 ppm, respectively. Additional analyses would be required to 
determine the full composition and structural assignments for each of these fractions. 
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3. Preliminary Characterization of Commercial Cranberry Products 
An optimized HPLC-ELSD method was used to detect oligosaccharides in commercial 
cranberry products. The semi-quantitative nature of ELSD (see Appendix B-4: ELSD 
overview) makes it possible to assess the relative ratios and concentrations of components 
across and within samples, regardless of the nature of the compounds. Direct quantification of 
oligosaccharides was not possible during these studies due to the lack of available standards, 
the complexity of the mixture, and instrument and detector limitations. Previous studies with 
urine samples (Chapter 2) using the same equipment and method indicated, however, that this 
system could be used to detect oligosaccharides in 20 µL samples at concentrations of less than 
10 mg/mL (Table 35; Figure 72). The use of a full gradient from 100% water to 100% MeOH 
allows for the elution of the majority of compounds present, with polar compounds eluting 
earlier (< 10 min) and nonpolar compounds eluting later (35–55 min) within a chromatogram. 
Possible evidence of oligosaccharides was detected in one of the four commercial 
cranberry dietary supplement products analyzed, the SN fruit powder (Figure 85). Of the 
samples tested, the SN product appeared to have the least amount of processing. Based on 
labeling (Appendix C-2), SN was a powder obtained through direct lyophilization of 
cranberries. It was therefore expected that it would contain components seen in the cranberry 
juice powder (18–30 min) as well as additional compounds (eluting between 4–18 min). When 
in solution, the SN material was different in appearance than the CJ material (Appendix A color 
plates: Figure 99), but this is likely due to the presence of fruit-derived components that had 
been removed during juice manufacturing. Further work with 100 g of the SN material in 
conjunction with CJA2 material resulted in the identification of two arabinoxyloglucan 
oligosaccharides from both sources (Master’s Thesis of Kimberly Auker 2013). 
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Evidence of oligosaccharides was not apparent in three of the four dietary supplement 
products analyzed: FN, NB, and NM (Figure 86). Based on the label claims of these products 
(Table 29, Appendices C-3, C-4), the amounts injected of these commercial “concentrates” 
should have been equivalent to much higher concentrations of cranberry metabolites (Table 
35), but there was no detectable evidence of such a concentration effect. Additionally, the 
HPLC-ELSD profiles of the dietary supplement fruit powder concentrates were markedly 
different from those of the SN cranberry fruit powder and the cranberry juice powder (CJ). This 
was consistent with the appearance of these materials as observed during preparation for HPLC 
(Table 29, Appendix A color plates: Figure 98). These data suggest that manufacturer 
processing methods for producing “concentrates” significantly alter the composition of the final 
product and probably remove the oligosaccharides of interest (see Appendix C-1 discussion). 
The HPLC-ELSD profile characteristic of oligosaccharides (18–24 min) was readily 
detected in four of the juice products analyzed: OSC, LCP, GVC, and GVNS (Figures 87–90). 
The other two juice products, BCB and NL also appeared to contain the profile of interest but 
these components were present at much lower concentrations and were almost undetectable 
(Figures 87, 89). All putative oligosaccharide components were minor constituents relative to 
the rest of the material present in the samples, and they could not be detected without baseline 
expansions (Figures 88, 90). The putative oligosaccharide components of LCP and OSC 
materials were similar to each other in appearance and relative concentrations (box; Figure 90). 
The GVC and GVNS profiles were also similar to each other, with lower concentrations of 
metabolites in the region of interest (18–24 min) for the GVNS material (box; Figure 88). The 
juice chromatograms for GVC, GVNS, OSC, and LCP were similar to each other from 18-48 
min with differences in relative concentrations.  
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The similarity of oligosaccharide profiles across juice brands indicates the presence of 
similar constituents, presumably due to the presence of cranberry juice concentrate in each 
product. As the same amount of each juice sample was analyzed for each product, the 
differences in relative concentration of putative oligosaccharides may reflect different 
percentages of cranberry juice in the different products. Only two of the six products analyzed 
indicated the percent content of cranberry juice (OSC: 27% and GVC: 30%), and both of these 
contained only sugar (presumably sucrose) and ascorbic acid as the other two added 
ingredients. These two products also had the highest detectable concentrations of 
oligosaccharide components. Of the other four products analyzed, cranberry juice is the second 
ingredient listed on the labels, indicating that it is at lower relative concentration than the first 
ingredient listed (either grape or apple juice concentrate). These other juice concentrates are 
added as a way to naturally sweeten and balance the flavors of cranberry juice, and are 
relatively less expensive to manufacture. Higher relative percentages of grape or apple juice 
therefore decrease the overall cost of the cranberry juice product for the manufacturer and 
provide the sweetness many consumers expect with the marketing benefit of a label claim of 
100% juice. Based on the semi-quantitative results of the preliminary HLPC-ELSD analyses in 
these studies, it is therefore likely that the products with lower apparent oligosaccharide 
concentrations (GVNS and LCP) have corresponding lower overall percentages of cranberry 
juice as an ingredient (probably less than 27%).  
All six juice products had a similar color (Appendix A color plates: Figures 100, 101), 
even though they differed in apparent cranberry oligosaccharide content, and therefore 
cranberry content, as detected by HPLC-ELSD. Products that contained grape or apple juice as 
the first ingredient still appeared to be the same color as cranberry-only products even though 
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both apple and grape juices are known to have distinct color profiles. This observation may 
reflect the efforts of manufacturers to ensure that their products meet consumer expectations of 
appearance for a juice product advertised as “cranberry juice.” The addition of “vegetable 
color” to products that have apple juice as the first ingredient (LCP and NL) may therefore 
further indicate lower relative concentrations of cranberry juice, as the resulting products 
without added “vegetable color” may not necessarily satisfy consumer expectations. 
The results of the preliminary studies of commercial juice products also indicate that 
grape and apple juices probably lack the oligosaccharide components of interest that are found 
in cranberry. The primary ingredient for the BCB product is grape juice, while the primary 
ingredient for the NL product is apple juice. Both of these products also contain cranberry juice 
as a reported ingredient, but have trace (NL) or undetectable (BCB) levels of the characteristic 
cranberry oligosaccharide profile.  These observations would support previous reports that the 
consumption of apple or grape juice does not lead to the production of urine with anti-adhesion 
properties by human volunteers (Howell et al. 2010).  
Overall, HPLC-ELSD profiles of cranberry juice products, including those with 
relatively lower percentages of cranberry, were similar in elution profile (8–48 min) to the 
cranberry juice powder (CJ) used for swine feeding studies (Chapter 2). The juice products 
profiles differed greatly from those of dietary supplement products, with juices containing 
many more detectable constituents in both polar (early eluting) and nonpolar (later eluting) 
regions of the chromatograms. These results further support the hypothesis that dietary 
supplement products lack the oligosaccharide components of interest, while juice products 
retain them. Additional studies will be necessary to fully quantify and characterize the 
occurrence of cranberry oligosaccharides in various commercial products.  
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Figure 85. Analytical HPLC-ELSD comparisons of commercial cranberry dietary supplements 
(AtldC18). 
Components of interest (box), indicative of possible oligosaccharide content, could not be 
detected in FN, NM, or NB materials. Based on this analysis it was determined that compounds 
of interest may have been present in SN material and further studies confirmed the presence of 
oligosaccharides in this product.  
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Figure 86. Analytical HPLC-ELSD comparisons of commercial cranberry dietary supplements, 
baseline expansion (AtldC19). 
Even with baseline expansions and multiple analytical separations, components indicative of 
oligosaccharides could not be detected in FN, NM, or NB materials.  
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Figure 87. Analytical HPLC-ELSD comparisons of commercial juice products (BCB, GVS, 
and GVNS) to CJ material. 
Early-eluting polar components constituted the majority of the BCB, GVS and GVNS juice 
samples. The presence of the putative oligosaccharide components (box) was not readily 
apparent.  
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Figure 88. Analytical HPLC-ELSD comparisons of commercial juice products (BCB, GVS, 
and GVNS) to CJ material with baseline expansions. 
Putative oligosaccharide components (box) in the GVS and GVNS juice samples could be 
detected with baseline expansion. The GVS and GVNS materials were similar in overall 
composition (18-45 min) with differences in the relative concentrations of the detected 
compounds. The BCB material contained lower concentrations of all compounds present and 
the oligosaccharide profile of interest was not detectable in this product at the sample 
concentration used.   
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Figure 89. Analytical HPLC-ELSD comparisons of commercial juice products (OSC, LCP, and 
NL) to CJ material. 
Early-eluting, polar components constituted the majority of the OSC, LCP and NL juice 
samples. The presence of the putative oligosaccharide components (box) was suggested for the 
OSC and LCP but was not readily apparent. 
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Figure 90. Analytical HPLC-ELSD comparisons of commercial juice products (OSC, LCP, and 
NL) to CJ material with baseline expansions. 
Putative oligosaccharide components (box) in the OSC and LCP juice samples could be 
detected with baseline expansion. The OSC and LCP materials were similar in overall 
composition (18-45 min), with differences in the relative concentrations of the detected 
compounds. The NL material contained lower concentrations of most compounds present and 
the presence of the oligosaccharide profile of interest is suggested but could not be confirmed 
in this product at the sample concentration used.   
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4. Bioactivity of CJ and CC Cranberry Components 
Two different anti-adhesion assays were available at different points in time. Selected 
samples were submitted to both assays based on the availability of the assay and logistical 
considerations.  
a. Anti-agglutination Assay  
Samples of CJ, CJA and selected CJA fractions were submitted for preliminary testing 
in the UPEC-HRBC anti-agglutination assay (Table 37). Samples that contained the 
oligosaccharides of interest appeared to be active while fractions that lacked such 
oligosaccharides (CJA2-05) were not active. The apparent low activity of fractions CJA2-03 
and CJA2-04 may have been due to issues with the repeatability of the assay rather than to an 
actual lack of activity, as exhibited by the differing results for the duplicated CJA samples. All 
fractions from CJA separations were therefore not exhaustively tested because of the 
questionable reproducibility of the assay.   
Table 37. Anti-agglutination assay results for cranberry fractions (CJ, CJA and CJA Sephadex 
LH-20 fractions). 
The aqueous fraction of CJ and early-eluting fractions from CJA Sephadex LH-20 columns 
showed anti-agglutination activity. 
Sample Description UM Scorea Test Date 
CJ (cranberry juice powder) +  07/2011 
CJA (aqueous fraction) +/– 07/2011 
CJAb (aqueous fraction) + + 07/2011 
CJA1-02B (Sep LH-20 fraction) + + 07/2011 
CJA2-02 (Sep LH-20 fraction) + + 07/2011 x2b 
CJA2-03 (Sep LH-20 fraction) +/– 07/2011 
CJA2-04 (Sep LH-20 fraction) +/– 07/2011 
CJA2-05 (Sep LH-20 fraction) – 07/2011 x2b 
a The criteria used to assign the UM Score can be found in Table 3. Raw data for these samples 
can be found in Appendix B-3: Table 58. b Sample was tested in duplicate for this test date. 
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b. Anti-adhesion Assay 
Selected CJA2 and SN fractions were tested in the radiolabeled version of the UPEC-
UEC anti-adhesion assay using methods described previously (Auker 2013, Mathison et al. 
2013). 
The fluorescence-based version of the UPEC-UEC anti-adhesion assay (Kimble et al. 
2014) was used for the CCA1 fractions and IC50 values from these analyses are shown below 
(Table 38). Fraction CCA1-01 had the highest activity (IC50 = 0.25 mg/mL), and fractions 
CCA1-01 – CCA1-03 appear to account for the majority of the anti-adhesion activity observed 
in the CCA material. Fractions CCA1-04 – CCA1-12 are either not active or have relatively 
low activity. The differences in structure and composition as determined by NMR spectroscopy 
and HPLC-ELSD for fraction 04 versus fractions CCA1-01 – CCA1-03 appear to correlate to 
activity, with fraction 04 having lower activity than CCA1-01 – CCA1-03. Fractions CCA1-01 
to CCA1-03 lack components that elute early in HPLC-ELSD chromatograms (Figure 82), 
further supporting the assignment of anti-adhesion activity to the components of the complex 
oligosaccharide mixtures present in these fractions.  
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Table 38. UPEC-UEC anti-adhesion assay results for CCA1 fractions. 
The aqueous fraction of the CC material (CCA) displayed higher anti-adhesion activity than the 
EtOAc fraction (CCE). This anti-adhesion activity could be attributed to Sephadex LH-20 
fractions CCA1-01 – CCA1-03P. 
Sample IC50 (mg/mL) 
CCE (EtOAc fraction of CC material) 2.88
CCE (EtOAc fraction of CC material) 2.87
CCA1 (aqueous fraction of CC material) 1.21
CCA1 (aqueous fraction of CC material) 1.10
CCA1-01 (Sep LH-20 fraction) 0.25
CCA1-02 (Sep LH-20 fraction) 1.55
CCA1-03 (Sep LH-20 fraction) 1.22
CCA1-03P (precipitate from Sep LH-20 
fraction CCA1-03 in EtOH) 
1.50
CCA1-04 (Sep LH-20 fraction) 3.81
CCA1-04P (precipitate from Sep LH-20 
fraction CCA1-04 in EtOH) 
2.06
CCA1-05 (Sep LH-20 fraction) 3.05
CCA1-06 (Sep LH-20 fraction) >10
CCA1-07 (Sep LH-20 fraction) NAa
CCA1-08 (Sep LH-20 fraction) >10
CCA1-09 (Sep LH-20 fraction) 4.03
CCA1-10 (Sep LH-20 fraction) >10
CCA1-11 (Sep LH-20 fraction) >10
CCA1-12 (Sep LH-20 fraction) >10
a This fraction was not available for testing when samples were submitted. 
c. Antimicrobial Assays 
For the NCNPR antimicrobial assays, compounds or fractions that show greater than 
50% growth inhibition at the test concentration were considered to be active and would be 
tested in secondary assays. All of the cranberry materials submitted to these assays had less 
than 50% growth inhibition and were therefore considered inactive (Table 39). These results 
indicate that cranberry materials do not possess cidal or growth-inhibitory activity against the 
microbes tested at the concentrations used. Cranberry oligosaccharide fractions prepared from 
SN and CJA2 cranberry material by K. Auker (2013) were also submitted to the antimicrobial 
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assays offered by NCNPR at UM, as well as to two separate breast cancer cell viability assays. 
These assays produced similar negative results, further confirming the lack of antimicrobial 
activity and additionally indicating a lack of cytotoxicity.  
The negative results for cranberry materials in the antimicrobial assays and cytotoxicity 
assays of NCNPR supports the relative safety of cranberry in general, as would be expected for 
a common food product. These results also support the hypothesis that cranberry components 
exhibit anti-adhesion-specific bioactivity without concurrent antimicrobial effects. 
Table 39. Results of the NCNPR antimicrobial assays for CJ material and fractions. 
The CJ material and the water (CJA) and EtOAc (CJE) fractions of this material showed no 
apparent antimicrobial activity in the NCNPR assays. 
↓ Organism 
Conc. 
Tested 
(µg/mL) 
Percent Growth 
Inhibition  
by Sample (%) 
→ Sample Code  CJ CJE CJA 
Plasmodium falciparum (D6 Clone) 15.9 29 6 7 
Leishmania donovani 80 4.37 7.89 5.07 
Candida albicans 50 0 0 0 
Candida glabrata 50 0 8 0 
Candida krusei 50 0 9 1 
Candida neoformans 50 8 12 8 
Aspergillus fumigatus 50 0 1 0 
Staphylococcus aureus 50 0 0 0 
Methicillin-Resistant Staphylococcus aureus 50 0 14 1 
Escherichia coli 50 0 10 0 
Pseudomonas aeruginosa 50 0 5 0 
Mycobacterium intracellulare 50 16 0 24 
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D. Conclusions 
It is likely that a number of compounds are present in cranberry that contribute to the 
anti-adhesion properties of the juice. Cranberry PACs and NDM are already known to have 
anti-adhesion activity, and these compounds were likely to be retained by MW cut-off 
centrifugal filters under the conditions used in these studies. Additional compounds, such as 
oligosaccharides could also have been retained through reversible associations with high-MW 
components. All three classes of compounds would also likely be stable under the acid/base 
incubation conditions used.  
The use of methods similar to those developed for the isolation of oligosaccharides 
from urine enabled the identification of similar oligosaccharide components in cranberry. 
Analyses using HPLC-ELSD/UV and NMR spectroscopy provide strong support for the 
presence of an entire pool of such structurally related carbohydrate compounds in spray-dried 
cranberry juice powder, cranberry juice concentrate and certain commercial products. Two 
cranberry oligosaccharides were isolated and fully elucidated from CJA material (Auker Thesis 
2013) and found to have similar structures as the fully elucidated urinary octasaccharide (1). 
These studies are the first reports of arabinoxyloglucan oligosaccharides from cranberry. 
The similarities in structures for the oligosaccharides from both cranberry and urine 
sources, combined with the similar HPLC-ELSD profiles of oligosaccharides from both sources 
(Figure 74), strongly supports the hypothesis that cranberry oligosaccharides are the source of 
urinary oligosaccharides. In foods, hemicellulose oligomers such as arabinoxyloglucans are 
considered to be a type of dietary fiber due to their lack of human metabolic biotransformation 
(Haard & Chism 1996). The presence of β-(1→4)-linked glucose backbones in 
oligosaccharides from both sources therefore further supports the hypothesis that these 
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compounds are stable to normal digestive processes and may be directly excreted without 
metabolic modification.  
Numerous clinical trials that have tested the effectiveness of cranberry products have 
used cranberry dietary supplements rather than cranberry juice or cranberry juice concentrate. 
A possible reason for the failure of some of these trials is therefore the absence of anti-adhesive 
cranberry metabolites from the products used. This hypothesis is supported by the observation 
that oligosaccharides were absent from three of the four cranberry fruit dietary supplement 
products analyzed. In contrast, the characteristic oligosaccharide HPLC-ELSD profile was 
readily detectable in four of the six juice products analyzed at concentrations corresponding to 
the marketed juice preparations. This observation supports the traditional use of cranberry juice 
for preventing UTIs, and provides a possible reason for why cranberry dietary supplements 
manufactured using current processes may not be as effective for this same application. 
Knowledge of the active metabolites of cranberry will help to resolve many of the existing 
issues with regards to clinical trial testing and cranberry dietary supplement composition.  
In these studies, oligosaccharide mixtures with similar chemical profiles were isolated 
in large scale from two sources, and comprised 2–6% of the CJ and CCA starting materials. 
The oligosaccharide-containing fractions from the CJA separations constituted a relatively high 
percentage of this starting material (25-30%), but this may reflect a lower degree of enrichment 
rather than a higher actual yield of oligosaccharides. In contrast, only 1% of the total CJ 
material was extractable by EtOAc. This EtOAc fraction was found to contain PACs and as 
well as other known flavonoids. These data indicate that PACs and other flavonoids are present 
at lower relative concentrations than oligosaccharides (Santos-Buelga & Scalbert 2000).  
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The presence of a similar complex profile of oligosaccharide components in the CJ, CC, 
and SN (Auker 2013) materials, as well as in commercial juice products from multiple 
manufacturing sources, supports the hypothesis that these compounds are a native component 
of cranberry that is naturally enriched in cranberry juice, rather than a processing or extraction 
artifact. The structures of the two arabinoxyloglucan oligosaccharides isolated from cranberry 
material and the 1H NMR data of the oligosaccharide-enriched Sephadex LH-20 fractions 
indicate that the series of oligosaccharide compounds present are all structurally related and are 
all likely to be arabinoxyloglucans derived from hemicellulose. Plant hemicellulose polymers 
are components of plant primary cell walls that are enzymatically cleaved and solubilized 
during fruit ripening (Redgewell & Fry 1993, York et al. 1996, Brummell et al. 2004, Goulão 
& Oliveira 2008). Complex mixtures of such compounds with arabinoxyloglucan structures 
unique to cranberry could therefore reasonably end up in the juice of pressed ripe cranberries at 
relatively high concentrations. The relatively high yield of oligosaccharide mixtures from 
cranberry materials indicates that cranberry could therefore be a valuable source from which to 
obtain additional oligosaccharides. 
The results from two independent anti-adhesion assays using fractions from three 
cranberry source materials (CJ, CC, and SN) confirmed the anti-adhesion activity of cranberry 
arabinoxyloglucan mixtures. These studies are the first report of the E. coli anti-adhesion 
properties of arabinoxyloglucan oligosaccharides. Active cranberry samples, both crude and 
enriched fractions, contained similar HPLC-ELSD and 1H NMR profiles as active urine 
fractions, with the presence of a series of UV-transparent oligosaccharides. These results, 
combined with the high degree of structural similarity between urinary and cranberry 
oligosaccharides, further support the anti-adhesion properties of urinary oligosaccharides.  
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Future studies are required to conclusively establish the bioactivity profiles of 
individual arabinoxyloglucans oligosaccharides using additional bioassay resources and 
methods. The large scale isolation of cranberry oligosaccharides during these studies has 
resulted in the collection of sufficient amounts of material (~20 g) to facilitate future studies 
involving the isolation and detailed structure elucidation of individual oligosaccharide 
components. It also provides sufficient material for future bioassay testing and analytical 
method development. The potential use of cranberry anti-adhesive oligosaccharides for the 
prevention of infections, especially UTIs, warrants continued investigation into the structural 
characteristics and biological properties of these compounds.   
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CHAPTER 4: CHANGING THE CRANBERRY PARADIGM 
A. Introduction: The Story of a Paradigm Transition 
1. Swine Urine Studies 
The primary objectives of these studies were (1) to isolate and identify the urinary 
metabolites of cranberry juice that are responsible for the prevention of UPEC adherence, and 
(2) to identify the compounds present in cranberry that are related to the anti-adhesive urinary 
metabolites. This work started under the paradigm and guiding hypothesis that the compounds 
of interest would be PACs or PAC-derived (Howell et al. 1998, Howell et al. 2010, Ofek et al. 
1996). Efforts to isolate such compounds from active urine fractions failed, however, and 
delayed the identification of the actual, active components of interest.  
The chance observation of a 1H NMR spectrum for a pectin sample during a conference 
presentation led to the realization that the 1H NMR spectra of active fractions FA1 and FA2 
were similar to those of complex carbohydrates. Subsequent comparisons of active samples to 
the 1H NMR spectra of commercial monosaccharides, pectin, synthetic PACs, and other 
samples, combined with chemical analyses using TLC spray reagents, confirmed the 
observation that the compounds of interest were probably UV-transparent carbohydrates. The 
hypothesis that PACs were the target urinary metabolites was discarded based on data collected 
during initial studies, and investigations were continued under the newly formulated hypothesis 
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that complex carbohydrates were the compounds of interest. These observations and this newly 
formed hypothesis prompted the use of ELSD, a mass-sensitive, semi-quantitative detection 
method, to monitor subsequent HPLC separations. 
Multiple swine feedings were required to obtain sufficient material and suitable 
methods for the isolation of the compounds of interest from active fractions. Ultimately, a 
sufficient quantity (12 mg) of a single pure compound (1), low quantities of other pure 
compounds (1-2 mg), and many other partially purified compounds were obtained from the 
complex carbohydrate mixture. The structure of 1 was elucidated using multiple carbohydrate-
specific analyses and NMR spectroscopic techniques. This compound was highly similar in 
structure to the other purified and partially purified compounds present in the mixture of 
interest, and all were determined to be arabinoxyloglucan oligosaccharides. Data indicated that 
these urinary oligosaccharides contained cellulose-type β-(1 → 4)-linked glucose backbones, 
supporting the newly formed hypothesis that these compounds were plant-derived. 
Circumstantial evidence suggested that components of this arabinoxyloglucan oligosaccharide 
mixture were responsible for the UPEC-HRBC anti-agglutination activity of active fractions: 
oligosaccharides were the only compounds detectable in some active fractions, were present in 
all active fractions, and were absent from all inactive fractions. Material limitations and issues 
with assay reproducibility made it impossible, however, to directly confirm the anti-adhesion 
properties of the isolated urinary arabinoxyloglucan oligosaccharides. Additionally, 
arabinoxyloglucans from cranberry had not been previously identified, and there were no 
previous reports of anti-adhesion properties for arabinoxyloglucan oligosaccharides. The 
conclusions of the urinary metabolites study led to the formulation of the new hypothesis that 
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the anti-adhesive compounds present in urine after cranberry consumption were 
arabinoxyloglucan oligosaccharides derived from cranberry. 
2. Cranberry Studies 
Cranberry materials were investigated using the same methods developed for urine 
samples to determine if similar oligosaccharides were present in the starting material fed to 
swine. Analytical HPLC-ELSD data showed evidence of a highly similar elution profile for the 
compounds of interest from cranberry material. Direct separation of cranberry juice powder on 
preparative HPLC, with no prior extractions or enrichments, led to the isolation of sufficient 
quantities (2-4 mg) of several cranberry oligosaccharides, confirming that the same class of 
compounds was present and was of highly similar chemical composition. More material was 
required, however, for full structural elucidation of the cranberry oligosaccharides of interest. 
Large scale isolation of cranberry oligosaccharide mixtures was pursued using the 
Sephadex LH-20 methods similar to those developed for urine separations. Cranberry source 
materials used included cranberry juice powder, cranberry juice concentrate, and cranberry fruit 
powder. These isolations led to the total collection of approximately 20 g of enriched 
oligosaccharide material from all three sources. Enriched cranberry oligosaccharide mixtures 
were used for further analyses and bioactivity testing. The purification and structure elucidation 
of two compounds from the cranberry oligosaccharide series was the subject of the Master’s 
Thesis for Kimberly M. Auker (2013). The two purified and fully characterized cranberry 
oligosaccharides were also found to be arabinoxyloglucan oligosaccharides that were highly 
similar in structure to the urinary octasaccharide and the associated series of urinary 
oligosaccharides. The similar structures of urine- and cranberry-derived oligosaccharides 
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supports the hypothesis that swine urine oligosaccharides are derived from ingested cranberry 
products and provided support for the new hypothesis that cranberry arabinoxyloglucan 
oligosaccharides are absorbed and excreted unchanged into mammalian urine. 
Oligosaccharide-enriched fractions from cranberry materials were submitted to two 
different anti-adhesion assays and showed activity in both. These assays both used 
uropathogenic P-fimbriated E. coli (UPEC) and included the original, qualitative, anti-
agglutination assay and a newly-developed, quantitative, uroepithelial cell (UEC) anti-adhesion 
assay. The results of the newly-developed assay confirmed those of the original anti-
agglutination assay. The results from testing cranberry fractions in antimicrobial assays 
provided additional support for the published hypothesis that cranberry-derived compounds 
prevent adhesion without direct antimicrobial effects. The anti-adhesion assay results for the 
cranberry oligosaccharides confirmed, by association, the previously putative anti-adhesion 
activity of urinary oligosaccharides. The conclusions of these studies supported the hypotheses 
that urinary and cranberry arabinoxyloglucan oligosaccharides can both prevent the adhesion of 
UPEC to uroepithelial cells.  
Analysis of commercial cranberry products (dietary supplements and juices) by an 
oligosaccharide-optimized HPLC-ELSD method showed that some products lack detectable 
levels of oligosaccharides while others contain readily detectable amounts of the 
oligosaccharide mixture of interest. Many clinical studies testing the effectiveness of cranberry 
for UTI prevention have used cranberry products enriched for PACs or standardized to PAC 
content. Such products may therefore lack detectable levels of carbohydrates such as 
arabinoxyloglucan oligosaccharides. These observations and the results of these studies 
therefore support the hypothesis that the inconclusive results of certain clinical studies may be 
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due, in part, to the use of cranberry products that lack cranberry oligosaccharide compounds 
with anti-adhesion activity. 
3. Overview of Results 
As reported here, cranberry arabinoxyloglucan oligosaccharide mixtures prevent the 
adhesion of uropathogenic P-fimbriated E. coli in two different anti-adhesion assays, are 
present in relatively high percentages in renewable source material, and are present in 
mammalian urine after the consumption of cranberry products. These observations and the 
availability of enriched cranberry oligosaccharide fractions lay the groundwork for future 
studies based on many new hypotheses concerning oligosaccharides. 
B. Significance of Cranberry-Derived Urinary Oligosaccharides 
1. Cranberry Oligosaccharides as Anti-adhesion Compounds 
Carbohydrates have many roles with regards to host-pathogen interactions (Beachey 
1981, Pieters 2007). Eukaryotic cell surface carbohydrates are the natural ligands for many 
types of microbial adhesins, including the P fimbriae of E. coli (Enerbäck et al. 1987). Free 
oligosaccharides are recognized to be natural interference ligands, and various sources of such 
compounds with anti-adhesion properties are of significant medical interest for the prevention 
of infections (Zopf & Roth 1996, Sharon 2006, Pieters 2007, Shoaf-Sweeney & Hutkins 2008). 
Carbohydrates that mimic the natural carbohydrate ligands of microbial adhesins may be able 
to directly interfere with microbial adhesion to cell surfaces by competitive binding. 
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Alternatively, carbohydrates that bind to microbial fimbriae in other locations may prevent 
fimbrial adhesion to target ligands by indirect mechanisms such as by altering fimbrial 
conformations.  
Carbohydrates are well recognized as compounds that can prevent P-fimbriated E. coli 
adhesion. For example, globotriose [α-D-Gal-(1→4)-β-D-Gal-(1→4)-β-D-Gal], galabiose, 
multivalent galabiose, and tetrasaccharides containing an α-Gal-(1→4)-β-Gal moiety are able 
to inhibit E. coli adhesion both in vitro and in vivo by binding to P fimbriae in place of cell 
surface receptors (Svanborg-Edén et al. 1984, Korhonen et al. 1986, Leach et al. 2005, Turner 
et al. 2005, Salminen et al. 2007). The binding of the PapG adhesin of E. coli P fimbriae can 
also be inhibited by dipentasaccharide fragments derived from the globoseries of glycolipids 
that contain the minimum α-Gal-(1→4)-β-Gal binding epitope (Larsson et al. 2003). Studies 
have shown that mixtures of neutral oligosaccharides isolated from breast milk and the urine of 
breast-feeding babies are able to interfere with E. coli adhesion (Rosenstein et al. 1988, Coppa 
et al. 1990). While these and other studies show proof-of-principle for the ability of 
carbohydrates to prevent E. coli adhesion, currently known compounds are not clinically viable 
agents due to non-specific lectin binding, limited material availability, and high manufacturing 
costs, among other reasons (Larsson et al. 2003, Turner et al. 2005, Sharon 2006, Pieters 2007). 
Additional carbohydrate-type compounds that can prevent the adhesion of P-fimbriated E. coli 
are of great medical interest but suitable compounds have not yet been identified and developed 
into therapies.  
Studies investigating the effects of cranberry juice on the P fimbriae of individual E. 
coli using the nanoscale tool of AFM microscopy indicate that cranberry components directly 
interact with fimbriae and prevent adhesion by affecting the conformations of E. coli surface 
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macromolecules (Liu et al. 2006). Studies of E. coli strains with variations in Pap-G adhesin 
types indicate that the conformation and overall structure of cell surface carbohydrate chains 
influences bacterial binding (Strömberg et al. 1991). Specifically, the Pap-G adhesin isotype 
that is most often found in UPEC preferentially binds to neutral, 4- and 5-sugar containing, 
cell-surface glycosphingolipid isoreceptors containing the minimum Gal-(α1→4)-Gal binding 
epitope, the major isoreceptor of uroepithelial cells (Strömberg et al. 1991, Strömberg et al. 
1990).  The UPEC-associated Pap-G adhesin isotype also preferentially binds to compounds 
containing multiple versions of the target galabiose disaccharide (multivalent compounds), 
showing higher binding affinities for these compounds than for compounds with a single 
version of the galabiose disaccharide (monovalent compounds) (Figure 91) (Salminen et al. 
2007). 
 
 
Figure 91. Examples of monovalent and multivalent carbohydrate derivatives containing the 
galabiose binding epitope (Salminen et al. 2007).  
The octavalent compound shown inhibited the adhesion of UPEC with the PapGJ96 adhesin to 
epithelial cells at an IC50 value of 22 µM and inhibited HRBC agglutination at an MIC of 7 
µM. In contrast, the monovalent compound shown inhibited cell adhesion at an IC50 value of 
170 µM and inhibited HRBC agglutination at an MIC of 320 µM in the same assays (Salminen 
et al. 2007). 
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Together, these data support the proposed hypothesis that the neutral cranberry 
oligosaccharides identified in the present studies bind to the Pap-G adhesin of UPEC P 
fimbriae, changing its conformation and thereby preventing the adhesion of UPEC to 
uroepithelial cells. Numerous further studies are necessary, however, to fully characterize the 
mechanisms by which cranberry oligosaccharides alter interactions between bacterial and 
epithelial cells to prevent adhesion. Studies using AFM could be used to confirm that cranberry 
oligosaccharides are able to cause the changes in fimbrial conformation observed with 
cranberry juice (Liu et al. 2008). Modeling, crystal structures, and various types of labeling 
could be used to investigate putative binding sites for oligosaccharides on P fimbriae and to 
characterize how different PapG adhesin classes and isotypes interact with oligosaccharides of 
different structures (Strömberg et al. 1991, Larsson et al. 2003, Salminen et al. 2007). The 
effectiveness of oligosaccharides for preventing the adhesion of E. coli during different stages 
of infection, of different clinical strains of E. coli, or of clinical E. coli strains with different 
fimbrial variants could also be examined (Marrs et al. 2002, Howell & Foxman 2002, Justice et 
al. 2004). Many additional types of studies are also likely to be proposed by other researchers 
in relation to their chosen specialties. 
Various clinical approaches that aim to interfere with adhesin-ligand binding between 
pathogen and host cells have met with mixed success, due partly to the complexities of in vivo 
systems and partly to the structural complexities of carbohydrates (Zopf & Roth 1996, Sharon 
& Ofek 2000, Sharon 2006). The approaches that currently show the greatest potential are those 
that use multivalent carbohydrates or mixtures of oligosaccharides (Sharon & Ofek 2000, 
Pieters 2007, Salminen et al. 2007). Neutral oligosaccharides composed of four to six 
monosaccharide units, or compounds containing multiple versions of the known carbohydrate 
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binding epitope of E. coli (oligovalent or multivalent compounds; see Figure 92) have also 
shown increased binding affinities and higher anti-adhesion activity against P-fimbriated E. coli 
(Svanborg-Edén et al. 1984, Coppa et al. 1990, Larsson et al. 2003, Salminen et al. 2007, 
Pieters 2007). Complex carbohydrates or oligosaccharide mixtures possess superior anti-
adhesion abilities as compared to mono- or disaccharides, and are believed to be more effective 
at preventing adhesion due to their ability to mimic host cell carbohydrate receptors and their 
simultaneous interactions with multiple bacterial adhesions (Pieters 2007, Salminen et al. 
2007). Microbes typically express multiple adhesion mechanisms during infection, and 
mixtures of compounds may be required to prevent all types of adhesion and obtain clinical 
efficacy. These observations support the hypothesis that the anti-adhesion properties of 
cranberry and urinary oligosaccharides may be enhanced due to the presence of mixtures of 
complex, neutral oligosaccharides. Numerous studies would be necessary to investigate this 
hypothesis, and all would require the availability of sufficient quantities of purified and fully 
characterized individual oligosaccharides for the controlled testing of known ratios of 
compounds.  
2. Implications for Cranberry Bioactivity 
The identification of oligosaccharides as anti-adhesive components of cranberry 
products provides a new direction for all researchers interested in cranberry bioactivity. Data 
from the present studies indicate that oligosaccharides are likely to be partly responsible for 
previously observed cranberry product anti-adhesion effects (Ofek et al. 1996, Howell et al. 
1998, Howell et al. 2010, Tao et al. 2011, Turner et al. 2005). The structural and 
chromatographic characteristics of oligosaccharides also indicate that these compounds may be 
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present, but undetected, in many other “enriched” bioactive fractions derived from cranberry. 
Unlike many typical small molecule natural products, oligosaccharides are of relatively high 
MW, are UV transparent and are not readily ionized or detected by generalized MS-based 
methods (Table 40).  
 
Table 40. Overview of reasons for the difficulty of detection, isolation, and structural 
characterization of oligosaccharides using classical bioassay-guided fractionation. 
Compound 
Type Typical Natural Product Oligosaccharides 
Extraction Organic extracts Water soluble, not organic soluble 
Isolation Relatively few components with structural similarity in a series 
Complex series of many structurally related 
components 
Detection UV detection possible No chromophore, ELSD or other chromatographic detection method required 
Ionization  Readily ionized for detection by (+) or (-) LC-MS  
Poor ionization for LC-MS, requires 
derivatization, specialized MS methods 
and/or custom calibration 
NMR Spectra Simple NMR spectra, <30 carbons Complex NMR spectra, >30 carbons 
Structural 
Elucidation 
Full characterization possible 
using spectroscopic/ 
spectrometric methods  
Full characterization requires multiple, 
complementary methods that are typically 
destructive  
MW 200-800 Da, < 10 mg yields usable NMR data at 400 MHz 
800-2000+ Da, requires 15 + mg to yield 
usable NMR data at 400 MHz, MW > 
typical LC-MS detection threshold 
Bioassay 
Types 
Established, quantitative assays, 
or identified by high-throughput 
screening 
Qualitative or new assays, specific to an 
individual organism or research question 
Bioassay 
Endpoints 
Based on clear endpoints such 
as the death of the target 
organism or growth inhibition 
Based on a biological response of a living 
organism that can be difficult to quantify 
and correlate to in vivo effects. e.g. anti-
adhesion 
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As PAC-enriched fractions are typically characterized through the use of MS or UV 
data (Porter et al. 2001, Kandil et al. 2002, Howell et al. 2005, Ermel et al. 2012), 
oligosaccharide constituents would not have been detected. Many methods for enrichment or 
partial purification would also not necessarily have eliminated oligosaccharides as possible 
components of the “enriched” final product. Oligosaccharides may also form reversible 
hydrogen bonds with PAC oligomers or other oligosaccharide components in solution to form 
complexes with high apparent MWs. It is therefore possible that oligosaccharides may be 
present in the PAC-enriched or high-MW fractions used by many researchers and may 
contribute to the anti-adhesion effects and other biological properties observed for these 
fractions (Delehanty et al. 2007, Shmuely et al. 2004, Steinberg et al. 2004). Future studies will 
be necessary to investigate the contributions of cranberry oligosaccharides to the various 
biological properties attributed to cranberry.  
Multiple compounds with various mechanisms of action are likely to be involved in the 
reported bioactivities of cranberry products (Shmuely et al. 2012). With regards to the anti-
adhesion properties of cranberry, multiple compounds have been identified that have been 
shown to prevent microbial adhesion. These include fructose (Zafriri et al. 1989, Ofek et al. 
1996), mannose (Ofek & Beachey 1978), PACs (Howell et al. 1998, Foo et al. 2000a,b), 
myricetin (Mathison et al. 2013, Kimble et al. 2014), and now also oligosaccharides, as shown 
by the present studies. All of these compounds, and possibly others that have yet to be 
identified, are likely to act together by various mechanisms to prevent bacterial-mammalian 
cell adhesion in different parts of the human body after cranberry consumption. All may 
participate in the prevention of biofilm formation within the human mouth, and all may affect 
gut microbes by altering species composition or gene expression profiles, including that of E. 
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coli (Ofek et al. 1996, Weiss et al. 1998, Rajan et al. 1999, Yamanaka et al. 2004, Howell et al. 
2005, Duarte et al. 2006, Labrecque et al. 2006). Current data, however, give the strongest 
support to the hypothesis that carbohydrate-type compounds including mannose, fructose, and 
now oligosaccharides have the most significant roles for the prevention of microbial adhesion 
in the urinary tract, and therefore for the in vivo prevention of urinary tract infections. Many 
types of additional studies of cranberry products and cranberry-derived compounds will be 
necessary to fully elucidate all of the ways in which cranberry components may work together 
to prevent microbial adhesion to epithelial cells.  
3. Cranberry Oligosaccharides as Urinary Components 
Data from the present studies support the hypothesis that cranberry oligosaccharides are 
absorbed intact and excreted into urine without modification by mammalian enzymes or 
digestive processes. The urinary octasaccharide (1) and the octa- and hepta-saccharides (2 & 3) 
purified from cranberry oligosaccharide mixtures (Auker 2013) are arabinoxyloglucans with 
highly similar structures, all have cellulose-type β-(1 → 4)-linked glucose backbones, and all 
are relatively stable over time. In general, hemicelluloses such as these are considered to be a 
type of dietary fiber, are water soluble, acid stable, and resistant to degradation during 
mammalian digestion, as mammals lack β-glucosidase digestive enzymes (Haard & Chism 
1996, Robyt 1998). Crude cranberry materials containing oligosaccharides were also found to 
retain anti-adhesion activity after incubation at human body temperature at pH 2, 4, and 8. 
Comparison of analytical HPLC-ELSD profiles for urinary and cranberry oligosaccharide 
mixtures indicated similar ratios for the different components of the mixture in both materials 
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(Figure 74), further supporting the hypothesis that many of the compounds present in the 
cranberry mixture are absorbed and excreted intact into the urine in similar ratios. 
The primary objective of the present studies was to identify active urinary constituents, 
but attempts were also made to monitor sample recovery for relative quantification of the active 
constituents. Such quantification proved difficult, however, due to numerous, uncontrollable 
sources of sample loss (ELSD-based separations) and to the need for pooling starting materials 
across collection periods and study animals to provide sufficient cumulative amounts for the 
isolation of active components. Conservative estimates can be made for oligosaccharide urinary 
concentrations in relation to cranberry consumption, but additional, detailed studies will be 
necessary to fully quantify cranberry oligosaccharide absorption, distribution, and excretion 
profiles. Currently available data suggests a minimum urinary oligosaccharide mixture 
concentration of approximately 0.15 mg/mL, corresponding to a minimum excretion of 0.04% 
w/w oligosaccharides per gram of ingested cranberry powder. This concentration is expected to 
vary based on the urinary solute concentrations of individual organisms, but is within a 
reasonable range for compounds that are excreted into the urine (Saude et al. 2007, Bouatra et 
al. 2013). Currently available data also indicates that the cranberry powder used for swine 
feedings contained a maximum oligosaccharide content of 16-30% w/w, with the wide range 
based on the method used for enrichment. Together, these data indicate that a minimum of 
0.13-0.25% of ingested cranberry oligosaccharides are excreted into urine. While the values 
presented here are rough estimates, these data support the hypothesis that orally ingested 
cranberry oligosaccharides are also excreted through feces or retained in body compartments 
and excreted into urine over time. 
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Direct absorption and rapid elimination of unmodified oligosaccharides into 
mammalian urine would be consistent with the reported rapid appearance of anti-adhesion 
activity in human urine after the consumption of cranberry juice (Howell et al. 2005). 
Oligosaccharides have been previously isolated from normal human urine (Parkkinen & Finne 
1984), and reports have shown that mixtures of complex oligosaccharides ranging in size from 
trimers to heptamers and larger can be ingested and subsequently found in adult and infant 
human urine (Rosenstein et al. 1988, Coppa et al. 1990). These studies have reported 500-800 
mg/day of uncharacterized oligosaccharide mixtures in the urine of adult women (Coppa et al. 
1990). Mice gavaged with high doses of globotriose [Gal-(α1→4)-Gal-(β1→4)-Glc] (Figure 
92) were found to rapidly clear this trisaccharide from plasma (t½ = 6 min) and excrete it 
primarily into urine without metabolic biotransformation at levels of > 5 mg/mL for 4-12 hours 
after administration, indicating that this compound is orally bioavailable and retaind for later 
excretion over time (Leach et al. 2005).  
 
 
Figure 92. Structure of globotriose [Gal-(α1→4)-Gal-(β1→4)-Glc] depicted with IUPAC 
stereodescriptors (a) and chair conformers (b). 
 
Together these observations further support the hypothesis that cranberry-derived 
oligosaccharides are orally bioavailable and excreted relatively rapidly into urine without 
metabolic biotransformation. These data also support the feasibility of oral administration of 
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cranberry juice for the prevention of UTIs. Future detailed studies regarding cranberry 
oligosaccharides will be needed to quantitatively examine the absorption, distribution, 
metabolism, and excretion (ADME) profiles of these compounds, individually and as mixtures. 
Such studies will be facilitated by the availability of cranberry compounds as analytical 
standards, and the apparent lack of biotransformation, but will require the development of 
targeted, sensitive methods for oligosaccharide detection and quantification. High-throughput 
analytical platforms optimized for oligosaccharide detection and quantification will also be 
required for effective evaluation of clinical samples and dietary source materials that may 
contain oligosaccharides.  
4. Implications for Human Clinical Trials 
Studies are currently in progress at UM to identify the anti-adhesive components of 
human urine collected after cranberry juice consumption using isolation and detection methods 
similar to those applied to swine urine samples and cranberry oligosaccharides. Human urine 
fractions with anti-adhesion activity are hypothesized to contain cranberry-derived 
oligosaccharides and preliminary evidence suggests that these compounds are indeed present. 
The identification and characterization of cranberry-derived oligosaccharides from human urine 
is the minimum piece of information necessary to directly link the current report to probable in 
vivo efficacy. Additional studies will be necessary to assess the clinical relevance of 
oligosaccharides for the prevention of UTIs in various patient populations. Knowledge of these 
active compounds will make it possible to quantify oligosaccharide consumption and excretion 
for individual study subjects. These data could then be correlated to long and short term clinical 
outcomes, including an absence of UTIs and the oligosaccharide content and anti-adhesion 
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properties of patient urine. Improved knowledge regarding the anti-adhesive components of 
cranberry that are excreted into urine will also help to resolve many of the current uncertainties 
regarding the efficacy of cranberry for preventing UTIs (Jepson et al. 2012). 
The variation in procedures for commercial cranberry product preparation and the 
probable lack of oligosaccharide constituents in certain products is a possible explanation for 
some of the heterogeneity of results obtained from cranberry-focused clinical trials (Jepson et 
al. 2012). Preliminary profiling of cranberry dietary supplements with regards to 
oligosaccharide content indicates that “concentrated” cranberry dietary supplements may not 
contain anti-adhesive oligosaccharides. Most dietary supplement manufacturers do not disclose 
the full product manufacturing processes. It is therefore difficult to determine whether certain 
products may contain oligosaccharides without subjecting product samples to HPLC-ELSD, 
NMR spectroscopy, and other analyses. It is likely, however, that many manufacturers are 
enriching for flavonoid content based on the hypothesis that PACs are the target anti-adhesive 
constituents, and the methods used for flavonoid enrichment may or may not also enrich for 
oligosaccharides. Additional studies are needed to independently quantify the relative amounts 
of cranberry oligosaccharides in different dietary supplements prior to the use or marketing of 
such products for UTI prevention. 
One survey of cranberry clinical trials compared the reported efficacy of cranberry juice 
to that of dietary supplements and found that juice was more effective (Wang et al. 2012a). The 
authors hypothesized that this may be due to improved patient hydration (Wang et al. 2012a), 
but this observed result may also have been due to the presence of cranberry oligosaccharides 
in juice products but not in dietary supplement products, as observed in the present studies.  
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It is also possible that clinical studies using various cranberry products are showing that 
certain cranberry preparations do or do not contain the active ingredients, rather than that 
cranberry itself isn’t active. For example, in one of the clinical trials that reported a lack of 
cranberry efficacy (Beerepoot et al. 2011), the cranberry product used was a dietary 
supplement called Cran-Max® (Proprietary Nutritionals, Inc., Kearny, NJ) that contained a 
standardized dose of A-type PACs. Based on published product literature, it appears that the 
Cran-Max® extract had been enriched for anthocyanins and flavonoids and likely lacked 
oligosaccharides (Proprietary Nutritionals 2007, Appendix C-5). A different study that 
supported the effectiveness of cranberry products (Howell et al. 2010) used a cranberry dietary 
supplement known as ElluraTM (Ellura, Trōphikōs Nutritive Health, Atlanta, GA) that 
reportedly contained “cranberry powder.” The limited product literature that could be found on 
the internet regarding ElluraTM (Appendix C-6) indicated that this material was derived from 
cranberry juice and standardized with regards to PAC content, but provided minimal 
information regarding other possible constituents. Another study that used whole cranberry 
powder with standardized PAC content also showed efficacy for preventing UTIs (Sengupta et 
al. 2011). Additional cranberry compounds, such as oligosaccharides, may have therefore been 
present in cranberry products that have shown efficacy (Howell et al. 2010, Sengupta et al. 
2011).  
The most recent survey of cranberry clinical trials (Jepson et al. 2012) has concluded 
that “cranberry products cannot be recommended for preventing UTIs” and that more studies 
are needed that quantify the amount of active ingredient in source material. The results of the 
studies presented in this report indicate that such quantification may now be possible for both 
source material and patient samples.  
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C. Occurrence & Potential Uses of Arabinoxyloglucan Oligosaccharides 
1. Natural Sources of Arabinoxyloglucan Oligosaccharides  
The oligosaccharides identified in both urine and cranberry are structurally related to 
known hemicellulose polymers, specifically xyloglucans and arabinoxyloglucans. 
Hemicelluloses are heterogeneous, branching polymers with a high degree of variety in 
structural components and arrangements (Scheller & Ulvskov 2010). They typically contain 
backbones composed of β-(1 → 4)-linked glucose units, but backbones may also be composed 
of xylose, mannose, or galactose units. Branching patterns and side chain compositions vary 
across plant families and species, and any given plant may produce a wide range of 
hemicelluloses with common structural motifs. Monosaccharides commonly found in side 
chains include galactose, mannose, arabinose, glucuronic acid, xylose, fucose, and rhamnose. 
The xyloglucans, composed of cellulose-type β-(1 → 4)-linked glucose backbones and xylose-
containing side chains, are one of the most common classes of hemicelluloses (Figure 93). 
Hemicelluloses are an essential component of plant primary cell walls, crosslinking cellulose 
fibers to provide structure and strength (York et al. 1986, Scheller & Ulvskov 2010). Native 
hemicellulose polymers are typically studied using enzymatic cleavage via fungal enzymes, and 
it has been shown that hemicellulose polymers are naturally cleaved during fruit ripening 
(Hisamatsu et al. 1992, York et al. 1996, Brummell et al. 2004, Goulão & Oliveira 2008).  
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Figure 93. Structures of cellulose (a) and xyloglucan (b) segments showing the cellulose-type 
backbone of xyloglucans and the preferred equatorial and boat conformations of the glucosyl 
and xylosyl units, respectively. 
 
Current research supports the potential for complex oligosaccharides to play a clinical 
role in the prevention of UTIs, but the availability of such compounds has been limited, 
delaying progress in this area. As oligosaccharides are relatively difficult and expensive to 
synthesize de novo, there is a need for renewable natural sources of oligosaccharides that 
possess anti-adhesion properties (Sharon & Ofek 2000, Larsson et al. 2003, Turner et al. 2005). 
Hemicellulose-derived oligosaccharides may be able to meet this need, and cranberry 
oligosaccharides could be used to guide investigations of similar compounds from other 
possible human dietary sources.  
Investigations to identify anti-adhesive hemicellulose-derived oligosaccharides could 
begin with examinations of variations in oligosaccharide content for juice produced from 
cranberry at different stages of fruit ripeness (Vvedenskaya & Vorsa 2004) or from different 
cranberry cultivars. Additional studies may investigate other plants of the Vaccinium genus, 
especially the closely related blueberry (V. corymbosum), using quantitative survey approaches 
similar to those applied to characterize resveratrol and other stilbenes in Vaccinium species 
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(Rimando et al. 2004, Rimando & Barney 2005, Rimando & Cody 2005). Plant species within 
the same genus often share biosynthetic pathways, especially for the biosynthesis of “primary 
metabolites” such as hemicellulose, and it is likely that other Vaccinium species produce 
oligosaccharides with similar structures during fruit ripening.  
Blueberry juice has been reported to possess an ability similar to that of cranberry juice 
to prevent P-fimbriated E. coli adhesion (Ofek et al. 1991, Ofek et al. 1996). Similar, partially 
characterized, high-MW inhibitors were reported to be present in both cranberry and blueberry 
juices and the active fractions were initially characterized to contain a type of PAC. While 
PACs were subsequently purified from cranberry and shown to have in vitro anti-adhesion 
properties (Foo et al. 2000a,b), the active fractions described in the initial reports of cranberry 
and blueberry anti-adhesion activity could also have contained oligosaccharides (Ofek et al. 
1991, Ofek et al. 1996). The presence of oligosaccharide-type compounds in blueberry has, 
however, yet to be confirmed. Additional studies involving the detection, quantification, 
isolation and structural elucidation of oligosaccharides from multiple Vaccinium species will be 
necessary to support or refute the hypothesis that the anti-adhesive oligosaccharides identified 
in cranberry are present in other Vaccinium species. 
Plants other than cranberry, such as tobacco, tomato, and flax, are known to produce 
xyloglucan and arabinoxyloglucan containing polymers, but the structures of free, soluble 
oligosaccharides derived from these polymers are unknown (York et al. 1990, York et al. 1996, 
Naran et al. 2008). Free arabinoxyloglucan oligosaccharides produced by non-Vaccinium plants 
may also possess anti-adhesive properties, but such compounds have yet to be identified. Many 
studies regarding hemicellulose-derived oligosaccharides have focused on characterizing 
biosynthesis pathways and structural variation and on genetic modifications to improve animal 
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feedstock or biofuel production (Scheller & Ulvskov 2010). These studies often employ fungal 
hemicellulases that cleave polymers to produce lower-MW compounds that can be more easily 
studied, and studies that do exist typically have a botanical or agricultural focus rather than a 
human medicine focus (Scheller & Ulvskov 2010). Neutral oligosaccharides are inherently 
difficult to detect, isolate, and characterize structurally (York et al. 1996, Chai et al. 2002, 
Yamagaki et al. 2006, LaMotte 2008). Studies of the biological properties of naturally-
occurring, plant-derived oligosaccharides as pure compounds or as native mixtures have 
therefore been limited, and additional work is needed in this area. 
2. Cranberry Oligosaccharides as Analytical Standards 
To date, two cranberry oligosaccharides have been purified to the degree necessary for 
full structural elucidation and identification as arabinoxyloglucans (Auker 2013). Evidence 
from NMR and HPLC-ELSD data indicates the presence of a series of structurally related 
compounds in cranberry, all of which are hypothesized to be arabinoxyloglucans based on the 
presence of anomeric 1H NMR resonances characteristic of this chemical class. Current data 
also supports the hypothesis that the absolute configurations of the primary monosaccharide 
units will be D-Glc, D-Xyl, and L-Ara, consistent with the natural abundances of these 
monosaccharides. An additional monosaccharide that may be present is galactose based on 
preliminary chemical analysis of cranberry oligosaccharide fractions (CJA2, Auker 2013).  
Further work to isolate individual cranberry oligosaccharides is still necessary and full 
structural elucidation for each compound will require the application of multiple 
complimentary techniques (Hisamatsu et al. 1992, York et al. 1996, Weiskopf et al. 1997, Chai 
et al. 2002, Yamagaki et al. 2006, LaMotte 2008). Multiple structural features for each 
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oligosaccharide must be determined before complete structures can be assigned, including (a) 
molecular weight, (b) glycosyl composition, (c) glycosyl linkage positions, (d) glycosyl 
configuration (D vs. L), (e) glycosyl anomeric configuration (α vs. β), and (f) glycosyl 
sequence. Individual oligosaccharides within the series may differ by single structural 
elements, such as a single change in linkage position or anomeric configuration between any 
two compounds (York et al. 1990, Hisamatsu et al. 1992, York et al. 1996, Scheller & Ulvskov 
2010). Any analytical methods used to detect individual compounds within the series must 
therefore be appropriate for discriminating between such closely related compounds or must 
consider this limitation when assigning putative structures (York et al. 1996, Weiskopf et al. 
1997, Chai et al. 2002, Yamagaki et al. 2006, LaMotte 2008).   
The present studies have yielded a large quantity (~20 g) of enriched cranberry 
oligosaccharide fractions that can be used for further studies, and the methods presented here 
provide simple, reproducible, low cost procedures for obtaining relatively large amounts of 
oligosaccharides from renewable and readily available starting material. These cranberry 
oligosaccharide mixtures will primarily be useful as starting material for further purification of 
individual components. Once obtained, purified compounds will be useful for detailed 
structural assignments, biological mechanism of action studies, and as analytical standards for 
many applications. Individual cranberry oligosaccharides and oligosaccharide mixtures with 
known composition have the potential to be used as analytical standards for (a) the 
development of optimized methods suited to rapid detection of oligosaccharides, (b) the 
detection of oligosaccharides in clinical biofluids, (c) the detection of oligosaccharides in 
various plants and dietary sources, and (d) the standardization of cranberry-containing dietary 
supplements. Additional applications will also likely be found by future researchers.  
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3. Commercial Product Development  
Preparations of cranberry-derived oligosaccharides, as mixtures or as pure compounds, 
could potentially be developed into numerous products with commercial applications. These 
include dietary supplements, botanical drugs (FDA CDER 2004), and anti-adhesion coatings 
for medical devices (Nickel et al. 1994), among others. Cranberry is a common food item, and 
cranberry-derived oligosaccharides would therefore be generally regarded as safe (GRAS) for 
human consumption and medical use (McCaleb et al. 2000). As a botanical drug, or as 
oligosaccharide-enriched dietary supplements, cranberry-derived oligosaccharides could be 
used in place of whole cranberry products or cranberry juice for the prevention of UTIs.  
Enrichments for anti-adhesive oligosaccharides and the removal of other cranberry 
compounds may increase the potential marketability of cranberry-derived materials, providing 
the benefits of cranberry anti-adhesion properties while avoiding the inclusion of unwanted 
components. Common reasons given for patient withdrawal from clinical trials concerning 
cranberry were the “unpalatable or intolerable nature of the cranberry product” (Jepson et al. 
2012). The objectives of avoiding caloric intake (simple sugars) or cranberry flavor (tartness) 
and the convenience of a pill form are common reasons consumers may choose cranberry 
dietary supplements instead of the traditionally recommended cranberry juice (Jepson et al. 
2012, Proprietary Nutritionals 2007). Cranberry compounds can also cause herbal-drug 
interactions such as those reported for warfarin (Aston et al. 2006). Enriched preparations of 
oligosaccharides could be prepared from cranberry materials to exclude simple sugars, flavor 
components, and other compounds that cause interactions, while providing consumers with a 
convenient product form.  
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As the active anti-adhesive metabolites of cranberry that are excreted into urine have 
remained unidentified prior to this report, the “concentrated” versions of cranberry currently 
sold as dietary supplements are not necessarily enriched for the appropriate cranberry 
components. The need for standardization of dietary supplement materials to appropriate 
concentrations of active constituents is a well-recognized problem, but requires that the 
constituents responsible for a given bioactivity have been suitably characterized. The 
identification of oligosaccharides as anti-adhesive components of cranberry in this report will 
enable researchers to identify, quantify, and standardize to target these active components in 
various commercial products. The preliminary analyses presented here regarding the 
oligosaccharide composition of commercially obtained cranberry products suggests that juice 
products with a sufficient percentage of cranberry juice already contain the active components. 
These studies also suggest that dietary supplement manufacturers may need to redesign their 
cranberry processing protocols and implement new standardization procedures to ensure that 
their products contain sufficient oligosaccharide content to provide the target biological 
activity.    
D. Summary of Future Directions 
The above discussion addresses the results of the current study within the context of 
existing research and highlights the need for additional research regarding both the chemistry 
and biological properties of cranberry oligosaccharides. Future research will need to address 
many different areas, especially with regards to clinical, agricultural, and basic science 
applications.  
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The anti-adhesion properties of cranberry oligosaccharides, as both pure compounds 
and as mixtures, need further study, especially with regards to the mechanism of action for the 
prevention of UPEC adhesion and possible synergistic effects of oligosaccharide mixtures. 
Further anti-adhesion studies will also be needed to determine if oligosaccharides contribute to 
the reported abilities of cranberry to prevent the adhesion or biofilm formation of bacteria other 
than E. coli. The inherent difficulties of oligosaccharide detection without specialized methods 
suggests that these compounds may be present in many cranberry materials that have been 
attributed with different biological activities. The possible bioactivities of cranberry 
oligosaccharides will therefore need to be assessed in many different types of bioassays.  
Additional cranberry oligosaccharides need to be purified and fully elucidated, and the 
natural occurrence of these or similar compounds in cranberry, in related Vaccinium species, 
and in other plants needs to be assessed. Purified oligosaccharides and oligosaccharide 
mixtures can be used as analytical reference standards for any future study that aims to 
investigate the presence of these compounds. Such studies may include investigations of 
cranberry oligosaccharide content as a function of fruit ripeness, investigations of possible 
dietary sources other than cranberry, mammalian ADME studies, and studies that aim to 
establish clinical correlations between oligosaccharide intake, urinary excretion and UTI 
occurrence, among others.   
Cranberry oligosaccharides, as pure compounds or as mixtures, have potential for 
development into a variety of commercial products, including anti-adhesive coatings for 
medical devices, oligosaccharide-enriched dietary supplements, and even possibly a botanical 
drug product. Such products would be useful as clinical therapies for the prevention of UTIs 
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caused by P-fimbriated E. coli and may have other applications that have not yet been 
identified. 
E. Final Conclusions 
These studies have identified mixtures of arabinoxyloglucan oligosaccharides as the 
anti-adhesive components of both cranberry products and the urine of swine after the 
consumption of cranberry products. The anti-adhesion activity of oligosaccharide mixtures has 
been confirmed using two separate assays. The structure of a representative arabinoxyloglucan 
octasaccharide from swine urine was fully elucidated and found to be similar in structure to two 
arabinoxyloglucan oligosaccharides isolated from cranberry products. Similar HPLC-ELSD 
profiles are present in both cranberry and urine materials, indicating direct absorption and 
excretion of a complex mixture of structurally related oligosaccharides. The results of these 
studies support the new hypothesis that cranberry-derived oligosaccharides are a major 
constituent responsible for the anti-adhesion effects of urine produced after cranberry product 
consumption. Overall, the hypotheses presented in this report provide a new guiding paradigm 
for future research regarding the bioactive constituents of cranberry fruit and juice products. 
The information presented here regarding the anti-adhesion properties of cranberry 
oligosaccharides and their hypothesized role as urinary anti-adhesion metabolites will 
significantly change how researchers and the general public view cranberry for the prevention 
of UTIs.   
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1. Overview of Appendix A 
The images shown below are included here to show color characteristics in support of 
the methods and materials described in Chapters 2 and 3. All photographs included as color 
plates were taken by C. M. Coleman during the studies discussed in this report.  
 
 
 
 
Figure 94. A cranberry bog located in northeastern U.S. with an inset that shows the cranberry 
plant. This photograph was taken by C. M. Coleman on 2013-05-20. 
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Figure 95. Sephadex LH-20 column for the FC urine separation. 
The control urine material was similar in appearance to the active urine study materials, with an 
apparent lack of pink color. This photograph was taken by C. M. Coleman on 2008-05-07. 
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Figure 96. Sephadex LH-20 column for the F5 urine separation. 
Compounds of interest eluted as the first fraction below the lowest visible band of yellow. The 
darker bands visible on this column (redish, orange, and brown) constituted the bulk of the 
collected material, and the dried fractions from these bands were hygroscopic. This photograph 
was taken by C. M. Coleman on 2007-07-20. 
 
247 
 
 
Figure 97. Sephadex LH-20 column for the IF2 urine separation showing elution progression 
(2, 9.5 and 20 h) and the appearance of the resulting fractions in test tubes. 
These photographs were taken by C. M. Coleman on 2009-06-23 and 2009-06-24. 
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Figure 98. Cranberry dietary supplement products analyzed by HPLC-ELSC, showing 
packaging, labeling, capsules, and samples in aqueous solution. 
All four dietary supplement products resulted in aqueous solutions that had high amounts of 
insoluble material. These solutions were not similar to that obtained from cranberry juice 
powder (see Figure 99). These photographs were taken by C. M. Coleman on 2011-03-24. 
 
 
 
 
Figure 99. Cranberry fruit (SN) and juice (CJ) powders in aqueous solution, showing the 
differences in appearance. This photograph was taken by C. M. Coleman on 2011-03-24. 
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Figure 100. Cranberry juice products analyzed by HPLC-ELSD (BCB, GVC, and GVNS), 
showing packaging, label information, and juice appearance. 
All juice products analyzed appeared similar in color in spite of the differences in primary 
ingredient. These photographs were taken by C. M. Coleman on 2011-04-20. 
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Figure 101. Cranberry juice products analyzed by HPLC-ELSD (OSC, LCP, and NL), showing 
packaging, label information, and juice appearance. 
All juice products analyzed appeared similar in color in spite of the differences in primary 
ingredient. These photographs were taken by C. M. Coleman on 2011-04-20. 
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Figure 102. Sephadex LH-20 column for the CJA1 cranberry separation showing elution 
progression (10 min – 18 h) and the appearance of resulting fractions in test tubes. 
Oligosaccharide components eluted early from this column, below the visible lavender band. 
The pink/red material remaining on the column at 18 h produced a relatively low quantity of 
material in spite of the visible color. These photographs were taken by C. M. Coleman on 
2010-09-24 and 2010-09-25. 
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Figure 103. Sephadex LH-20 column for the CCA2 cranberry separation showing elution 
progression (3–35 h).  
Distinct visible bands are apparent with this column (e.g. 6 h), corresponding to the higher 
resolution of components into discrete fractions. These photographs were taken by C. M. 
Coleman on 2013-09-03 and 2013-09-04. 
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Figure 104. Overview of the configuration and equipment set-up for the CCA2 Sephadex LH-
20 column. 
This photograph was taken by C. M. Coleman on 2010-09-25. 
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1. Overview of Appendix B 
The data in this appendix is provided in support of the discussion points presented in the 
main text. This appendix contains additional discussion points in relation to the UPEC-HRBC 
anti-agglutination assay and the raw data provided by this assay as discussed in Chapter 2; 
Section C1, and Chapter 3; Sections C1 and C4a. This appendix also contains figures with 
NMR spectra and chromatograms in support of the efforts made to isolate active urine 
components, as discussed in Chapter 2; Sections C2 – C4. 
2. Additional Discussion of the UPEC-HRBC Anti-agglutination Assay 
Results were provided by RU to UM in the form of Excel spreadsheets that contained 
dilution endpoint values (mg/mL) assigned by RU corresponding to the sample codes provided 
by UM. These data were decoded at UM and interpreted using qualitative activity scores 
assigned by UM (UM Scores) as discussed above (Chapter 2, Section B3, Table 3: reproduced 
below). The results of a given data set were compared to those of previously obtained assay 
data sets to evaluate relative data quality and interpretations. For some data sets (Tables 45, 47, 
49, 51), the visual agglutination scores (VAS) determined for each dilution of each sample 
were included by RU. Most result files did not include VAS values and the number of two-fold 
dilutions used to obtain the reported dilution endpoint value was calculated based on the 
methods reported by RU. The reported number of two-fold dilutions does not include the 
starting concentration.  
The initial dilution volume used for a given sample was arbitrarily determined by RU 
based on the weight of the sample within a range. An example of a sample weight range to 
dilution volume is as follows: sample mg > 80: 400 µL, 79 > mg > 40: 200 µL, 39 > mg > 10: 
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150 µL, 9 > mg > 7: 100 µL. The dilution volumes used per sample weight range varied 
between sample sets over time. An example of this variation is the use of 150 µL PBS for 24.5 
mg (08/2006 sample; Table 43), 200 µL for 24.5 mg (06/2008 sample; Table 52), and 100 µL 
for 27.0 mg (12/2008 sample; Table 56). Changes in sample initial dilution volumes combined 
with the variety of submitted sample weights resulted in the testing of a range of sample 
starting concentrations at any one time; e.g. 74–420 mg/mL; Table 44, and 26–740 mg/mL; 
Table 54. Two-fold dilutions performed on these starting concentrations yielded yet another set 
of varied concentrations and ultimately yielded the reported dilution endpoint values. These 
variations in sample concentration throughout the performance of the assay may have affected 
the overall assay sensitivity and contributed to issues with assay reproducibility. 
 
Table 3. Description of the qualitative scoring system developed by UM to interpret the results 
provided by the UPEC-HRBC anti-agglutination assay. 
Samples were assessed within an individual sample set test date and then across test dates. 
Scoring criteria were applied in the order shown to determine the probable activity of 
individual samples and assign a UM Score. Replicates were not available for most samples. 
Scoring Criteria: First Second Third Fourth 
UM 
Score 
UM Assessment 
of Sample 
Activity 
Dilution 
Endpoint 
Range 
No. of 
Two-fold 
Dilutions 
Sample 
Compared to 
Parent Fraction: 
Replicates  
(if available): 
+ + active < 10 mg/mL 5+ more active  show activity 
+ probably active 10–30 mg/mL 4 more active show activity 
+/– may or may not be active  30–60 mg/mL 3 about the same  
may or may not 
show activity 
– probably not active 60–100 mg/mL 2 less active show no activity 
– – not active > 100 mg/mL 0, 1 less active show no activity 
 
Samples for which the dilution endpoint was equal to the starting concentration may 
have had visual agglutination scores of ‘1’ or ‘2’ but the apparent activity for these samples 
was not retained (VAS = ‘0’) after the first two-fold dilution. Single-concentration sample 
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activity cannot be accurately assessed without VAS values, but most of these samples were 
tested at starting concentrations of > 100 mg/mL and were therefore assigned as inactive. 
Samples that were assigned a dilution endpoint of “Neg” (= negative) were found to have no 
ability to inhibit HRBC agglutination at the highest (first) concentration tested.  
Samples that were assigned a dilution endpoint of “Solv” (= solvent) were associated 
with the bursting of HRBCs at the highest concentration tested. Although RU attributed this 
bursting of HRBCs to the presence of solvent in the samples, most samples that could have 
contained solvent had been dried completely, re-dissolved in water, lyophilized, and then 
provided to RU as dry powders. These samples were therefore unlikely to have contained 
sufficient solvent to have caused this effect. While samples may have contained other 
components that could have contributed to the bursting of HRBCs, no sample-related pattern 
could be discerned regarding the assignment of the “Solv” dilution endpoint. Replicates of 
some samples that showed the “Solv” effect (e.g. FG; Table 44) were found to lack activity and 
all samples for which this was the reported dilution endpoint were assigned a negative UM 
score (‘– –’ Table 3). The “Solv” effect may have been related to issues with the HRBCs 
themselves or other methodological factors unknown to UM.  
When provided, the VAS values assigned to samples were predominantly ‘1’ or ‘2’. 
The assay methods suggested that higher VAS values of ‘3’ or ‘4’ could be obtained, indicating 
the inhibition of agglutination for 70-95 and 95-100% of HRBCs, respectively. Published 
evidence could not be found in support of the ability of the assay to yield these VAS values 
with positive controls, and VAS values or other information for positive control samples tested 
with the samples from this study were not provided to UM.  
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False negative results were more likely than false positive results for most samples, as 
the reported dilution endpoints may have been higher than actual sample concentrations. Many 
urine fractions were hygroscopic and the absorption of water from the atmosphere would have 
resulted in higher than actual apparent weights for these samples, yielding lower actual solute 
concentrations. Crude urine materials often had significant sample heterogeneity, containing 
insoluble and soluble components within any give aliquot. Efforts were made to homogenize 
these materials prior to assay submission, but only part of a given sample may have been 
soluble in the PBS used for the assay. The low-volume drops used for the assay were also 
reported to be affected by ambient humidity, absorbing water from the atmosphere on days 
when it rained and further diluting test samples (A. B. Howell, personal communication). 
Cumulative results indicate that samples did not lose activity when stored at –20 oC as dry 
powders, and the apparent changes in sample activity (e.g. the FF aqueous fraction; Chapter 2, 
Table 8) are likely to be false negative results due to some of the reasons presented here.  
Additional assay variation can be attributed to the subjective nature of human judgment 
and visual assessments, variations between collections of HRBCs, and variations in the 
characteristics of the clinical strains of E. coli used. While E. coli were subcultured on 
colonization factor agar to enhance the expression of P fimbriae (Evans et al. 1977) prior the 
use of the bacteria for sample testing, the expression of P fimbriae was not quantified for each 
sample set. Changes in P fimbriae expression or strain characteristics over time may therefore 
have affected the assay results. Other unknown factors may also have contributed to the 
inconsistencies that were observed in sample data. 
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3. Supporting Data Tables for the UPEC-HRBC Anti-agglutination Assay  
The raw data results for the UPEC-HRBC anti-agglutination assay are included in the 
following tables (Tables 41–59). These tables are arranged in date order by test date. Samples 
within a given test date were sent from UM to RU within a single shipment but were not 
necessarily tested on the same day at RU. Individual samples within a test date were coded, 
randomized, and not necessarily tested in the order shown. Sample descriptions contain sample 
codes as well as brief descriptions of sample origins. Urine samples and fractions are discussed 
in more detail in Chapter 2 while cranberry samples and fractions are discussed in Chapter 3. 
 
Table 41. Urine fractions (D) tested in the anti-agglutination assay, 03/2006. 
Sample 
Description 
Test 
Date 
UM 
Score 
Dilution 
Endpoint 
(mg/mL)
No. of 
Two-
fold 
Dilutions
Amount 
Submitted 
(mg) 
Dilution 
Volume 
(µL) 
Starting 
Conc. 
(mg/mL)
D (crude urine) 03/2006 – – 111.0 1 110.6 500 221.2
DE (D EtOAc 
fraction 03/2006 – – Neg 0 16.1 150 107.3
DS (D sec-
BuOH fraction) 03/2006 – – Solv 1 120.2 500 240.4
DA (D aqueous 
fraction) 03/2006 +/– 87.4 1 87.4 500 174.8
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Table 42. Urine fractions (DA Sephadex LH-20 fractions) tested in the anti-agglutination assay, 
05/2006. 
Sample 
Description 
Test 
Date 
UM 
Score 
Dilution 
Endpoint 
(mg/mL)
No. of 
Two-
fold 
Dilutions
Amount 
Submitted 
(mg) 
Dilution 
Volume 
(µL) 
Starting 
Conc. 
(mg/mL)
DA1 05/2006 – 52.2 2 52.2 250 208.8
DA2 05/2006 – 112.0 1 56.0 250 224.0
DA3 05/2006 +/– 43.1 2 86.1 500 172.2
DA4 05/2006 +/– 43.2 2 172.9 1000 172.9
DA5 05/2006 – – 226.4 1 226.4 500 452.8
DA6 05/2006 – – Neg 2 57.6 250 230.4
DA7 05/2006 – – Neg 2 77.7 250 310.8
DA8 05/2006 – – Neg 1 91.7 500 183.4
DA9 05/2006 – – Neg 2 59.1 250 236.4
DA10 05/2006 – – 202.4 0 50.6 250 202.4
DA11 05/2006 – – 328.4 0 82.1 250 328.4
DA12 05/2006 – – 106.0 0 53.0 250 212.0
DA13 05/2006 + + 1.4 7 44.9 250 179.6
DA14 05/2006 + + 5.3 4 21.3 250 85.2
DA15 05/2006 + + 1.4 7 46.3 250 185.2
DA16 05/2006 + + 1.6 7 51.4 250 205.6
DA17 05/2006 – – 191.6 0 47.9 250 191.6
DA18 05/2006 + + 7.7 4 30.9 250 123.6
DA19 05/2006 + + 0.8 8 48.0 250 192.0
DA20 05/2006 – – Neg 0 50.6 250 202.4
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Table 43. Urine fractions (DA Sephadex LH-20 fractions) tested in the anti-agglutination assay, 
08/2006. 
Sample 
Description 
Test 
Date 
UM 
Score 
Dilution 
Endpoint 
(mg/mL)
No. of 
Two-
fold 
Dilutions
Amount 
Submitted 
(mg) 
Dilution 
Volume 
(µL) 
Starting 
Conc. 
(mg/mL)
DA13 08/2006 + + 2.5 5 14.4 150 96.0
DA14 08/2006 – 76.0 1 11.4 150 76.0
DA15 08/2006 – 74.6 2 37.3 250 149.2
DA16 08/2006 +/– 48.9 2 48.9 250 195.6
DA17 08/2006 + + 5.0 5 24.5 150 163.3
DA18 08/2006 + + 2.5 5 13.4 150 89.3
DA19 08/2006 + + 2.5 6 19.1 150 127.3
DA20 08/2006 – – Neg 2 35.3 250 141.2
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Table 44. Urine fractions (F and Sephadex LH-20 fractions for DA and FF columns 1 & 2) 
tested in the anti-agglutination assay, 03/2007. 
Sample 
Description 
Test 
Date 
UM 
Score 
Dilution 
Endpoint 
(mg/mL)
No. of 
Two-
fold 
Dilutions
Amount 
Submitted 
(mg) 
Dilution 
Volume 
(µL) 
Starting 
Conc. 
(mg/mL)
DA1 03/2007 + + 2.6 5 12.2 150 81.3
DA2 03/2007 + 23.2 2 13.9 150 92.7
DA3 03/2007 + 10.0 3 8.0 100 80.0
DA4 03/2007 – – 74.6 0 11.2 150 74.7
DA5 03/2007 – – Solv 0 14.6 150 97.3
DA6 03/2007 – – Solv 0 9.3 100 93.0
DA7 03/2007 – – 186.0 0 37.2 200 186.0
DA8 03/2007 + + 5.1 5 32.5 200 162.5
FF (aqueous 
fraction) 03/2007 +/– 35.8 3 114.5 400 286.3
FF (aqueous 
fraction) 03/2007 +/– 52.5 3 168.1 400 420.3
FG (F solids) 03/2007 – – Neg 0 62.7 200 313.5
FG (F solids) 03/2007 – – Solv 0 47.7 200 238.5
FG (F solids) 03/2007 – – Neg 0 42.1 200 210.5
FF1-1 03/2007 + + 9.7 3 11.6 150 77.3
FF1-2 03/2007 + + 6.2 4 9.9 100 99.0
FF1-3 03/2007 – – Neg 0 42.5 200 212.5
FF1-4 03/2007 – – Solv 0 53.5 200 267.5
FF1-5 03/2007 – 84.6 2 135.4 400 338.5
FF1-6 03/2007 +/– 31.4 3 50.3 200 251.5
FF1-7 03/2007 + + 2.6 5 12.5 150 83.3
FF1-8 03/2007 – – Neg 0 11.6 150 77.3
FF1-9 03/2007 – – Neg 0 16.5 150 110.0
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Table 45. Urine fractions (F and Sephadex LH-20 fractions for DA and FF columns 1 & 2) 
tested in the anti-agglutination assay, 03/2007, showing dilution concentrations tested and 
visual agglutination scores (VAS). 
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Table 46. Urine fractions (FF Sephadex LH-20 fractions, columns 2 & 3) tested in the anti-
agglutination assay, 05/2007. 
Sample 
Description 
Test 
Date 
UM 
Score 
Dilution 
Endpoint 
(mg/mL)
No. of 
Two-
fold 
Dilutions
Amount 
Submitted 
(mg) 
Dilution 
Volume 
(µL) 
Starting 
Conc. 
(mg/mL)
FF (aqueous 
fraction) 05/2007 + + 11.8 5 75.2 200 376.0
FF (aqueous 
fraction) 05/2007 + 19.9 3 79.9 500 159.8
FF (aqueous 
fraction) 05/2007 – 105.8 2 84.7 200 423.5
FF2-1 05/2007 + + 2.5 5 11.9 150 79.3
FF2-2 05/2007 + 12.8 4 30.8 150 205.3
FF2-3 05/2007 + 14.3 4 135.8 600 226.3
FF2-4 05/2007 + 13.6 4 32.8 150 218.7
FF2-5 05/2007 – – Neg 0 55.6 200 278.0
FF2-6 05/2007 +/– 42.5 2 25.5 150 170.0
FF2-7 05/2007 +/– 34.3 2 20.6 150 137.3
FF2-8 05/2007 – – 222.5 0 44.5 200 222.5
FF3-1 05/2007 + + 9.3 3 11.2 150 74.7
FF3-2 05/2007 + + 3.7 5 17.9 150 119.3
FF3-3 05/2007 – – 119.6 1 35.9 150 239.3
FF3-4 05/2007 – – Neg 0 56.8 200 284.0
FF3-5 05/2007 – – Neg 0 23.3 150 155.3
FF3-6 05/2007 +/– 38.8 2 38.1 250 152.4
 
 
 
265 
 
Table 47. Urine fractions (FF Sephadex LH-20 fractions, columns 2 & 3) tested in the anti-
agglutination assay, 05/2007, showing dilution concentrations tested and visual agglutination 
scores (VAS). 
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Table 48. Urine fractions (FF Sephadex LH-20 fractions, columns 4 & 5) tested in the anti-
agglutination assay, 06/2007. 
Sample 
Description 
Test 
Date 
UM 
Score 
Dilution 
Endpoint 
(mg/mL)
No. of 
Two-
fold 
Dilutions
Amount 
Submitted 
(mg) 
Dilution 
Volume 
(µL) 
Starting 
Conc. 
(mg/mL)
FF (aqueous 
fraction) 06/2007 +/– 54.6 2 43.7 200 218.5
FF (aqueous 
fraction) 06/2007 +/– 53.0 3 84.8 200 424.0
FF (aqueous 
fraction) 06/2007 – 73.4 2 117.4 400 293.5
FF4-1 06/2007 + 12.4 4 29.7 150 198.0
FF4-2 06/2007 + 25.5 2 15.3 150 102.0
FF4-3 06/2007 – 105.0 2 168.2 400 420.5
FF4-4 06/2007 – – 120.6 2 193.0 400 482.5
FF4-5 06/2007 – – 120.0 0 98.5 820 120.1
FF4-6 06/2007 – – 300.0 0 60.1 200 300.5
FF4-7 06/2007 – – 323.0 0 129.3 400 323.3
FF4-8 06/2007 – – 116.0 0 17.5 150 116.7
FF5-1 06/2007 + + 9.8 3 7.9 100 79.0
FF5-2 06/2007 – – 204.6 0 30.7 150 204.7
FF5-3 06/2007 – – 240.6 0 36.1 150 240.7
FF5-4 06/2007 – – 371.0 0 148.4 400 371.0
FF5-5 06/2007 – – 120.0 0 18.1 150 120.7
FF5-6 06/2007 – – 374.0 0 149.6 400 374.0
FF5-7 06/2007 – – 208.0 0 31.3 150 208.7
FF5-8 06/2007 – 62.3 2 49.9 200 249.5
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Table 49. Urine fractions (FF Sephadex LH-20 fractions, columns 4 & 5) tested in the anti-
agglutination assay, 06/2007, showing dilution concentrations tested and visual agglutination 
scores (VAS). 
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Table 50. Urine fractions (FF and FC fractions, and FA Sephadex LH-20 fractions) tested in the 
anti-agglutination assay, 09/2007. 
Sample 
Description 
Test 
Date 
UM 
Score 
Dilution 
Endpoint 
(mg/mL)
No. of 
Two-
fold 
Dilutions
Amount 
Submitted 
(mg) 
Dilution 
Volume 
(µL) 
Starting 
Conc. 
(mg/mL)
FF (aqueous 
fraction) 09/2007 – 92.5 2 74.0 200 370.0
FF (aqueous 
fraction) 09/2007 – 95.3 2 152.5 400 381.3
FB (F EtOAc 
fraction) 09/2007 – Neg 0 6.3 100 63.0
FA (combined 
active F 
fractions) 
09/2007 +/– 35.2 2 21.1 150 140.7
FA1 (Sep LH-20 
fraction) 09/2007 + + 5.8 4 14.0 150 93.3
FA2 (Sep LH-20 
fraction) 09/2007 + 13.9 4 33.3 150 222.0
FA3 (Sep LH-20 
fraction) 09/2007 – – 204.0 0 30.6 150 204.0
FA4 (Sep LH-20 
fraction) 09/2007 +/– 55.7 1 16.7 150 111.3
FA5 (Sep LH-20 
fraction) 09/2007 – – Neg 0 27.5 150 183.3
FC (control 
urine) 09/2007 – – 305.5 0 61.1 200 305.5
FCE (FC EtOAc 
fraction) 09/2007 +/– 35.0 2 21.0 150 140.0
FC1 (FC 
aqueous fraction) 09/2007 – 106.8 2 170.8 400 427.0
FC1 (FC 
aqueous fraction) 09/2007 – 99.9 2 159.8 400 399.5
FC1 (FC 
aqueous fraction) 09/2007 – 82.6 2 132.1 400 330.3
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Table 51. Urine fractions (FF and FC fractions, and FA Sephadex LH-20 fractions) tested in the 
anti-agglutination assay, 09/2007, showing dilution concentrations tested and visual 
agglutination scores (VAS). 
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Table 52. Cranberry juice powder fractions (CJ, and MW-filter and Acid/Base experiments) 
tested in the anti-agglutination assay, 06/2008. 
Sample 
Description 
Test 
Date 
UM 
Score 
Dilution 
Endpoint 
(mg/mL)
No. of 
Two-
fold 
Dilutions
Amount 
Submitted 
(mg) 
Dilution 
Volume 
(µL) 
Starting 
Conc. 
(mg/mL)
CJ (cranberry 
juice powder) 06/2008 + + 3.8 6 49.2 200 246.0
CJ (cranberry 
juice powder) 06/2008 + + 3.4 6 44.3 200 221.5
CJ-MA3a (3 kDa 
retentate) 06/2008 + + 0.7 7 9.5 100 95.0
CJ-MB3a (10 
kDa retentate) 06/2008 + + 0.7 7 8.7 100 87.0
CJ-MC3a (30 
kDa retentate) 06/2008 + + 0.5 7 6.3 100 63.0
CJ-MA3b (3 kDa 
filtrate) 06/2008 – – Neg 0 21.4 200 107.0
CJ-MB3b (10 
kDa filtrate) 06/2008 – – Neg 0 23.7 200 118.5
CJ-MC3b (30 
kDa filtrate) 06/2008 – – Neg 0 19.1 200 95.5
CJ pH 2.0, 2 h 06/2008 + 13.4 3 21.4 200 107.0
CJ pH 2.0, 4 h 06/2008 + 13.6 3 21.8 200 109.0
CJ pH 2.1, 8 h 06/2008 + 12.3 3 19.7 200 98.5
CJ pH 5.9, 2 h 06/2008 + + 1.8 6 23.0 200 115.0
CJ pH 6.0, 4 h 06/2008 + + 1.9 6 24.5 200 122.5
CJ pH 6.1, 8 h 06/2008 + + 1.8 6 23.2 200 116.0
CJ pH 7.9, 2 h 06/2008 + + 1.7 6 22.2 200 111.0
CJ pH 8.0, 4 h 06/2008 + + 2.0 6 25.3 200 126.5
CJ pH 8.2, 8 h 06/2008 + + 1.9 6 24.6 200 123.0
CJ Native pH 
(2.7), 2 h 06/2008 + + 1.6 6 20.1 200 100.5
CJ Native pH 
(2.7), 4 h 06/2008 + + 1.8 6 23.6 200 118.0
CJ Native pH 
(2.7), 8 h 06/2008 + + 3.6 5 23.1 200 115.5
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Table 53. Urine fractions (FA and FC Sephadex LH-20 column fractions) tested in the anti-
agglutination assay, 06/2008. 
Sample 
Description 
Test 
Date 
UM 
Score 
Dilution 
Endpoint 
(mg/mL)
No. of 
Two-
fold 
Dilutions
Amount 
Submitted 
(mg) 
Dilution 
Volume 
(µL) 
Starting 
Conc. 
(mg/mL)
FA (combined 
active F 
fractions) 
06/2008 +/– 45.2 1 18.1 200 90.5
FA1 (Sep LH-20 
fraction) 06/2008 – – Neg 0 3.7 100 37.0
FA2 (Sep LH-20 
fraction) 06/2008 – – Neg 0 3.3 100 33.0
FA3 (Sep LH-20 
fraction) 06/2008 – – Neg 0 6.9 100 69.0
FA4 (Sep LH-20 
fraction) 06/2008 +/– 47.2 1 18.9 200 94.5
FA5 (Sep LH-20 
fraction) 06/2008 +/– 34.0 1 8.5 125 68.0
FC1-1 (Sep LH-
20 fraction) 06/2008 – – 182.5 1 73.0 200 365.0
FC1-2 (Sep LH-
20 fraction) 06/2008 – – Neg 0 46.5 200 232.5
FC1-3 (Sep LH-
20 fraction) 06/2008 – – 118.2 1 47.3 200 236.5
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Table 54. Urine fractions (H) tested in the anti-agglutination assay, 08/2008. 
Sample 
Description 
Test 
Date 
UM 
Score 
Dilution 
Endpoint 
(mg/mL)
No. of 
Two-
fold 
Dilutions
Amount 
Submitted 
(mg) 
Dilution 
Volume 
(µL) 
Starting 
Conc. 
(mg/mL)
H (crude urine) 08/2008 +/– 40.8 4 653.7 1000 653.7
HCE (H EtOAc 
extract, water  
soluble) 
08/2008 + 13.1 3 20.9 200 104.5
HCM (H EtOAc 
fraction, MeOH 
soluble) 
08/2008 – – Neg 0 1.3 50 26.0
HD (H EtOAc: 
MeOH fraction, 
water soluble) 
08/2008 – – 157.5 1 94.5 300 315.0
HF (H aqueous 
fraction) 08/2008 + 23.1 5 369.8 500 739.6
HG (H solids) 08/2008 – – Neg 0 71.8 1000 71.8
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Table 55. Urine fractions (FC and I) tested in the anti-agglutination assay, 12/2008. 
Sample 
Description 
Test 
Date 
UM 
Score 
Dilution 
Endpoint 
(mg/mL)
No. of 
Two-
fold 
Dilutions
Amount 
Submitted 
(mg) 
Dilution 
Volume 
(µL) 
Starting 
Conc. 
(mg/mL)
FC1 (FC aqueous 
fraction) 12/2008 – 73.3 3 146.6 250 586.4
FC1-1 (Sep LH-
20 fraction) 12/2008 – 102.8 2 82.2 200 411.0
I (crude urine) 12/2008 +/– 45.1 3 72.2 200 361.0
ICE (I EtOAc: 
MeOH fraction, 
water soluble) 
12/2008 + + 9.5 2 5.7 150 38.0
ICM (I EtOAc: 
MeOH fraction, 
EtOAc soluble) 
12/2008 – – Neg 0 38.7 100 387.0
ID (EtOAc: 
MeOH fraction, 
water soluble) 
12/2008 – – Neg 0 100.7 200 503.5
IF (I aqueous 
fraction) 12/2008 +/– 57.4 3 68.9 150 459.3
IZ (I stability 
test) 12/2008 + 14.1 3 16.9 150 112.7
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Table 56. Urine fractions (H and HF Sephadex LH-20 fractions) and reference compounds 
tested in the anti-agglutination assay, 12/2008. 
Sample 
Description 
Test 
Date 
UM 
Score 
Dilution 
Endpoint 
(mg/mL)
No. of 
Two-
fold 
Dilutions
Amount 
Submitted 
(mg) 
Dilution 
Volume 
(µL) 
Starting 
Conc. 
(mg/mL)
H (crude urine) 12/2008 +/– 61.7 3 123.4 250 493.6
HD (H EtOAc-
MeOH fraction, 
water soluble) 
12/2008 – – 120.8 2 96.7 200 483.5
HF (H aqueous 
fraction) 12/2008 – – 169.5 2 203.4 300 678.0
HF1-1 (Sep LH-
20 fraction) 12/2008 + + 8.5 5 27.3 100 273.0
HF1-2 (Sep LH-
20 fraction) 12/2008 +/– 55.3 3 66.3 150 442.0
HF1-3 (Sep LH-
20 fraction) 12/2008 – 108.6 2 86.9 200 434.5
HF1-4 (Sep LH-
20 fraction) 12/2008 – 102.7 2 82.2 200 411.0
HF1-5 (Sep LH-
20 fraction) 12/2008 – – 269.0 1 107.6 200 538.0
HF1-6 (Sep LH-
20 fraction) 12/2008 – 109.6 2 65.8 150 438.7
HF1-7 (Sep LH-
20 fraction) 12/2008 – – 416.7 0 62.5 150 416.7
D-Glucose 12/2008 +/– 35.8 3 28.7 100 287.0
D-Glucuronic 
Acid 12/2008 – – 388.0 0 38.8 100 388.0
D-Galacturonic 
Acid 12/2008 – – 270.0 0 27.0 100 270.0
D-Sorbitol 12/2008 – – 226.0 0 22.6 100 226.0
Sucrose (Great 
Value Brand) 12/2008 – – 224.0 0 22.4 100 224.0
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Table 57. Urine fractions (DA19, FC, FF, I, H and HI) tested in the anti-agglutination assay, 
07/2011. 
Sample 
Description 
Test 
Date 
UM 
Score 
Dilution 
Endpoint 
(mg/mL)
No. of 
Two-
fold 
Dilutions
Amount 
Submitted 
(mg) 
Dilution 
Volume 
(µL) 
Starting 
Conc. 
(mg/mL)
DA19 07/2011 + + 3.4 6 21.8 100 218.0
FC1 (aqueous 
fraction) 07/2011 – 87.5 2 52.5 150 350.0
FC1 (aqueous 
fraction) 07/2011 – – Neg 0 49.8 150 332.0
FC1-1 (Sep LH-
20 fraction) 07/2011 – – 199.0 1 59.7 150 398.0
FC1-1 (Sep LH-
20 fraction) 07/2011 – – 353-176 1 53.0 150 353.3
FC1-2 (Sep LH-
20 fraction) 07/2011 – – 338.0 0 50.7 150 338.0
FF (aqueous 
fraction) 07/2011 + 11.9 5 57.1 150 380.7
FF (aqueous 
fraction) 07/2011 + 28.6 4 68.6 150 457.3
IZA (IZ aqueous 
fraction after 
stability test) 
07/2011 + + 10.8 5 51.9 150 346.0
H (crude urine) 07/2011 +/– 47.7 3 57.3 150 382.0
HI1 (Combined 
H & I Active 
fractions, HF2-1 
+ IF1-1) 
07/2011 + + 6.3 5 20.1 100 201.0
HI2 (Combined 
H & I Active 
fractions, HF1-1 
+ HF2-2 + IF1-2) 
07/2011 + 12.7 4 20.4 100 204.0
HI3 (Combined 
H & I Active 
fractions, HF1-2 
+ IF1-3 + HF2-3) 
07/2011 – – 101.0 1 20.2 100 202.0
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Table 58. Cranberry fractions (CJ, CJA, and CJA Sephadex LH-20 fractions) tested in the anti-
agglutination assay, 07/2011. 
Sample 
Description 
Test 
Date 
UM 
Score 
Dilution 
Endpoint 
(mg/mL)
No. of 
Two-
fold 
Dilutions
Amount 
Submitted 
(mg) 
Dilution 
Volume 
(µL) 
Starting 
Conc. 
(mg/mL)
CJ (cranberry 
juice powder) 07/2011 + 21.3 4 51.2 150 341.3
CJA (aqueous 
fraction) 07/2011 + + 7.1 6 51.2 150 341.3
CJA (aqueous 
fraction) 07/2011 +/– 43.3 3 52.0 150 346.7
CJA1-02B (Sep 
LH-20 fraction) 07/2011 + + 5.1 6 49.0 150 326.7
CJA2-02 (Sep 
LH-20 fraction) 07/2011 + + 10.5 5 50.7 150 338.0
CJA2-02 (Sep 
LH-20 fraction) 07/2011 + 21.2 4 50.9 150 339.3
CJA2-03 (Sep 
LH-20 fraction) 07/2011 +/– 42.7 3 51.3 150 342.0
CJA2-04 (Sep 
LH-20 fraction) 07/2011 +/– 42.9 3 51.5 150 343.3
CJA2-05 (Sep 
LH-20 fraction) 07/2011 +/– 41.2 3 49.5 150 330.0
CJA2-05 (Sep 
LH-20 fraction) 07/2011 – – 168.0 1 50.4 150 336.0
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Table 59. Reference compounds tested in the anti-agglutination assay, 07/2011. 
Sample 
Description 
Test 
Date 
UM 
Score 
Dilution 
Endpoint 
(mg/mL)
No. of 
Two-
fold 
Dilutions
Amount 
Submitted 
(mg) 
Dilution 
Volume 
(µL) 
Starting 
Conc. 
(mg/mL)
Glucose Tabs 
(ReliOn Glucose 
Tablets 
commercial 
product, 
powdered) 
07/2011 + + 5.2 6 50.2 150 334.7
Glucose Tabs 
(ReliOn Glucose 
Tablets 
commercial 
product, 
powdered) 
07/2011 + + 10.3 5 49.3 150 328.7
D-Glucose 
(Sigma Aldrich 
99.5%) 
07/2011 + + 10.7 5 51.4 150 342.7
D-Glucose 
(Sigma Aldrich 
99.5%) 
07/2011 + + 10.8 5 52.1 150 347.3
D-Fructose 
(CalBioChem) 07/2011 +/– 41.4 3 49.7 150 331.3
D-Fructose 
(CalBioChem) 07/2011 – 81.6 2 49.0 150 326.7
Sucrose (Great 
Value Brand) 07/2011 – 82.6 2 49.6 150 330.7
 
 
 
 
  
278 
 
4. Overview of Principles for Evaporative Light-Scattering Detection  
Evaporative light-scattering detection (ELSD) is a semi-quantitative, mass-sensitive 
method (Mourey & Oppenheimer 1984). Solvent is introduced to the detector and nebulized 
using a gas such as nitrogen to form a cloud of sample droplets. The resulting cloud of droplets 
is carried into a flight/evaporator tube by the stream of nebulizing gas where heat is used to 
evaporate solvent and produce dry solute particles. This cloud of dried particles moves past a 
light source and scatters the incident light. The scattered light is collected by a photomultiplier 
tube detector to generate an electronic signal (mV) that corresponds to the concentration of 
sample present (more particles of solute = more signal). Adjustable parameters that affect 
detector sensitivity and function include the nebulizor temp, the evaporator tube temp, and the 
gas flow rate. The inlet solvent flow rate and the solvent used for a given separation dictate the 
settings for these parameters. This type of detector is moderately compatible with gradient 
separations as long as the solvents used for the gradient can be removed by relatively similar 
evaporator temperatures.  
Non-volatile and semi-volatile compounds can be detected by ELSD regardless of the 
presence or absence of specific structural features such as chromophores. In contrast, UV 
detection methods require that compounds contain chromophores with absorbances typically 
above 210 nm (for MeOH as an eluting solvent). 
 
Image reproduced from Polymer Laboratories PL-ELS 2100 Operator’s 
Manual, Version 1.01, Revision August 2003, Document # 6/26069B 
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5. Additional Chromatographic & Spectroscopic Data 
The additional figures included below contain supporting information relevant to the 
text of Chapters 2 and 3. 
 
Figure 105. Analytical HPLC-ELSD of glucose, fructose, and sucrose standards (AtldC18) 
showing the early elution (< 5 min) of these compounds. 
Standards of the monosaccharides glucose and fructose, and the disaccharide, sucrose, were 
analyzed via analytical HPLC-ELSD using the optimized method used for detecting the 
oligosaccharides discussed in Chapters 2 and 3. All three standards eluted with 100% water at < 
5 min, and were therefore not significantly retained by the C18 sorbent of the AtldC18 column. 
Compounds such as these low-MW carbohydrates also elute at later retention times from gel-
filtration chromatography sorbents such as Sephadex LH-20. In contrast, the oligosaccharide 
mixtures of interest from both cranberry and urine samples eluted with the void volume from 
the Sephadex LH-20 sorbent, indicating larger MW, and at ~20 min on the AtldC18 analytical 
column with the method shown here. 
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Figure 106. The 1H NMR spectrum of urine fraction DA18 showing the low quality of the data, 
400 MHz, D2O. 
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Figure 107. The 1H NMR spectrum of urine fraction DA19 showing the low quality of the data, 
400 MHz, D2O. 
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Figure 108. Analytical HPLC-UV (210 and 256 nm) chromatograms of fractions FA1 and FA2 
(HILIC). 
The material eluting at ~270 min appears to be a major component of the FA1 sample with the 
scale used, but actually has a relatively low absorbance (0.07 AU), and would normally be 
considered part of a baseline. A HILIC method similar to the one shows for these analytical 
separations was used to isolate the detectable components from the FA2 sample, especially 
those corresponding to the FA1 sample. The resulting fractions were tested in the anti-
agglutination assay but showed no detectable activity, possibly due to the low amounts of 
sample submitted (< 10 mg each).  
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Figure 109. Comparisons of the analytical HPLC-ELSD spectra for active urine fraction HF1-1 
and control urine fractions (FC1-11, FC1-2, and FC1-3) (AtldC19). 
These spectra were collected using the same HPLC-ELSD method as applied to HF1-1 
previously. Additional baseline expansions of the region of interest (18-24 min) for Fraction 
FC1-1 show no evidence of possible oligosaccharide components. The components visible in 
this region for FC1-1 and FC1-3 both contain chromophores detectable by UV. 
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Figure 110. Comparisons of the analytical HPLC-ELSD/UV spectra for active urine fraction 
HF1-1 and crude urine fractions (HF and HD) (AtldC19). 
The HF material was the parent fraction for the HF1-1 material and both showed activity in the 
anti-agglutination assay. The oligosaccharide components of HF1-1 were not readily apparent 
in the HF material via HPLC-ELSD at the concentration of sample used above, indicating that 
enrichments or methods with increased sensitivity are necessary to detect oligosaccharide 
components in mammalian urine samples. The HD fraction (the EtOAc fraction of H urine) did 
now show anti-agglutination activity, did not contain detectable oligosaccharide components, 
and the majority of this fraction eluted in the polar region between 0-10 min. The composition 
of HF and HD appeared similar when examined with ELSD/UV, indicating the predominantly 
polar nature of the urine material.  
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APPENDIX C: EXAMPLES OF CRANBERRY 
DIETARY SUPPLEMENT PRODUCT 
LITERATURE 
  
286 
 
1. Overview of Appendix C 
Many consumers make decisions regarding their use of dietary supplements based on 
the product literature that is most easily accessible to them. Most of this literature is, 
unfortunately, inaccurate and often contains pseudo-scientific content that can be misleading to 
consumers. The actual composition and method of preparation for many dietary supplement 
products is often incompletely reported, making it impossible to propose possible compounds 
that may be present in any given material. For example, a product label may specify that the 
material contains an “extract” or “concentrate” but no information is given as to the method or 
solvents used, thereby making it impossible to determine the types of compounds that may 
have been enriched in the resulting material. Claims of equivalency (concentrate equivalent to 
X g of fruit) are also specious as no information is given as to the basis for comparison between 
the original material and the final dietary supplement product. 
Many ‘supplement facts’ labels on products in the U.S. include an entry for ‘total 
carbohydrate’ with sub-entries for ‘dietary fiber’ and ‘sugars.’ Current nutrition science 
considers compounds with cellulose-type backbones to be a type of dietary fiber as such 
compounds are not digested by mammalian enzymes (Haard & Chism 1996). The 
oligosaccharides identified as active components of cranberry in these studies would therefore 
most likely be represented as a component of the carbohydrate label fields currently on 
products. Although detection and accurate measurement of oligosaccharide-specific content 
would depend on the method used for assessment, products that currently claim to have no 
sugars or carbohydrates are probably less likely to contain the active oligosaccharides identified 
in these studies. Sensitive methods for the detection of soluble oligosaccharides would need to 
be used to determine the presence or absence of these compounds in products.  
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2. Sundown Naturals® Product Literature 
Below is a reproduction of the label from the SN product used in Chapter 3, analyzed in 
Section B6, and discussed in Section C3. No additional information was available on the 
internet for this product during these studies. 
 
 
 
  
288 
 
3. Nature’s BountyTM Product Literature 
Below is a reproduction of the label from the NB product used in Chapter 3, analyzed in 
Section B6 and discussed in Section C3. The information available for this product on the 
internet during these studies is also included on the following page. 
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4. Nature MadeTM Product Literature 
A reproduction of the product label was not available for the NM product used in 
Chapter 3, analyzed in Section B6, and discussed in Section C3. The limited information 
available for this product on the internet during these studies is included in the following five 
pages and includes a reproduction of the product label. The product shown here differs slightly 
from that used by the added presence of vitamin C; the study product lacked vitamin C but was 
otherwise the same in labeling and apparent composition.  
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5. CranMax® Product Literature 
A reproduction of the product label was not available for the CranMax® product 
discussed in Chapter 4, Section B4, and used in the studies of Beerepoot and coworkers (2011). 
Selected information for this product excerpted from the Proprietary Nutritionals 2007 White 
Paper found on the internet during the writing of this report is included below for ease of future 
reference. This literature is an excellent example of the pseudo-scientific content that ends up 
in the advertisements for many dietary supplement products. Note the relatively large number 
of nonsensical and contradictory statements.  
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6. ElluraTM Product Literature 
 
A reproduction of the product label was not available for the ElluraTM product discussed 
in Chapter 4, Section B4, and used in the studies of Howell and coworkers (2010). An excerpt 
of the information for this product found on the internet during the writing of this report is 
included below for ease of reference. This literature is an excellent example of the pseudo-
scientific content that ends up in the advertisements for many dietary supplement products. 
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VITA 
EDUCATION   
Bachelor of Science in Botany, Magna Cum Laude (3.78), University Honors Scholar,  
Aug 2000 – May 2004. Auburn University (AU), Auburn, AL, Honors College, College of 
Sciences & Mathematics, Dept. of Biological Sciences. Undergraduate Honors Thesis: 
“Extending the Elemental Defense Hypothesis: Metals May Protect Plants from Herbivores at 
Accumulator and Hyperaccumulator Concentrations.” 
RESEARCH EXPERIENCE 
Graduate Research Assistant   Aug 2004 – Aug 2014 
UM, Dept. of Pharmacognosy, Dr. Daneel Ferreira  
- Isolation and identification of cranberry juice metabolites from porcine urine  
- Isolation and identification of cranberry juice chemical constituents 
- Electronic circular dichroism (ECD) of flavonoids and other small molecule natural 
products 
- Training & supervision of post-doctoral research associates, visiting scientists, and graduate 
students 
- General lab and equipment maintenance and supply ordering 
Research Assistant/Personal Assistant  Dec 2006 – May 2008 
UM, Office of Research & Sponsored Programs (Vice Chancellor), Dr. Alice Clark 
- Literature searches, document summaries & reviews, PowerPoint slide preparation (see 
below), fact finding, source verification 
- Collaborated with the preparation of the following invited oral PowerPoint presentations 
given by Dr. Alice Clark: 
o “The Role of Natural Products in Drug Discovery and Development,” National 
Institutes of Health Staff Training in Extramural Programs Symposium, Bethesda, MD, 
January 17, 2008. 
o “The Evolution of Antimicrobial Drug Discovery & Development,” University of GA, 
Athens, GA, April 2007. 
o “The Evolution of Antifungal Drug Discovery,” First Tennessee Chair of Excellence 
Symposium, University of Tennessee Health Science Center, Memphis, TN, January 
25, 2007. 
Undergraduate Research Assistant Oct 2001 – Dec 2003 
AU, Dept. of Biological Sciences, Dr. Robert Boyd & AU, Dept. of Entomology & Plant 
Pathology, Dr. Micky Eubanks 
- Conducted experiments to determine the toxicity of heavy metals hyperaccumulated by 
plants, using the diamondback moth, Plutella xylostella, as a bioassay herbivore 
- Optimized colony maintenance protocols for maximal production of quality diamondback 
moth eggs 
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Undergraduate Research Assistant Jan 2001 – Dec 2003 
AU, Dept. of Biological Sciences, Dr. Robert Locy & José M. Barbosa 
- Aseptic growth of Arabidopsis thaliana on modified agar media to determine the growth 
effects of β-alanine and other amino acids 
- Feeding of 13C-labeled L-alanine to A. thaliana and subsequent tissue preparation for GC-
MS and NMR analysis of metabolic pathway components 
- Cultivation and selection of A. thaliana mutants for subsequent gene screening 
Undergraduate Laboratory Assistant May – Aug 2001 
AU, USDA-ARS National Soil Dynamics Lab, Dr. Hugo Rogers & Dr. Michael Davis 
Global Change Research Project (study of the effects of elevated CO2)  
- Assisted with the collection and preparation of plant samples for TEM and SEM analysis 
- Collection of Redheaded Pine Sawfly life cycle data 
- Assisted with field sample plot harvesting and sample sorting 
TEACHING EXPERIENCE 
Instructor for PHCG 422: Natural Product Derived Pharmaceuticals Jan – May 2013 
UM, Dept. of Pharmacognosy, School of Pharmacy, Professional Curriculum Course  
Full responsibility for all course material related to antimicrobial agents (70% of the course).  
Dr. Jordan Zjawiony as the instructor of record.   
 
Laboratory Technical Training Instructor 2007 – Present 
UM, Dept. of Pharmacognosy & the UM School of Pharmacy, Research Institute of 
Pharmaceutical Sciences 
Instructed research scientists, postdoctoral scientists and graduate students regarding 
background theory and correct equipment use and maintenance for the following instruments:  
- OLIS DSM 20 Circular Dichroism Spectrophotometer 
- JASCO 815 Circular Dichroism Spectrometer 
- Various HPLC systems: Waters Prep 400, 600, and 2695 Separations Modules with PDA, 
UV, and ELS Detectors 
- 400 MHz Bruker NMR instrument with Topspin 2.1 software  
Graduate Teaching Assistant    Aug 2005 – Dec 2010  
UM, Dept. of Pharmacognosy  
Courses Assisted: Pharmacognosy (PHCG): 
- PHCG 321 – Dr. Marc Slattery: Pathogenesis of Infectious Diseases, Spring 2009, Fall 
2009, Fall 2010 
- PHCG 421 – Dr. Marc Slattery: Pathogenesis and Etiology of Infectious Diseases, Fall 
2005 – 2008  
- PHCG 422 – Dr. Dale G. Nagle & Dr. Jordan Zjawiony: Natural Product Derived 
Pharmaceuticals, Spring 2006 – 2008, 2010 
- PHCG 544 – Dr. Daneel Ferreira: Departmental Seminar Series, Spring 2007 
- PHCG 627 – Dr. Daneel Ferreira: Natural Products Chemistry I, Fall 2005 – 2007 
- PHCG 628 – Dr. Daneel Ferreira: Natural Products Chemistry II, Spring 2006, 2007 
- PHCG 634 – Dr. Daneel Ferreira: Natural Product Biosynthesis, Spring 2006, 2007 
309 
 
Duties: 
PHCG 321/421/422: Exam preparation, proctoring & grading; student counseling, tutoring & 
group study sessions; preparation and presentation of selected lectures for 20-40% of 
course material (see below); management of Blackboard online student interface; 
preparation of study guides and question sets for each lecture to aid students in learning 
course material 
PHCG 627/628, 634: guest lecturer; typing, formatting & copying of exams and homework 
problem sets; preparation of lecture slides from book figures; hosting of student problem 
solving sessions; exam proctor 
 
Selected Lectures Given:  
– PHCG 321: Pulmonary Infections; CNS Infections; Cardiovascular Infections; 
Gastrointestinal Infections; HIV/AIDS, Group Book Exercises 
–  PHCG 421: Normal Flora and Gram (+) Bacteria Intro; Respiratory Acquired Gram (-) 
Rods; STD/Genitourinary Tract Infections; Retroviridae & HIV/AIDS  
–  PHCG 422: Introduction to Antibiotics, Drug Selection Criteria & Management of 
Antimicrobial Therapy; Broad Spectrum Agents & Principles of Combination Therapy; 
Antimicrobial Drug Resistance – Types, Mechanisms, & Prevention; Tetracyclines; 
Ribosomes Review & Antibiotics that Inhibit Protein Synthesis; Vitamins  
–  PHCG 627: Biosynthetic Construction Mechanisms; The Acetate Pathway: Prostaglandins, 
Aromatic Polyketides  
–  PHCG 634: Guest lecturer & problem solving sessions  
 
Undergraduate Teaching Assistant  Jan 2003 – May 2003 
AU, Dept. of Biological Sciences  
Biology (BIOL) 3101 – Dr. Joe Cherry: Plant Biology Laboratory 
- Solely responsible for laboratory lecture preparation, student instruction and assessment, 
laboratory set-up, and protocol revisions for assigned student experiments.  
GENERAL WORK EXPERIENCE 
Head Greenhouse Technician Feb 2002 – Sept 2002 
Flower Zone Nursery, Opelika, AL  
- Transplanting, watering, fertilizing, pruning, general greenhouse maintenance 
 
Assistant Manager, Designer, Decorator & Baker Feb 1997 – June 2000 
Ellen’s Creative Cakes, Huntsville, AL  
- Custom client sales, managed and trained employees, coordinated deliveries 
- Baking of cakes, pastries, and appetizers  
- Assembly, sculpting, and decorating of cakes 
- Catering of wedding receptions and other events  
- Training & supervision of regular empolyees and temporary event employees 
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AWARDS & HONORS  
Scholarships & Awards 
 NIH Common Fund Travel Fellowship to Attend the 2nd Annual Metabolomics Workshop 
at the University of Alabama, Birmingham, AL, June 2014  
 UM Graduate School Dissertation Fellowship, Spring 2012 
 UM Dept. of Pharmacognosy, Outstanding Service Award, Dec 16, 2010 
 UM Dept. of Pharmacognosy Retreat, Outstanding Podium Presentation Award, Dec 16, 
2010 
 UM Graduate School, Graduate Research Assistant Scholarship (full tuition), Fall 2004 – 
Summer 2014 
 Entomological Society of America and the Entomological Foundation, BioQuip 
Scholarship (1 of 1 awarded), Fall 2003 – Spring 2004 
 National Botanical Society of America Award for Best Student Poster in the Ecological 
Section, July 31, 2003 
 AU College of Sciences and Mathematics, Dean’s Undergraduate Research Fellowship (1 
of 4 awarded), Fall 2002 – Summer 2003 
 AU Dept. of Biological Sciences, Fund For Excellence Undergraduate Research Award (1 
of 9 awarded), Fall 2002 & Spring 2003 
 AU Honors College, Drummond Company Honors Scholarship, Fall 2002 & Fall 2003 
 AU Freshman Academic Scholarship (full tuition), Fall 2000 – Spring 2004 
 AU College of Sciences and Mathematics, Academic Scholarship, Fall 2000 
 Padgett Business Services, Book Scholarship, Huntsville, AL, Fall 2000 
Honors  
 Graduate Achievement Award in Pharmacognosy, April 2012 
 Who’s Who Among Students in American Universities and Colleges, Jan 2010 
 Teaching Assistant of the Year, 2008–2009, Selected by the P4 Class (4th Year Pharmacy 
Students), May 2009 
 Young Botanist of the Year, American Botanical Society, 2004 
 Student Spotlight in AU College of Sciences & Mathematics, Journey Newsletter (p. 38), 
2004 
 Dean’s List, AU College of Sciences & Mathematics, Fall 2000, Spring 2002 – Fall 2004 
 Junior Honors Certificate, AU Honors College, Spring 2002 
 Harry M. Rhett, Jr., Community Service Book Award, Randolph School, Huntsville, AL, 
May 26, 2000 
 National Merit Scholarship Program Letter of Commendation, Spring 2000  
Honor Societies  
 Rho Chi (Spring 2009), Phi Kappa Phi (Spring 2004), Beta Beta Beta (Spring 2003), Alpha 
Lambda Delta (Spring 2001), Phi Eta Sigma (Spring 2001), National Society of Collegiate 
Scholars (Spring 2001)   
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PROFESSIONAL SERVICE & INVOLVEMENT  
Peer Review 
 NIH-NCRR COBRE CORE-NPN Predoctoral Fellowship ad hoc Study Section 2009, 
Oxford, MS, Oct – Nov 2009 
- Mentored review of scientific research proposals submitted by UM graduate students. 
Mentor: Dr. David Pasco, UM National Center for Natural Products Research.  
 Peer Reviewer for Scientific Journals, May 2012 – Present 
- Journal of Natural Products 
- Molecular Nutrition and Food Research 
Professional Committee Positions 
 Department of Pharmacognosy Graduate Student Committee for Graduate Program 
Revision, May – Dec 2011 
- Revised Departmental published degree requirements for MS and PhD students  
 MALTO-PharmForum Joint Meeting, Executive Organizing Committee, Jan – May 2010 
- Participated in all aspects of planning necessary for meeting organization  
- Focused on recreational event planning, design and purchase of give-away items, 
volunteer coordination, and on-site operations  
 American Society of Pharmacognosy, Young Members Committee, July 2007 – July 2010  
- Contributed two biographies of previous ASP presidents for the 50th anniversary 
commemorative book 
 Phytochemical Society of North America, Young Members Committee, July 2007 – July 
2009 
- Organized & implemented conference activities, wrote newsletter articles, membership 
drive participation 
- Hosted: “Ask the Editor, A Panel Discussion on Common Manuscript Errors and Ways 
to Avoid Them.” Panel Members: Dr. Daneel Ferreira, Dr. John Pezzuto, Dr. John 
Romeo, and Dr. Norman Lewis. Hosts: Coleman, Christina M.; Kutrzeba, Lukasz; 
Mazourek, Michael. Phytochemical Soc. N. America Annual Meeting, Pullman, WA, 
June 25–30, 2008.  
 Historian – AU Beta Beta Beta Biological Honor Society Fall 2003 – Spring 2004  
 Social Committee Planner – AU Honors Congress  Fall 2000 – Fall 2002  
 Assistant Director, Outdoor Recreation – AU Program Council Spring 2001 – Spring 2002 
 President & Founder – AU Hiking Club Spring 2001 – Summer 2002 
 Committee Member, Outdoor Recreation – AU Program Council Fall 2000 – Spring 2001 
 Secretary and Assistant Event Organizer – Residence Hall Council Fall 2000 – Spring 2001 
Professional Organizations  
 American Society for Microbiology 
 American Society of Pharmacognosy 
 American Chemical Society 
 Phytochemical Society of North America 
  American Botanical Society 
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Volunteer Education & Outreach 
 Department of Pharmacognosy Representative, Fall 2007 – Spring 2014 
- Host and tour guide for prospective graduate students. 
- Poster: Ferreira, Daneel; Coleman, Christina M. “The Department of Pharmacognosy: 
An Overview” UM School of Pharmacy, National Center for Natural Products Research 
Annual Poster Session, Oxford, MS, Nov 8, 2012 & October 11, 2013  
 Science Fair Judge – North Mississippi Regional Science Fair; Grades 4–12, Botany 
Division, UM Tad Smith Coliseum, Oxford, MS, March of 2007, 2009 – 2012, 2014 
 Science Fair Judge – Local Science Fair; Grades 4–7, Oxford University School, Oxford, 
MS, Feb 5, 2008; Feb 5, 2009 
 Chemistry lab tour & career counseling for high school students attending a BISC 102 
summer course with the UM Department of Biology, June 2009 
 Adult GED Tutor – Algebra, vocabulary, reading skills; Lafayette County Literacy 
Coalition, Susan Nicholas, Managing Director, Oxford, MS, July 2005 – Mar 2006 
 Adult GED Tutor – Algebra, grammar, reading skills; Lee County Literacy Coalition, 
Opelika, AL, Aug 2003 – July 2004 
PROFESSIONAL DEVELOPMENT & ADVANCED TRAINING 
Professional Development  
 “Grants Workshop Series: (1) Proposal & Award Lifecycle, (2) Budgeting for Proposals, 
(3) Data Security, (4) Obtaining a Patent.” UM, Office of Research and Sponsored 
Programs, Oxford, MS, Sept 2013 
 UM, School of Pharmacy, Interdepartmental Faculty Retreat, June 6–7, 2013 
 UM, Dept. of Pharmacognosy Annual Retreat, Oxford, MS, Dec 16, 2010; Aug 26, 2011 
 Graduate Student/Post-doc Summer Institute, American Chemical Society Publications 
Division, Organizer: David Martinsen. ACS Headquarters Building, Washington, DC, Aug 
8–12, 2011 
 Objective of the Institute: “To bring together creative graduate students and 
postdocs to help [the ACS Publications Division] redefine how science is published, 
distributed, and incorporated into the research and learning workflow.”  
 Competitively selected from a pool of applicants nominated by ACS Journal 
Editors.  
 UM Women in STEM Dinner Program, Follow Up Round Table Discussion of recent 
attendees to the National Conference for College Women Student Leaders, Oxford, MS, 
Oct 26, 2010 
 UM Women in STEM Roundtable Series: “What Women Need to Know to Survive and 
Succeed in STEM Careers,” Hosted by the Sarah Isom Center for Women and Gender 
Studies, Spring 2010 
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Advanced Technical Training 
 University of Alabama at Birmingham, 2nd Annual Workshop on Metabolomics, Sponsored 
by the National Institute of General Medical Sciences as part of the NIH Common Fund 
Metabolomics Initiative, and by the Departments of Chemistry and Pharmacology and 
Toxicology at UAB, Birmingham, AL, June 2–5, 2014 
 University of Florida Metabolomics Workshop & Symposium, Sponsored by the Southeast 
Center for Integrated Metabolomics (SECIM), and the Clinical and Translational Science 
Institute, University of Florida, Gainesville, FL, May 20–23, 2014  
 Metabolomics Afternoon Workshop. Presenters: Dr. Paul Shiply, Dr. Susan Murch, & Dr. 
Christina Turi from the University of British Columbia. American Society of 
Pharmacognosy Annual Meeting, St. Louis, MO, July 13, 2013 
 Electronic and Vibrational Circular Dichroism Afternoon Workshop. Presenters: Dr. Nina 
Berova, Professor & Senior Research Scientist, Columbia University, and Dr. Ana Petrovic, 
Assistant Professor, New York Institute of Technology. American Society of 
Pharmacognosy Annual Meeting, New York, NY, July 28, 2012 
 X-Ray Crystallography Introductory Short Course, Dr. Frank Fronczek, Director of X-Ray 
Crystallography Facility, Dept. of Chemistry, Louisiana State University, Held at UM, June 
1–5, 2009 
 Bruker NMR Training Seminar Series. Mike Brown, Application Scientist for the Southern 
Region, Bruker South Training Center, Held at UM, Jan 2006 
Communications & Education Training 
 “Best Practices in Teaching Online” Workshop Series, Mark Yacovone, UM Graduate 
School, Oxford, MS, Spring 2013 
 “Introduction and Overview of the Wimba Classroom” Workshop, Randall Uncapher, IT 
Designer, UM Division of Outreach & Continuing Education, UM Faculty Technology 
Development Center, Oxford, MS, Sept 16, 2011 
 “Science: Becoming the Messenger” Full Day Workshop. Presenters: Dan Agan, President, 
Panthera Group LLC; Chris Mooney, Science Journalist; Joe Schreiber, President, Mattmar 
Productions. National Science Foundation EPSCoR Workshop, Mississippi State 
University, Starkville, MS, Aug 29, 2011 
 “The Use of Technology for Teaching,” iLearning Event Workshop for UM Faculty and 
TAs, UM Faculty Technology Development Center, Oxford, MS, Nov 18, 2010 
 “Elevator Talks,” Bringing Scientists to the People Workshop, Carolyn Gayle, Clear 
Communication Group, UM Graduate School, Oxford, MS, Nov 25, 2008 
 “School of Pharmacy Graduate Teaching Assistant Seminar Series” (Monthly meetings 
each fall). Dr. Alicia Bouldin, Professor & Teaching Assistant Mentor for the School of 
Pharmacy, UM, Fall 2006 – 2010 
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 “Using PRS RF-Clickers in Classrooms Workshop” (beginning & advanced sessions). Julie 
Weiss, InterWrite Inc., and Penny Rice, UM Faculty Technology Development Center, 
Oxford, MS, Jan 14, 2008 
 “Teaching Assistant Orientation & Training” (3 day workshop). Dr. Johnny Lott, UM 
Center for Excellence in Teaching and Learning, Oxford, MS, Aug 2007, 2008 
University of Mississippi: Selected Elective Courses 
 BISC 502: Mycology – Instructor: Dr. Jason Hoeksema, Fall 2008; Included laboratory 
work studying gross anatomy and microscopy of macro-fungi of the southeast U.S. 
 PHAD 692: Drug Development & Marketing – Instructor: Ms. Allyson Best, Spring 2006; 
Participated in the research and design of a development and marketing plan for a 
compound possessing antitumor activity. Acted as the group director with eight people in 
the group. 
 BISC 522: Microbial Ecology – Instructor: Dr. Clifford Ochs, Fall 2005 
 PHCL 381: Introduction to Toxicology (Audit) – Instructor: Dr. Kristie Willett, Fall 2005 
Auburn University: Selected Elective Courses  
 NUFS 643: Food Chemistry – Instructor: Dr. Leonard Bell, Spring 2004 
 HORT 622: Greenhouse Management Science – Instructor: Dr. Raymond Kessler, Fall 
2003; Developed a business plan for the foundation and management of a greenhouse 
business 
 BIOL 497 Special Topics: Plant Anatomy & Development – Instructor: Dr. Roland Dute, 
Spring 2003; Special Project: TEM sample preparation and TEM & confocal microscopy of 
wood tissue segments  
 ENTM 304: General Entomology – Instructor: Dr. Wayne Clark, Fall 2002; Special Project: 
Insect collection and preservation 
RESEARCH SUPPORT 
Ongoing Research Support 
Ocean Spray Cranberries, Inc. Ferreira (PI) 10/01/2011 – 03/15/2014 
Human Urinary Metabolites Produced as a Result of Cranberry Juice Consumption 
The goal of this study was to isolate and identify the anti-adhesive metabolites of human urine 
produced as a result of cranberry consumption. Role: Investigator & proposal co-author 
Completed Research Support 
1R21AT002076-01 NIH/NCCAM Howell (PI) 04/05/2004 – 04/04/2009 
Identification of Bioactive Cranberry Metabolites 
The goal of this study was to isolate and identify the anti-adhesive metabolites of swine urine 
produced as a result of cranberry consumption. Role: Investigator 
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PUBLICATIONS 
Refereed Original Research and Scholarly Review Articles 
1. Coleman, Christina M.; Boyd, Robert S.; Eubanks, Micky D. Extending the Elemental 
Defense Hypothesis: Dietary Metal Concentrations Below Hyperaccumulator Levels 
Could Harm Herbivores. Journal of Chemical Ecology, 2005, 31 (8), 1669-1681. 
PMID: 16222801. 
2. Coleman, Christina M.; Prather, Brian L.; Valente, Matthew J.; Dute, Roland R.; Miller, 
Michael E.; Torus Lignification in Hardwoods. International Association of Wood 
Anatomists (IAWA) Journal, 2004, 25 (4), 435-447. 
3. Ferreira, Daneel; Marais, Jannie P. J.; Coleman, Christina M.; Slade, Desmond. 
“Proanthocyanidins: Chemistry and Biology” In: Comprehensive Natural Products 
Chemistry II, Pergamon Press (Elsevier), New York, 2009, Chapter 6.15. 
4. Ferreira, Daneel; Coleman, Christina M. Towards the Synthesis of Proanthocyanidins: 
Half a Century of Innovation, Invited Review Publication, Planta Medica, 2011, 77 
(11), 1071-85. doi: 10.1055/s-0030-1270908. PMID: 21412691. 
5. Xu, Yong-Jiang; Foubert, Kenn; Dhooghe, Liene; Lemière, Filip; Maregesi, Sheila; 
Coleman, Christina M.; Zou, Yike; Ferreira, Daneel; Apers, Sandra; Pieters, Luc. 
Rapid Isolation and Identification of Minor Natural Products by LC-MS, LC-SPE-
NMR, and ECD: Isoflavanones, Biflavanones, and Bisdihydrocoumarins from 
Ormocarpum kirkii, Phytochemistry, 2012, 79, 121-128. doi: 
10.1016/j.phytochem.2012.04.004. PMID: 22575670. 
6. Belofsky, Gil; Kolaczkowski, Marcin; Adams, Earle; Schreiber, John; Eisenberg, Victoria; 
Coleman, Christina M.; Zou, Yike; Ferreira, Daneel. Fungal ABC Transporter-
Associated Activity of Isoflavonoids from the Root Extract of Dalea formosa 
(Fabaceae). Journal of Natural Products, 2013, 76 (5), 915-925. doi: 
10.1021/np4000763. PMID: 23631483. Accepted without change by two independent 
reviewers. 
7. Li, Jun; Coleman, Christina M.; Wu, Hankui; Burandt, Charles L.; Ferreira, Daneel; 
Zjawiony, Jordan K., Triterpenoids and Flavonoids from Cecropia schreberiana Miq. 
(Urticaceae). Biochemical Systematics and Ecology, 2013, 48 (June), 96-99. PMID: 
23459662. 
8. Campana, Priscilla R. V.; Coleman, Christina M.; Teixeira, Mauro M.; Ferreira, Daneel; 
Braga Fernão C., TNF-α Inhibition Elicited by Mansoins A and B, Heterotrimeric 
Flavonoids Isolated from Mansoa hirsuta. Journal of Natural Products, 2014, 77 (4), 
824-830. PMID: 24576254. 
9. Canuto, Kirley M.; Leal, Luzia K. A. M.; Lopes, Amanda A.; Coleman, Christina M.; 
Ferreira, D.; Silveira, Edilberto R. Amburanins A and B from Amburana cearensis: 
Daphnodorin-Type Biflavonoids That Modulate Human Neutrophil Degranulation. 
Journal of the Brazilian Chemical Society, 2014, 25 (4), 639-647. doi: 10.5935/0103-
5053.20140011. 
  
316 
 
10. Villinski, Jacquelyn R.; Bergeron, Chantal; Cannistra, Joseph C.; Gloer, James B.; 
Coleman, Christina M.; Ferreira, Daneel; Azelmat, Jabrane; Grenier, Daniel; Gafner, 
Stefan. Pyrano-Isoflavans from Glycyrrhiza uralensis with Antibacterial Activity 
Against Streptococcus mutans and Porphyromonas gingivalis. Journal of Natural 
Products, 2014, 77 (3), 521-526. PMID: 24479468. 
11. Belofsky, Gil; Aronica, Mario; Foss, Eric; Diamond, Jane; Santana, Felipe; Darley, Jacob; 
Dowd, Patrick; Coleman, Christina M.; Ferreira, Daneel. Antimicrobial and 
Antiinsectan Phenolic Metabolites of Dalea searlsiae (Fabaceae). Journal of Natural 
Products, 2014, 77 (5), 1140–1149. 
12. Du, Kun; Coleman, Christina M.; Van Vuuren, Sandy F.; Van Zyl, Robyn L.; Zietsman, 
Pieter C.; Ferreira, Daneel; Marston, Andrew; Van Der Westhuizen, Jan H. Flavonol 
Acyl Glucosides from the Aril of Schotia brachypetala Sond. and Their Antioxidant, 
Antibacterial and Antimalarial Activities. Phytochemistry Letters, Available online, 
June 2014. 
In Preparation for Refereed Journals 
Coleman, Christina M.; Howell, Amy B.; Krueger, Christian G.; Auker, Kimberly M.; Reed, 
Jess D.; Ferreira, Daneel. Porcine Anti-Adhesive Urinary Metabolites Produced as a Result 
of Cranberry Consumption. Journal of Agricultural and Food Chemistry, 2014, In 
Preparation. 
Auker, Kimberly M.; Coleman, Christina M.; Wang, Mei; Avula, Bharathi; Khan, Ikhlas; 
Ferreira, Daneel. Structural Characterization of Cranberry Oligosaccharides. Journal of the 
American Chemical Society, 2014, In Preparation.  
Auker, Kimberly M.; Coleman, Christina M.; Kimble, Lindsey; Mathison, Bridget; Chew, 
Boon P.; Howell, Amy B.; Ferreira, Daneel.  Human Anti-Adhesive Urinary Metabolites 
Produced as a Result of Cranberry Juice Consumption. In Preparation. 
Coleman, Christina M.; Akgul, Yurdanur; Auker, Kimberly M.; Kimble, Lindsey; Mathison, 
Bridget; Wang, Mei; Avula, Bharathi; Khan, Ikhlas; Chew, Boon P.; Ferreira, Daneel. Anti-
Adhesive Oligosaccharides from Cranberry Products. In Preparation. 
Coleman, Christina M.; Nael, Manal A.; Zou, Yike; Eisenberg, Victoria; Belofsky, Gil; 
Doerksen, Robert J.; Ferreira, Daneel. The Absolute Configuration of 3-
Hydroxyisoflavanones Through Experimental and Calculated Electronic Circular 
Dichroism. In Preparation. 
Coleman, Christina M.; Zou, Yike; Ferreira, Daneel. How to Study Small Molecule Natural 
Products by Electronic Circular Dichroism. In Preparation. 
Peddikotla, Prabhakar; Coleman, Christina M.; Adelli, Vijender R.; Marais, Johannes P. J.; 
Ferreira, Daneel, Synthesis of A-Type Proanthocyanidins. In Preparation.  
Radhakrishnan, Sri Vedavyasa Sri; Sharma, Vimal K.; Ankisetty, Sridevi; Coleman, Christina 
M.; Ferreira, Daneel; Zjawiony, Jordan K. 12a-Hydroxyrotenoids from Mirabilis 
multiflora. In Preparation. 
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Professional Newsletter Publications 
Clark, Alice M. & Coleman, Christina M. “The Changing Face of ASP: The Role of 
Women.” American Society of Pharmacognosy Newsletter, December 2007, 43(4), p 4, 9. 
Coleman, Christina M.; Mazourek, Michael; Biedrzycki, Meredith; Kutrzeba, Lukasz. 
“Potential Conference Activities for Young Members for PSNA 2008 General Scientific 
Meeting.” Phytochemical Society of North America Newsletter, December 2007, 46(2), p 
18-21. 
Technical Writing & Reports 
Coleman, Christina M. “Operational Instructions for the JASCO J-815 Circular Dichroism 
Spectrometer,” May 2013, Instrument Operation Manual. 
Coleman, Christina M. "Operational Instructions for the OLIS DSM-20 Circular Dichroism 
Spectrophotometer," May 2012, Instrument Operation Manual.  
Coleman, Christina M., “Toosendanin – Structure, Sourcing, Uses & General Notes.” 
Technical Report prepared for Dr. Alice Clark, March 03, 2007. 
 
PROFESSIONAL MEETINGS ATTENDED 
 American Society of Pharmacognosy Annual Meeting, St. Louis, MO, July 13–17, 2013 
 International Congress on Natural Products Research (Joint with ASP), New York, NY, 
July 28 – Aug 1, 2012 
 Joint Meeting of the American Society of Pharmacognosy and the Phytochemical Society 
of North America, St. Petersburg, FL, July 10–14, 2010 
 Joint Meeting of MALTO and PharmForum, Oxford, MS, May 23–26, 2010 
 American Society for Microbiology National Meeting, Philadelphia, PA, May 17–21, 2009 
 Phytochemical Society of North America Annual Meeting, Pullman, WA, June 25–30, 
2008 
 Phytochemical Society of North America Annual Meeting, St. Louis, MO, July 21–25, 
2007 
 American Society of Pharmacognosy Annual Meeting, Portland, ME, July 14–18, 2007 
 MALTO Medicinal Chemistry & Pharmacognosy Annual Meeting, Monroe, LA, May 20–
22, 2007 
 American Chemical Society National Meeting (Fifth Tannin Conference), San Francisco, 
CA, Sept 10–14, 2006 
 Phytochemical Society of North America Annual Meeting, Oxford, MS, July 8–12, 2006 
 MALTO Medicinal Chemistry & Pharmacognosy Annual Meeting, Houston, TX, May 21–
23, 2006 
 MALTO Medicinal Chemistry & Pharmacognosy Annual Meeting, Oxford, MS, May 22–
24, 2005 
 Botanical Society of America National Meeting, Mobile, AL, July 26–31, 2003 
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PRESENTATIONS  
Scientific Meetings – Presenting Author 
Coleman, Christina M.; Auker, Kimberly M.; Ferreira, Daneel. “Anti-adhesion Properties of 
Cranberry Products: Current Status and New Directions.” American Society of 
Pharmacognosy Annual Meeting, St. Louis, MO, July 17, 2013. Oral.  
Auker, Kimberly M.; Coleman, Christina M.; Wang, Mei; Avula, Bharathi; Kimble, Lindsey; 
Mathison, Bridget; Khan, Ikhlas; Chew, Boon P.; Ferreira, Daneel. “Structural 
Characterization and Bioactivity of Cranberry Oligosaccharides.” American Society of 
Pharmacognosy Annual Meeting, St. Louis, MO, July 15, 2013. Poster. 
Coleman, Christina M.; Zou, Yike; Eisenberg, Victoria; Belofsky, Gil; Ferreira, Daneel. 
“Absolute configuration of 3-hydroxyisoflavanones and conjugated 2-(5H)-furanones 
through electronic circular dichroism.” ICNPR/ASP Joint Meeting, New York, NY, July 28 
– Aug 1, 2012. Poster. 
Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian 
G.; Marais, Jannie P. J. “Anti-Adhesive Urinary Metabolites Produced as a Result of 
Cranberry Juice Consumption.” UM Department of Pharmacognosy Annual Retreat, 
Oxford, MS, Dec 16, 2010. Oral. 
Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian 
G.; Marais, Jannie P. J. “Anti-Adhesive Urinary Metabolites Produced as a Result of 
Cranberry Juice Consumption.” ASP/PSNA Joint Meeting, St. Petersburg, FL, July 13, 
2010. Oral. 
Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian 
G.; Marais, Jannie P. J. “Isolation and Identification of Anti-Adhesive Urinary Metabolites 
from Cranberry Juice.” Phytochemical Society of North America Annual Meeting, 
Pullman, WA, June 25–30, 2008. Poster. 
Coleman, Christina M.; Ferreira, Daneel; Marais, Jannie P. J.; Howell, Amy B.; Cihlar, 
Ronald; Cohen, Jesse. “Cranberry Juice Compounds with Anti-Adhesive Properties in 
Urine.” Phytochemical Society of North America Annual Meeting, Pullman, WA, June 25–
30, 2008. Poster. 
Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian 
G.; Marais, Jannie P.J. “Isolation and Identification of Anti-Adhesive Urinary Metabolites 
from Cranberry Juice.” Phytochemical Society of North America Annual Meeting, St. 
Louis, MO, July 21–25, 2007. Poster. 
Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian 
G.; Marais, Jannie P. J. “Bioactive Metabolites of Cranberry Juice.” American Society of 
Pharmacognosy Annual Meeting, Portland, ME, July 14–18, 2007. Poster  
Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian 
G.; Marais, Jannie P. J. “Bioactive Metabolites of Cranberry Juice.” MALTO Medicinal 
Chemistry & Pharmacognosy Annual Meeting, Monroe, LA, May 20–22, 2007. Poster.  
Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian 
G.; Marais, Jannie P. J. “Bioactive Metabolites of Cranberry Juice.” American Chemical 
Society National Meeting, CELL Division – Fifth Tannin Conference, San Francisco, CA, 
Sept 10–14, 2006. Poster. 
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Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian 
G.; Marais, Jannie P. J. “Bioactive Metabolites of Cranberry Juice.” Phytochemical Society 
of North America Annual Meeting, Oxford, MS, July 8–12, 2006. Oral. 
Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian 
G.; Marais, Jannie P.J.  “Bioactive Metabolites of Cranberry Juice.” MALTO Medicinal 
Chemistry & Pharmacognosy Annual Meeting, Houston, TX, May 21–23, 2006. Oral 
Coleman, Christina M.; Prather, Brian L.; Valente, Matthew J.; Dute, Roland R.; and Miller, 
Michael E.; “Torus Lignification in Hardwoods.” AU Undergraduate Research Forum, 
Auburn, AL, October 9–10, 2003. Poster.  
Coleman, Christina M.; Boyd, Robert S.; Eubanks, Micky D. “Herbivore Defense as an 
Explanation for Hyperaccumulation: Heavy Metal Toxicity to Diamondback Moth (Plutella 
xylostella)” Botanical Society of America National Meeting, Ecological Section, Mobile, 
AL, July 26–31, 2003. Poster.  
Invited Presentations – Presenting Author 
Coleman, Christina M. “Department of Pharmacognosy Innovative Teaching Strategies: 
PHCG 422.” UM, School of Pharmacy, Interdepartmental Faculty Retreat, June 6, 2013. 
Oral.  
Coleman, Christina M. “An Overview of PHCG 422: Natural Product Derived 
Pharmaceuticals, Spring 2013.” UM, School of Pharmacy, Interdepartmental Faculty 
Retreat, June 6, 2013. Poster.  
Coleman, Christina M.; Howell, Amy B.; Krueger, Christian G.; Auker, Kimberly M.; Reed, 
Jess D.; Ferreira, Daneel. “Anti-Adhesive Urinary Metabolites Produced as a Result of 
Cranberry Consumption.” Ocean Spray Cranberries, Inc., Corporate Headquarters Site 
Visit, Lakeville-Middleboro, MA, May 20, 2013. 
Coleman, Christina M. “Communications Technology and the ‘Scientist of the Future.’” 
Department of Pharmacognosy Annual Retreat, Oxford, MS, Aug 26, 2011. Oral. 
Coleman, Christina M. “Why Plants and Science are Both Awesome!” A visit to the 3rd grade 
class of Mrs. Judy Caldwell, Lafayette County Upper Elementary School, Oxford, MS, Aug 
18, 2011. Interactive presentation & demonstration. 
Aiyar, Avishek; Coleman, Christina M.; Havanki, Kathy; McCrary, Parker; Reilly, Maureen. 
“The Dynamic Scientist.” American Chemical Society Publications Division, Graduate 
Student/Postdoc Summer Institute, ACS Headquarters Building, Washington, DC, Aug 12, 
2011. Oral. 
Coleman, Christina M. “Cranberry Juice: What do we really know?” Invited presentation to 
UM Course PHCG 329, Herbal Dietary Supplements, Instructor: Dr. Charles Hufford, Feb 
24, 2011. Oral. 
Coleman, Christina M. “What Makes a Good PowerPoint Presentation?” Invited Seminar for 
UM Course PHCG 544, Instructor: Dr. Daneel Ferreira, Feb 2007. Oral. 
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Scientific Meetings & Invited Presentations – Collaborating Author 
Auker, Kimberly M.; Coleman, Christina M.; Wang, Mei; Avula, Bharathi; Kimble, Lindsey; 
Mathison, Bridget; Khan, Ikhlas; Chew, Boon P.; Ferreira, Daneel. “Structural 
Characterization and Bioactivity of Cranberry Oligosaccharides.” Ocean Spray 
Cranberries, Inc., Corporate Headquarters Site Visit, Lakeville-Middleboro, MA, May 20, 
2013. 
Ferreira, Daneel; Coleman, Christina M. “Absolute Configuration of Secondary Metabolites 
via Electronic Circular Dichroism.” ICNPR/ASP Joint Meeting, New York, NY, July 28 
– Aug 1, 2012. 
Auker, Kimberly M.; Coleman, Christina M.; Avula, Bharathi; Ferreira, Daneel. “Structural 
Elucidation of Complex Carbohydrates from Cranberry.” ICNPR/ASP Joint Meeting, 
New York, NY, July 28 – Aug 1, 2012. 
Ferreira, Daneel; Coleman, Christina M. “Absolute Configuration of Secondary Metabolites 
via Electronic Circular Dichroism.” Frank Warren 2012 Conference hosted by the South 
African Chemical Institute, Bloemfontein, South Africa, April 15–18, 2012. 
Ferreira, Daneel; Coleman, Christina M. “Absolute Configuration of Secondary Metabolites 
via Electronic Circular Dichroism.” PSNA 2011, Kohala Coast, HI, Dec 12, 2011. 
Ferreira, Daneel; Coleman, Christina M. “Half a Century of Proanthocyanidin/Polyphenol 
Research.” PSNA 2011, Kohala Coast, HI, Dec 13, 2011. 
Ferreira, Daneel; Coleman, Christina M.; Marais, Jannie P. J.; Howell, Amy B. “Cranberry 
Polyphenols and Urinary Tract Infections.” International Conference on Polyphenols & 
Health, Kyoto, Japan, Nov 2007.  
Ferreira, Daneel; Coleman, Christina M.; Marais, Jannie P. J.; Howell, Amy B. “Chemistry of 
Condensed Tannin & Effect of Cranberry Tannin.” Invited Presentation, Nippon 
Shinyaku Corporate Meeting Presentation, Kyoto, Japan, Nov 27, 2007. 
Ferreira, Daneel; Li, Xing-Cong; Ding, Yuanxing; Marais, Jannie P. J.; Coleman, Christina 
M. “Absolute Configuration of Proanthocyanidins via Circular Dichroism.” Barton 
Conference, St. Lucia, May 2007. 
Ferreira, Daneel; Marais, Jannie P. J.; Li, Xing-Cong; Coleman, Christina M. “Circular 
Dichroism: A Powerful Tool for the Definition of Absolute Configuration of 
Proanthocyanidins.” American Chemical Society National Meeting, Division of 
Agricultural and Food Chemistry, Chicago, IL, March 29, 2007. 
Ferreira, Daneel; Marais, Jannie P. J.; Li, Xing-Cong; Coleman, Christina M. “Absolute 
Configuration of Proanthocyanidins via Circular Dichroism.” American Chemical Society 
National Meeting, CELL Division – Fifth Tannin Conference, San Francisco, CA, Sept 
10–14, 2006. 
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Other Presentations – Presenting Author 
Coleman, Christina M. “Chemical Profiles of Microbial Interactions for Antimicrobial Drug 
Discovery.” Original Research Proposal, Oral Defense Seminar. Degree requirement. 
March 27, 2014 
Coleman, Christina M. “Bioprospecting for Novel Natural Products: Where can we look 
next?” Oral Seminar – Chosen Topic. Degree requirement. May 1, 2007 
Coleman, Christina M. “Viral Infections & HIV/AIDS,” Invited Lab Group Presentation, 
January 31, 2007 
Coleman, Christina M. “Saturation Transfer Difference (STD) NMR: Theory, Methods, and 
Applications.” Oral Seminar – Assigned Topic. Degree requirement. March 9, 2006 
Coleman, Christina M.  “Urinary Tract Infections: An Overview.” Invited Lab Group 
Presentation, September 30, 2005 
Coleman, Christina M.  “Genistein as a Molecular Probe: Tyrosine kinase inhibition & the 
role of tyrosine kinases in the cell.” Oral Seminar – Assigned Topic. Degree requirement. 
March 30, 2005 
Coleman, Christina M. Graduate Level Graded Coursework Presentations 
- PHCG 632: Structure Elucidation – “Brief Introduction to the Fundamentals of ORD & 
CD,” Spring 2005 
- PHCG 628: Natural Products Chemistry – “Porphyrins” and “Saponins,” Spring 2005 
- PHCG 627: Natural Products Chemistry – “Lignins & Lignans” and “Carbohydrates: 
Polysaccharides – Starch, Cellulose, and Fructans,” Fall 2004 
 
